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ABSTRACT 
 
DANIEL WESTREICH: HIV, antiretroviral therapy, and tuberculosis: outcomes in 
Johannesburg, South Africa 
(Under the direction of Annelies Van Rie) 
 
The rollout of highly active antiretroviral therapy (HAART) in sub-Saharan 
Africa poses many challenges. In one of the largest HAART clinics in Africa, we 
described overall outcomes of HAART, the impact of treated pulmonary tuberculosis 
(PTB) at the time of HAART initiation on all-cause mortality, and the impact of 
prevalent and incident tuberculosis treatment on the risk of the substitution of the 
antiretroviral drug stavudine. 
In these analyses, robust methods including inverse probability weighted 
marginal structural models were used where appropriate to control for confounding 
and bias due to losses to follow-up and competing risks.  This analytic approach 
made these results more robust compared with more “traditional” analyses. 
Relatively few patients died after HAART initiation. Risk of death during 
follow-up increased in individuals who at baseline were older or had low CD4 cell 
counts, low body mass index, low hemoglobin, or advanced disease stage. 
The crude hazard ratio (HR) for the effect of treated PTB at time of HAART 
initiation on mortality was 1.71 (95% confidence interval [CI] 1.31-2.23) and the 
adjusted HR was 1.06 (95% CI 0.75-1.49), a difference due to the fact that 
individuals with PTB at time of HAART initiation had more severe 
 iv 
immunodepression. Additionally, individuals who started HAART within 30 days of 
initiation of treatment for PTB were not at higher risk of death than other individuals, 
suggesting that early HAART initiation can be safely recommended. 
In analysis of the effect of treatment for pulmonary or extrapulmonary 
tuberculosis (TB) on risk of stavudine substitution, we found that if TB treatment is 
ongoing at the time of initiation of HAART, there was between a two- and sevenfold 
increase in risk of stavudine substitution during the early months of HAART. 
However, incident TB treatment after HAART initiation, did not raise the risk of 
stavudine substitution. These results were robust to sensitivity analysis, and suggest 
that the use of stavudine might be reconsidered in patients receiving treatment for 
TB. 
Overall, these results suggest that early initiation of HAART is warranted in 
patients with TB, but that clinicians need to monitor these patients closely for 
indications for stavudine substitution. 
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CHAPTER 1 
CRITICAL REVIEW OF THE LITERATURE 
 
GENERAL BACKGROUND 
 
Global and sub-Saharan African epidemiology of HIV.  In 2007, there 
were an estimated 33.2 million individuals living with human immunodeficiency virus 
(HIV) worldwide (UNAIDS/WHO 2007), 2.5 million of whom were newly infected 
(UNAIDS/WHO 2007); since the disease was first described in 1981, over 20 million 
individuals have died as a result of HIV infection (WHO 2006).  It is by now common 
knowledge that sub-Saharan Africa bears a disproportionate share of the world’s 
burden of current and new HIV infections:  1.7 million of the 2.5 million new 
infections in 2007 occurred in sub-Saharan Africa, and the average adult prevalence 
in sub-Saharan Africa is 5.0%, an order of magnitude greater than most other 
regions in the world, and perhaps five times the prevalence in the Caribbean, the 
region with the next-highest prevalence (UNAIDS/WHO 2007).  Sub-Saharan Africa 
likewise bears a disproportionate burden of AIDS deaths, with an estimated 1.6 of 
2.1 million deaths due to AIDS in 2007 (UNAIDS/WHO 2007). 
Epidemiology of HIV in South Africa. The South African National AIDS 
Council in the Department of Health estimates that the adult (15-49) prevalence of 
HIV was 18.8% in 2006,  and that there were approximately 5.5 million cases of HIV 
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prevalent in the country (Kapp 2007; South African National AIDS Council 2007) 
though other sources have offered lower prevalence estimates, including 22% of the 
adult population and 12.9% (UNAIDS 2006), and between 10.2% and 16.2% 
(Garcia-Calleja, Gouws, and Ghys 2006) of the general population, depending on 
location of the survey. 
While there is evidence that the epidemic is decreasing in intensity in parts of 
the eastern and even southern African regions (UNAIDS/WHO 2006), the evidence 
in South Africa is more mixed:  in 2006 the prevalence of HIV among pregnant 
women presenting in ante-natal care clinics was 29%, only 1% lower than the 
highest prevalence ever recorded in that population, in 2005, and 7% higher than the 
estimate from 1998 (UNAIDS/WHO 2007). And while HIV prevalence has decreased 
in prevalence in pregnant women ages 15-24, this population – especially at ages 20 
and 21 – appear to be at highest risk of HIV acquisition (Pettifor et al. 2005).  While 
there is some risk that population prevalence is overestimated due to over-reliance 
on antenatal clinic data, it is nevertheless clear that prevalence of HIV in South 
Africa is extremely high by global standards, and that this situation is not likely to 
change substantially in the near term. 
 
HIV: BIOLOGY AND TREATMENT 
 
Pathobiology of HIV.  Human immunodeficiency virus (HIV) is a single-
stranded RNA virus (Tronchet and Seman 2003).  HIV is a retrovirus, and replicates 
by using reverse-transcriptase to convert RNA into DNA, which is integrated into the 
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DNA of infected host cells.  HIV mutates rapidly, largely due to error-prone copying 
strategies (Stebbing and Moyle 2003), and to the production of a large number of 
copies per day, on the order of 109 (Ho et al. 1995).  This has resulted in the 
evolution of many distinct clades, or sub-species, of HIV, which have slightly 
different clinical implications (Stebbing and Moyle 2003).  HIV is classified into two 
major families, HIV-1 and HIV-2; the M, or Main clade of the former is responsible for 
the large majority of cases of HIV in the world, and is abbreviated as HIV in this 
paper (Stebbing and Moyle 2003).  The South African epidemic is chiefly HIV-1 C. 
HIV uses the viral glycoprotein gp120 to target cells of the human immune 
system that present the CD4 co-receptor, including CD4+ T-cells, dendritic cells, and 
macrophages (Janeway et al. 2005).  Long term HIV infection results in acquired 
immune deficiency syndrome, or AIDS, the consequence of a long-term depletion of 
immune system cells, especially CD4-cells.  When a patient’s CD4 cell counts fall 
below 200, “opportunistic” infections with bacteria and other pathogens become 
common, eventually leading to death (Janeway et al. 2005).  CD4 count and viral 
load monitoring are widely considered the key markers of HIV disease progression. 
Opportunistic and co-infections common to sub-Saharan Africa. There 
are many opportunistic infections and co-infections that impose significant burdens 
of morbidity and mortality; among the most important are Hepatitis B (Hoffmann and 
Thio 2007), Hepatitis C (Rockstroh and Spengler 2004), and HHV8 (strongly 
associated with Kaposi’s Sarcoma) (Malope et al. 2007).  Perhaps the two most 
important co-infections to consider in sub-Saharan Africa are tuberculosis (TB) 
(WHO 2007) and malaria (WHO 2007). 
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In South Africa, and Johannesburg in particular, TB is clearly the more 
important of these two co-infections.  TB infects an estimated two billion people 
worldwide and killed an estimated 1.6 million people in 2005 (WHO 2007).  The 
majority of those deaths were in southeast Asia and Africa, particularly South Africa, 
Zimbabwe, Tanzania, and Kenya (WHO 2007, 2007).  In Africa generally, TB 
mortality in 2005 was 77 per 100000 individuals, more than 3 times the global rate, 
more than twice the rate in southeast Asia (31/100000), and 10 times the European 
rate.  TB can be treated with a standard six-nine month course of pharmacotherapy, 
typically including at least two drugs such as isoniazid, rifampicin, pyrazinamide, and 
ethambutol.  Many of these drugs have significant side effects, including hepatitis, 
rash, anemia, nausea, and peripheral neuropathy (Subbaraman et al. 2007) – we 
defer a complete discussion of these issues for the literature review for Specific Aim 
3. 
Therapeutic strategies for HIV infection, including HAART. A 
consequence of the innate variability of HIV is that an effective HIV vaccine has so 
far proved elusive (Ho and Huang 2002).  Treatment for (though not cure of) HIV 
therefore relies on therapeutic drugs, known collectively as antiretroviral drugs.  
Antiretroviral drugs currently comprise six distinct classes and over 20 individual 
agents.  The first class of ARV agents developed were the nucleoside analogues, or 
nucleoside reverse transcriptase inhibitors (NRTIs), which inhibit reverse 
transcriptase by chain-termination (Portsmouth, Stebbing, and Gazzard 2003).  The 
two additional classes of ARVs in routine use are protease inhibitors (PIs), which act 
by inhibiting the cleaving of HIV particles from host cells (Wynn et al. 2004), and 
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non-nucleoside reverse transcriptase inhibitors (NNRTIs), which bind directly to – 
and thus inhibit – reverse transcriptase.  Additional classes of approved antiretroviral 
drugs include entry and fusion inhibitors (Portsmouth, Stebbing, and Gazzard 2003; 
Zapor et al. 2004) and integrase inhibitors (Evering and Markowitz 2008), while other 
classes (e.g., maturation inhibitors) are in development. 
The first of these drugs to be used clinically was zidovudine (AZT).  Early 
trials showed a significant virologic, immunologic, and clinical impact on HIV+ 
individuals of both AZT monotherapy and NRTI dual therapy (Collier et al. 1993; 
Fischl et al. 1990; Fischl et al. 1990).  Subsequently, the introduction of new drugs 
and drug classes allowed for the advent of the era of highly active antiretroviral 
therapy (HAART), usually involving at least three distinct ARVs, usually in at least 
two classes (Wynn et al. 2004).  It was hoped three drugs would result both in a 
greater viral suppression as well as an increase in the length of that suppression, the 
latter by delaying the emergence of HIV resistance mutations. 
Indeed, HAART has proven to be an enormous success (Chen, Hoy, and 
Lewin 2007; Detels et al. 1998).  While HAART is not able to eradicate HIV because 
of persistent infection in resting CD4 T-cells (Lehrman et al. 2005) and possibly 
additional reservoirs, methodologically definitive studies have demonstrated that 
HAART results in marked reductions in time to AIDS or death (Cole et al. 2003; 
Detels et al. 1998), as well as providing a longer duration of viral suppression 
compared to dual or monotherapy (Cole et al. 2003), albeit often with increased 
toxicities and side-effects of the medications (Wynn et al. 2004; Zapor et al. 2004), 
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and increased CD4 count reconstitution compared with dual therapy and 
monotherapy (Chen, Hoy, and Lewin 2007; Detels et al. 1998; Hammer et al. 1997). 
Even with multiple drugs and drug classes, adherence is a key determinant of 
patient success on HAART, because risk of therapy failure (generally defined as a 
confirmed viral load of > 400 copies/ml, six months after the start of therapy or after 
a suppression of virus under that level (Republic of South Africa Department of 
Health 2004; United States of America Department of Health and Human Services 
2005)) is strongly associated with imperfect adherence (Cote and Godin 2005; 
Paterson et al. 2000; Republic of South Africa Department of Health 2004).  
Although resistance mutations will eventually emerge in the course of any long-term 
antiretroviral therapy regimen, the rate of the emergence of those mutations is 
related directly to the evolutionary cost of those mutations, where such cost is 
measured in terms of replicative capacity, and also to the rate of replication of HIV 
given the current drug regimen.  In consequence, imperfect adherence to a drug 
regimen will allow HIV to replicate at a higher rate, which in turn will lead to a more 
rapid turnover of virus, and thus a faster evolution of resistance to the current drug 
regimen.  Monitoring of adherence – and indeed, counseling to improve that 
adherence – is thus a key component of good HIV clinical care (Cote and Godin 
2005; Paterson et al. 2000). 
An additional set of concerns with HAART is that co-treatment with antibiotics 
for TB – common in many rollout settings including throughout South Africa – can 
complicate and affect both treatment regimens significantly.  First, TB drugs, 
especially rifampicin, may interfere with the pharmacoavailability of PIs, NNRTIs 
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(including an approximately 25% reduction in concentrations of EFV), and some 
limited reports of the NRTI AZT (Chideya 2007; McIlleron et al. 2007; Patel et al. 
2007), through rifampicin induction of cytochrome P-450 enzymes; while this can be 
avoided by use of an alternative formulation of rifampicin (rifabutin), this formulation 
is currently too expensive for use in rollout settings (McIlleron et al. 2007).  Second, 
HIV infected patients appear to maintain lower concentrations of oral TB drugs 
including isoniazid, rifampicin, pyrazinamide, and ethambutol (Chideya 2007; 
McIlleron et al. 2007), especially in individuals with lower CD4 counts.  Third, a 
review of relevant studies suggest that major TB drug toxicities, particularly 
hepatotoxicity, are more common among HIV-positive than HIV-negative patients, 
and among HIV positive patients more common among those receiving HAART, 
though results are not conclusive nor easily generalized to the developing world 
(McIlleron et al. 2007).  TB-associated immune reconstitution disease (IRIS) may 
accompany rapid recovery of immune function with HAART in TB co-infected 
individuals, and may pose a serious threat to patient health and ability to maintain 
adherence to HAART and/or TB drugs (McIlleron et al. 2007).  Last, some reports 
suggest that use of isoniazid, known to cause peripheral neuropathy on its own, may 
lead to greater incidence of severe peripheral neuropathy when used in combination 
with HAART, and especially the NRTI stavudine (Forna et al. 2007), a subject 
germane to aim 3 of this dissertation. 
Rolling out HAART worldwide. The extraordinary burden of HIV in sub-
Saharan Africa contrasts sharply with the resources available to cope with the HIV 
epidemic in this region.  Despite early (and not evidence-based) fears that 
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adherence would be difficult to maintain in the developing world, trials and field 
experiences have demonstrated excellent adherence in resource-poor settings, 
especially where drugs are provided for free (Coetzee et al. 2004; Orrell 2005; Orrell 
et al. 2003; Oyugi et al. 2004), and have demonstrated convincingly that HAART can 
effect a substantial improvement of outcomes in the developing world (Coetzee et al. 
2004). 
There are serious challenges in providing HAART in the developing world, 
however.  Some cohorts have had difficulty maintaining adherence over time 
(Byakika-Tusiime et al. 2005; Laurent et al. 2002), although some of this poor 
adherence may be attributable to the need to pay for drugs (Byakika-Tusiime et al. 
2005).  In addition, while viral load and CD4 cell count monitoring are commonplace 
in the United States and Western Europe and considered essential to clinical 
management in those settings, these tests are often financially or logistically beyond 
the means of many clinicians in many sub-Saharan African or other developed world 
settings (Cheruiyot Bii 2007; Colebunders et al. 2006).  Likewise, toxicity of 
antiretroviral medications is a significant problem in the developed world, but lack of 
alternative medications may make toxicity a more serious problem in resource poor 
settings (Boulle et al. 2007).  In many developing world settings, simple malnutrition 
and poverty are serious problems in their own right (Cheruiyot Bii 2007; Muula 2004; 
Ncayiyana 2004), compounding HIV-related diseases as well as potentially making 
toxicities more severe. 
Despite these difficulties, the global community has begun to move towards 
providing HAART to all those in need in both sub-Saharan Africa and worldwide 
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(United Nations Special Assembly 2001), with the goal of universal access to 
HAART by 2010 (WHO 2007, 2006), an extension of “3x5 Initiative”, which planned 
to put 3 million individuals in resource-poor settings on HAART by 2005 (WHO 
2005).  An estimated 2 of the 7 million people in need of HAART in low- and middle-
income countries in 2006 received treatment, including 1.3 of the 4.6 million in need 
in sub-Saharan Africa(WHO 2007). 
Rapid expansion of access to HAART has been enabled by international 
initiative such as the Global Fund (The Global Fund 2007) and the United States of 
America’s President’s Emergency Plan For AIDS Relief (PEPFAR) (USAID 2005) 
have committed and invested heavily to providing HAART to millions of individuals 
worldwide.  PEPFAR, for instance, has committed US$15 billion to efforts to provide 
HAART to 2 million individuals in 15 target resource-poor countries, including South 
Africa (USAID 2005).  Collectively, these efforts to expand HAART to all those in 
need are referred to interchangeably as a “rollout” and a “scale-up”. 
Rolling out HAART in South Africa. South Africa has one of the largest 
unmet needs for HAART in the world.  An estimated 325,000 of the approximately 1 
million people in need of HAART in South Africa were receiving HAART by 
December of 2006 (WHO 2007).  South Africa is perhaps unique in sub-Saharan 
Africa in the relative robustness of its public health and general infrastructure, 
making it an ideal staging ground for many early HAART programs.  Many of the 
technical and logistical difficulties of HAART provision in sub-Saharan Africa are less 
acute in South Africa due to greater healthcare infrastructure and resources, though 
of course substantial challenges remain, especially in providing HAART to 
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individuals in the lower-income “townships” and rural South Africa (South African 
National AIDS Council 2007). 
While the South African response to the HIV epidemic has been complicated 
and slowed by political controversy (AVERT.ORG 2007; Smith and Novella 2007), 
nonetheless by 2004 the South African government had begun providing 
antiretroviral drugs free of charge.  The “government era” of HAART provision began 
in the spring of 2004 in Gauteng Province (AVERT.ORG 2007, 2007), when the 
government dedicated US $62 million to the antiretroviral program rollout in 2004-
2005 (UNAIDS 2006) and establishing guidelines for the national HAART rollout 
program (Republic of South Africa Department of Health 2004). 
By the end of 2005, an estimated 200,000 individuals were receiving HAART 
in South Africa (Nattrass 2006), though many more remain in need.  The 
government of South Africa has continued to show a commitment to HIV and AIDS 
palliative and preventive care over the past few years, issuing a new, extremely 
ambitious five year plan to combat and treat HIV and AIDS (Kapp 2007), which 
hopes to “appropriate packages of treatment, care and support to 80% of HIV 
positive people and their families by 2011” (South African National AIDS Council 
2007).  Indeed, the effort to initiate large numbers of patients on HAART is only part 
of the larger effort to fight HIV and AIDS in South Africa (WHO 2007); other aspects 
of this effort concentrate on prevention of new infections through education, poverty 
reduction, and addressing gender based violence; addressing mother-to-child 
transmission of HIV; encouraging research into new prevention and treatment 
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technologies; reducing HIV-related stigma; and supporting the human rights of those 
with HIV and AIDS (South African National AIDS Council 2007). 
HAART provisioning programs in South Africa provide two full HAART 
regimens, one an NNRTI-based regimen, one a PI-based regimen, both with a 
double nucleoside analogue backbone; but, except where circumstances permit, no 
additional medications.  First-line HAART typically comprises stavudine (d4T), 
lamivudine (3TC),and either efavirenz (EFV) or nevirapine (NVP), and second-line 
HAART comprises zidovudine (AZT), didanosine (ddI), and lopinavir-ritanovir 
(Kaletra®) (Republic of South Africa Department of Health 2004).  In addition, some 
pregnant women receive lopinavir-ritanovir in place of nevirapine. 
HAART rollout and scale-up in resource-poor settings:  goals and 
challenges.  The overall goal of HAART is to optimize the treatment benefit for 
patients, maximizing survival as well as quality of life.  However, large scale rollouts 
of HAART in developing world settings – and in sub-Saharan Africa in particular, the 
region with the greatest need of HAART – pose a unique set of challenges due to 
several factors.  Among these are an extremely high rate of new patients initiating 
HAART and high throughput per clinic more generally, not enough doctors to treat 
these high numbers of individuals, geographically diverse settings in which HAART 
must be provided, limited options for alternative HAART regimens, and possibly 
limited available of some laboratory tests (Harries et al. 2007; Muula 2004; 
Ncayiyana 2004; Van Damme, Kober, and Laga 2006; Carpenter 2006; McCarthy, 
O'Brien, and Rodriguez 2006). 
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 Specific concerns, both public health and medically-oriented, have arisen 
from these general challenges, finding voice in numerous editorials and research 
reports.  Among the most prominent public health fears are whether a rollout might 
lead to the emergence of greater amounts of HIV drug resistance (Blower et al. 
2005; Ncayiyana 2004), and related concerns about public health infrastructure and 
the ability to ensure an uninterrupted drug supply to rural settings (Harries et al. 
2007; Muula 2004).  Others have voiced the concern that a HAART rollout might 
exacerbate existing socio-economically-based health inequalities (Egger et al. 
2005).  Underlying all these concerns, however, lies the more fundamental question:  
can we maintain a high quality of patient care in a rollout situation, despite the 
aforementioned obstacles and challenges? 
The WHO has proposed a public-health approach to solving these problems 
(Gilks et al. 2006), emphasizing standardized treatment regimens, simplified clinical 
decision making, emphasizing the “four Ss” (“start; substitute for toxicity; switch 
treatment after failure; and stop, moving to end-of-life care”), simplified management 
of the threat of the emergence of HIV drug resistance, and decentralized provision of 
care, including shifting of many clinical responsibilities from doctors to mid-level 
health care workers including nurses and physicians assistants.  In practice many of 
these guidelines are being followed, and problems solved, but many questions 
remain unresolved within the context of this approach.  A report from WHO 
investigators notes that “Gaps in knowledge have limited the standardisation [sic] of 
some treatment approaches; others have not yet been adequately assessed.”  
Among the key questions that remain unanswered are “How is failure best 
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defined?...[How can we] construct clear and simple protocols for switching 
therapy[?]” (Gilks et al. 2006) 
Other unresolved challenges are hybrids of substantive and methodological 
issues.  The nature of a rollout is such that there are rarely enough personnel or 
resources to follow-up all individuals who fail to return for a scheduled visit (though 
attempts are made); thus, there is likely to be significant loss to follow-up in most 
scale-up situations, a situation which may worsen with time, as total enrollment 
increases and resources are stretched ever thinner.  At the same time, cohorts 
which track down a portion of those who do not return to clinic, typically find that 
between ½ and 2/3 of those patients on whom vital status can be ascertained are 
dead.  For instance, in one study in Botswana, of 68 patients categorized as lost in 
passive follow-up, 40 were categorized as dead in active follow-up (Bisson et al. 
2007); the Themba Lethu Clinical Cohort in Johannesburg, South Africa has found 
similar results.  Likewise, in a conference abstract, Stafford et al. reported that 
Zambian patients who were lost to follow-up resembled deceased patients in 
measured covariates and time-to-event analysis (Stafford et al. 2007), and suggest 
that the majority of patients lost to follow-up ought to be included in mortality 
estimates. 
Thus, using complete case analysis in a situation of substantial loss to follow 
up – characteristic of rollouts in general and our rollout in Johannesburg particularly 
– can result in biased estimates of mortality (Anglaret et al. 2004) or of risk factors 
for mortality.  One possible solution to this problem is suggested by Martin et al. of 
the IEDEA Consortium in a conference abstract (Martin et al. 2007):  a validation 
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sub-study, in which investigators try very hard to find the true vital status of a 
random sample of lost to follow-up patients; because the validated patients are a 
random sample, their vital status can be regarded as an unbiased estimate of the 
vital status of all those lost to follow-up. 
There are two key problems with this approach:  first, many people who 
become lost to follow-up – especially in longer term historical cohorts such as the 
TLCC – will be difficult to track down, and continuing stigma attached to HIV 
diagnosis may make cause of death or even vital status itself difficult to ascertain 
with confidence.  Second, estimate from this technique will remain unbiased only if 
those who cannot be tracked down despite these efforts (22% in Martin et al.) are 
themselves an unbiased sample, which will be difficult to verify in the small sample 
size mandated by this technique.  While this may well improve our estimates of raw 
mortality, it may introduce substantial bias in causal estimates for outcomes if 
reasons for unverifiable loss to follow-up correlate with reasons for the outcome of 
interest.  In addition, while validation sub-study approaches may work well for 
unambiguous outcomes such as vital status, their use of such an approach in a 
study of an outcome such as virologic or immunologic success or drug toxicity is 
likely to introduce substantial misclassification of the outcome.  We propose that 
inverse probability weighting and multiple imputation to solve the problem of 
informative censoring more robustly. 
A lesser methodological issue – addressed by some reports but not others – 
is that of repeated outcomes measures.  Most reports on rollout outcomes 
concentrate on six-month increase in CD4 count; it is clear that twelve-month 
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increase is also an important measure of treatment success.  Because CD4 
measures are strongly correlated within individuals, appropriate models must be 
used to account for inter-individual correlation.  In addition, there is good evidence to 
support the idea that CD4 count rises more rapidly in the first six months of therapy 
than in the next 12-18 months; and then plateaus around 24 months after HAART 
initiation.  Thus, modeling CD4 count over time requires both random effects models 
to account for correlations within individuals, as well as static change points to 
account for changing slopes of CD4 count over time. 
Last, many rollout reports have taken a somewhat narrow, medical view of 
public health problems.  For instance, it is obviously important to characterize the 
reasons for drug substitution, especially those reasons which relate to toxicity.  
Enumerating the particular risk factors for a particular drug toxicity – say, lactic 
acidosis associated with stavudine – allows clinicians to monitor obese women (at 
particular risk of the condition) more closely.  But because lactic acidosis is rare, the 
positive predictive value of obesity and female gender for the condition is likely to be 
quite low; thus, we will not necessarily achieve better outcomes at the population 
level by removing stavudine from the first line regimens of all obese women.  
Another question, perhaps better for the whole population, is “who is likely to require 
a stavudine substitution within 18 months of initiation on the drug?”  This question, 
answered well, may lead us more quickly to an ability to consider customization of 
initial HAART regimen in those at high risk of substitution. 
Thus, key data analysis challenges of rolling out HAART on the massive 
scale required to meet the stated goals of the WHO and other organizations include 
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evaluating overall effectiveness of HAART in settings with continuing stigma of HIV 
infection, significant loss to follow-up, and a lack of resources to track down patients 
who do not return to clinic; lack of options, resources, and time to enable the 
customization of HAART regimens to individuals; the related problems of drug 
toxicity compounded by poor nutritional status of HIV-infected individuals; basic 
problems of maintaining quality of care while expanding treatment access as rapidly 
as possible; and possible local constraints on laboratory test availability. 
 
REPORTS OF HAART ROLLOUTS 
 
Approach to literature review.  The main search to find evaluations of 
HAART rollouts in the developing world was performed in the NLM PubMed 
database with the search term [(“scale-up” or “scale up” or “roll out” or “rollout” or 
“rollout” or "scaling up" or "scaling-up") AND (“antiretroviral therapy” or “antiretroviral 
therapy” or “ART” or "HAART”) AND ("HIV" or "AIDS")].  This search returned 120 
articles, which were reviewed by hand for inclusion.  Other searches for other topic 
areas were performed similarly, with search terms such as “drug substitution 
antiretroviral toxicity” (18 results), “stavudine substitution antiretroviral toxicity” (5 
results), and “stavudine switching antiretroviral toxicity” (9 results).  Additional 
references were found by examining relevant references from articles already found, 
as well through use of the PubMed “related articles” search option.  Finally, abstracts 
from recent relevant conferences were searched and reviewed, including 14th 
Conference on Retroviruses and Opportunistic Infections (CROI 2007) and the 4th 
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International AIDS Society Meeting on HIV Pathogenesis and Treatment (IAS 2007), 
using similar search strategies. 
The main literature review in each of the following sections includes only 
reports from sub-Saharan Africa, which is the focus of our investigations and of the 
bulk of scale-up efforts.  In addition, in the main literature review we wish to address 
only HAART rollouts or efforts to scale-up HAART access.  Rollouts are 
characterized chiefly by very high volume of new enrollments of patients – while 
there is no absolute rate of new patient enrollment and initiation that meets this 
definition, a review of the literature suggests that defining a rollout as a cohort which 
enrolls approximately 50 new patients per month for 9 or more months is an 
acceptable lower limit for defining a rollout. 
After the main literature review is completed, selected additional studies are 
reported, including conference abstracts and reports from non-sub-Saharan rollouts, 
where they provide appropriate and valuable context.  
 Reports of HAART rollouts:  methodological challenges and substantive 
gaps.  Articles relevant to evaluating outcomes of HAART in sub-Saharan Africa in a 
scale-up context are reviewed below.  It is worth noting that in most of the studies 
reviewed below, the baseline characteristics of those initiating HAART are similar:  
more than half and as many as 70% of those initiating HAART are women; many 
individuals have a body mass index (BMI) < 20, CD4 counts less than 50 cells/mm3, 
and/or are in WHO stage III or IV HIV disease.  The vast majority of patients in these 
studies initiated HAART with d4T or AZT, 3TC, and EFV or NVP. 
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In most settings, as well, the overall conclusions are the same; a summary of 
the major findings of outcomes from key studies is shown in Tables 1.1, 1.2, and 1.3.  
Rates of viral suppression are typically 75%-85% at 6 months or earlier among those 
still in therapy and with viral loads available for analysis; median CD4 gain by month 
6 (among those remaining in therapy with CD4 counts available) is approximately 
100-110 cells.  More qualitatively, nearly all studies found similar associations 
among baseline risk factors and key outcomes.  For instance, for the outcome of 
death, baseline characteristics of low CD4 count, low BMI, WHO stage IV (and to a 
lesser extent III) and – in some studies – male gender – was found to be associated 
with increased hazard or risk of death consistently in nearly every study that 
examined such associations. 
There is substantially more variation in mortality and loss to follow-up (as 
shown in Table 1.1), with values ranging from 0%(Severe et al. 2005) to 
19%(Ferradini et al. 2006) depending on setting and rollout design (though nearly all 
studies saw the majority of deaths occur in the first three to six months of follow-up).  
The issue of loss-to-follow-up – which was often found to be associated with key 
characteristics predictive of death in these studies including low CD4 count and low 
BMI at baseline – is a key issue for a large scale rollout of HAART.  Furthermore, it 
seems likely that if differential and informative loss to follow up were accounted for, 
six and twelve month CD4 gains as well as other outcomes (such as weight gain) 
might also change.  Accordingly, we will review key methodological aspects of 
published literature evaluating rollouts of HAART (or equivalent, high-capacity 
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HAART provisioning situations) in the developing world, to see where bias may be 
introduced into estimates of key outcome parameters. 
Outcomes in rollouts:  peer reviewed reports.  The following will review 
only peer-reviewed reports of rollouts of HAART in the sub-Saharan Africa; 
conference abstracts and additional peer-reviewed studies from non-sub-Saharan 
Africa locations are reviewed below. 
Stringer and colleagues (Stringer et al. 2006) initiated 16198 individuals 
onto HAART in 18 clinical centers in the Lusaka district of Zambia over 
approximately 18 months, with funding from PEPFAR, the Global Fund, and other 
sources, a mean enrollment rate of 50 patients/month/site initiated.  All drugs and 
clinical care were provided for free.  There was significant loss to follow up in this 
cohort, with over 3400 of the 16198 individuals recorded as more than 30 days late 
for a pharmacy appointment.  Enrollment characteristics were typical of a rollout 
setting, and 11% of patients had active tuberculosis at baseline; outcomes are 
described in Table 1.1 above.  Median follow-up time was less than six months. 
Stringer et al. used Cox proportional hazards models, and “accounted for 
imperfect ascertainment of death increasing over time by including a term to adjust 
for calendar time at the initiation of therapy”, noting that follow-up teams may have 
less opportunity to trace individuals who go missing if they disappeared later in the 
18 month assessment period.  They used mixed (random effects) models with 
individual random intercepts to assess CD4 gain over time.  They performed 
sensitivity analysis indicating that that “some predictors of failure or death also 
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predicted loss to follow-up”, concluding that “loss to follow-up likely represents a 
heterogeneous mixture of individuals, including some who have died”. 
The main limitation of this work was the authors’ approach to analyzing 
individuals lost to follow-up was somewhat naïve; given that 21% of patients became 
lost during follow-up, there is an enormous potential for bias in estimates of mortality 
and relative risks of various covariates for outcomes.  As noted previously, this 
problem can be addressed with inverse probability weighting (see Methods section), 
both of which allow data analysts to estimate the outcomes without bias in the 
presence of informative censoring given an assumption of no unmeasured predictors 
of both outcome and missingness.  While they concluded that “some” of those lost to 
follow-up had died, Cox proportional hazards models assume that those who are 
missing died in the same proportions of those who died; that is, that perhaps 7% of 
lost individuals had died.  Our experiences in the Themba Lethu Clinical Cohort 
suggest strongly that the proportion of lost individuals who have died is as high as 
50%, suggesting that – sensitivity analysis aside – their estimates of death are 
significant underestimates. 
Other shortcomings of the work included relatively short median follow-up 
time (207 days among those who initiated ART); lack of control for correlation within 
clinical sites with either random effects or GEE models; lack of control for duration of 
active TB treatment at baseline; and that some categories used in their analyses do 
not appear to coincide well with internationally accepted standards of (for instance, 
BMI < 16 is not a standard category).  However, in most respects aside from dealing 
 21 
with informative censoring, the authors were admirably methodologically 
responsible. 
Libamba and colleagues (Libamba et al. 2005) report on 13183 patients 
(12527 of them adults) in Malawi who were initiated on antiretroviral therapy at 24 
health facilities over approximately 10 months, a mean enrollment rate of slightly 
more than 50 patients/month/site.  They note that approximately as many people 
who were found to be dead were found to be missing or lost to follow-up (in both 
cases, 8% at one year).  They reported secondary outcomes (including quality of life 
measures) among those alive and still on therapy, excepting those for whom there 
was poor or incomplete information, or where clinics were too busy to record the 
information.  They reported no results from any kind of multivariable analysis. 
The lack of multivariate analysis is obviously the largest methodological deficit 
in this study.  Such an analysis would need to control for correlations within site of 
treatment, as well as for site-specific effects and characteristics – for instance, the 
authors noted that patients had to pay for medications only in some clinics.  In 
addition, their reports of secondary outcomes could be systematically flawed if 
patients at busier clinics are less often reported and have worse outcomes. 
Fairall et al. (Fairall et al. 2008) and colleagues presented a sophisticated 
analysis of a population of 14267 individuals of whom 3619 received HAART during 
follow-up, initiating about 48 patients per site per month on HAART.  Fairall et al. 
used marginal structural models (see Methods) to examine the effect of HAART and 
(separately) cotrimoxazole therapy on HR for death in their cohort, finding that both 
markedly reduced HR of death, while use of HAART increased weight and CD4 from 
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baseline, and was protective for incidence of tuberculosis.  While this study reports 
some high level outcomes such as CD4 count only in passing, it is a rigorous and 
thorough study of survival and other outcomes in the context of HAART in the 
developing world. 
In a model including both individuals who initiated HAART and those who did 
not, Fairall et al. found a reduced hazard of mortality among individuals who had TB 
at baseline in a model which controlled for a number of other important factors (HR = 
0.71, 95% CI 0.56-0.90).  This is a counterintuitive finding, and the authors suggest 
that, despite the fact that it was reported as applying to all individuals (Table 1.1), 
this reduced hazard of mortality associated with baseline TB “was only true for 
patients who did not receive HAART.”  They also suggested that the finding might be 
due to selection bias due to left truncation, in that the sickest patients with 
tuberculosis may have died before entering care. 
Wools-Kaloustian (Wools-Kaloustian et al. 2006) and colleagues reported 
on 2059 individuals initiated on HAART between November 2001 and February 
2005 in Kenya, a mean of 52 patients/month enrolled.  They reported 5.4% mortality 
and 24.5% loss to follow-up; other outcomes are summarized in Table 1.1.  They 
also assessed weight gain directly as an outcome.  The authors used Kaplan-Meier 
methods and log-rank tests, and Cox models, for survival outcomes; they used 
random effects models to model change in square-root of CD4 count with a change-
point mixed model (apparently implemented using a constant or linear b-spline) with 
within-subject random intercepts and slopes.  They used similar models for 
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longitudinal models of change in weight.  The authors excluded all pregnancies from 
their analysis, and median follow-up time was 40 weeks. 
The methods used for change in CD4 count and weight were appropriate, 
accounting for the correlation of CD4 counts within individual, while allowing slope of 
CD4 increase to change with time.  This represents directly the way that CD4 
changes are typically large in the first three to six months of HAART, but rate of 
change declines thereafter, eventually flattening out around 2 years post-HAART 
initiation (Chu et al. 2005).  Another strength of this paper is that it assessed weight 
gain directly as a clinical outcome.  This is important because in many rollout 
settings, CD4 monitoring may not be available; as such, weight may be an important 
means of assessing success on HAART. 
However, this study suffered from large loss to follow-up over the study period 
in comparison to total recorded mortality (24.5% vs. 5.4%); this strongly suggests 
that without imputations of outcomes for those lost to follow-up, conclusions drawn 
from survival analysis of these data are likely to be biased.  Additionally, they note 
that self-pay patients in the cohort did not have all laboratory testing done at all time-
points.  A large multi-center study (Braitstein et al. 2006) saw a clear association 
between the need to pay for drugs and worse outcomes of HAART; if those in the 
Kenya study who had to pay for medications also had worse outcomes, this would 
result in a bias of laboratory outcomes (CD4 gain, viral suppression) that would 
make the program look as if it had performed better than it was indeed performing, a 
limitation acknowledged by the authors. 
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Ferradini and others (Ferradini et al. 2006) published on 1308 patients in a 
scale-up in rural Malawi, enrolled over a period of several years (rate unclear, but 
apparently accelerating).  They found 19% mortality at a median of 36 weeks of 
follow-up, 7% loss to follow up, and median CD4 gains of 138 and 176 at six and 
twelve months.  Their analysis was intention-to-treat, and they analyzed both known 
deaths as an outcome and the combined outcome of dead or lost to follow-up.  
Otherwise their methods were straightforward, making use of Cox proportional 
hazards models, logistic regression, and similar methods.  Virologic outcomes were 
assessed among those still in therapy at 6 months.  Last, they used the outcome of 
virologic success to validate their adherence measures. 
There were a number of methodological shortcomings of this work. Their Cox 
models to find important predictors of early mortality (within six months) did not 
account for informative loss to follow-up – since early losses to follow up is exactly 
those most likely to be related to death, their results are likely to be biased in this 
analysis.  Similarly, if early virologic failure is related to death, then assessing 
virologic outcomes only among those still in therapy will provide an overestimate of 
true virologic outcomes.  They failed to report or control for tuberculosis in any 
analyses.  Last, they apparently performed no modeling of predictors of CD4 gain, 
an important outcome. 
Hawkins et al. (Hawkins et al. 2007) reported on 1286 patients enrolled over 
24 months from 2004 to 2006, a mean enrollment rate of 54 patients/month.  They 
observed an extremely low risk of death (1.1% in median 350 days follow-up), but 
435 (34%) patients were lost to follow-up.  They saw mean gains in CD4 counts of 
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169 and 208 cells/mm3 at 6 and 12 months, respectively.  They used Cox models, 
including switching therapy as a time-varying covariate.  The authors did not attempt 
to model LTFU.  HAART was not provided for free in this cohort. 
There are two serious methodological issues with this analysis.  First, the 
extremely high loss-to-follow-up rate, due in part to passive patient reporting 
systems which they note are characteristic of low-resource settings, undoubtedly 
explains the very low observed risk of death; in addition, this loss to follow-up rate 
likely contributes to higher than typical mean CD4 gain at six and twelve months by 
selecting for those with better immunologic response to HAART.  Second, using 
traditional Cox models to account for time-varying therapy – which is confounded in 
a time-varying way by CD4 count, a confounder which is also affected by prior 
exposures – will result in biased estimates of effect if proper methods (e.g., inverse 
probability of treatment weighted marginal structural Cox proportional hazards 
models) are not utilized (Hernan, Brumback, and Robins 2000; Robins, Hernán, and 
Brumback 2000). 
Lawn and colleagues have published a series of papers describing a rollout 
cohort in Cape Town, South Africa, including the burden and incidence of 
tuberculosis and effect of tuberculosis on HAART outcomes (Lawn, Badri, and Wood 
2005; Lawn et al. 2006), CD4 gain among those who initiated HAART by baseline 
CD4 counts (Lawn et al. 2006), early mortality (Lawn et al. 2005), and reasons for 
both mortality and “nondeath losses” (Lawn et al. 2006).  Separately, Bekker et al. 
(Bekker et al. 2006) reported outcomes on many of the same individuals. 
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In a paper examining early mortality (Lawn et al. 2005) Lawn et al. reports 
that 66% of first-year deaths in this cohort occur within the first 90 days of HAART 
initiation.  They found that major predictors of death included WHO clinical stage 3 
or 4 disease and a baseline CD4 count < 50.  In contrast to other studies, they did 
not find any significant effects of age or sex on risk of death. They used (what 
appears to be) generalized estimating equations-based maximum likelihood 
regression accounting for inter-individual correlation with an exchangeable working 
correlation structure robust standard errors to model associations between mortality 
rate and treatment status as treated.   
The authors did not account for informative loss to follow-up in this study, 
possibly because loss to follow-up was quite small (4%).  The as-treated nature of 
this analysis makes it unique among papers reviewed here; all other reports have 
taken an intent-to-treat approach.  While this alternative approach is admirable in 
that it may give us a better estimate of the true effect of antiretroviral therapy on 
mortality, an intent-to-treat analysis may well give us a better idea of the outcome of 
individuals initiated on HAART in a rollout setting, taking into account all 
management available to them.  In addition – as with Hawkins et al., above – 
because  the relationship of treatment status to mortality may be confounded by 
CD4 count in a time-varying manner, and CD4 counts themselves may by affected 
by treatment, then these results may be biased when the stratification techniques 
typical of standard maximum likelihood regression are used rather than inverse 
probability of treatment weighting techniques used with marginal structural models 
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(Cole et al. 2003; Hernan, Brumback, and Robins 2000; Robins, Hernán, and 
Brumback 2000). 
Lawn and colleagues also analyzed CD4 count increases in pre-specified 
time-spans (0-16 weeks, 16-32 weeks, and 32-48 weeks), thus accounting for 
changing slopes over time (Lawn et al. 2006).  In addition, they examined a 
dichotomous “immunologic non-response” CD4 cutoffs of 50 cells/mm3 gained by 48 
weeks, as well as dichotomous cutoffs of CD4 count ≥ 200 cells/mm3 and 500 
cells/mm3 by 48 weeks.  They used linear regression to examine rate of CD4 
increase within time period, and logistic regression to examine factors predicting 
success reaching the dichotomous targets.  One potential drawback of this 
methodology is that it fails to account for intra-individual correlation, which might be 
addressed using a random effects or GEE model. 
In addition the authors do not account explicitly for the possibility of 
differential CD4 recovery rates among those lost to follow-up in this cohort analysis.  
However, they do comment on the potential bias that might result from such 
informative censoring, arguing that resulting bias is likely to be small because 
(among other things) the majority of deaths that occurred in this cohort happened 
earlier (and thus are unlikely to be related to immune reconstitution) and also that, 
although “WHO clinical stage of disease is the strongest predictor of death in this 
cohort…this variable was not associated with CD4 cell responses.”  If those who 
died early were profoundly immunocompromised, and such immune status affected 
their CD4 recovery rates, then estimates of CD4 recovery will be biased.  However, 
as the primary concern with individuals who do not receive follow-up treatment may 
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be their overall survival, the as-treated assessment of CD4 count among only those 
who remained in the cohort may be useful in its own right for assessing (for 
instance) whether CD4 gain is adequate among those who remain in care.  For 
these purposes, this modeling approach is likely adequate.  However, if we were to 
decide that the CD4 gain in the entire cohort was important, then  modeling the 
combined risk of death and CD4 reconstitution is a situation which might be better 
served by a zero-inflated (or hurdle) linear model, where the data analyst first 
models the dichotomous outcome of survival, and then subsequently models the 
increase in CD4 cell count among the survivors. 
Separately, logistic regression may have been a poor choice for predicting 
virologic success, because odd ratios derived from logistic regression are known to 
overestimate the (more-interpretable) risk ratios when events are common, and the 
dichotomous events being modeled here are fairly common (for instance, 49% of 
patient with baseline CD4 count < 50 failed to achieve a CD4 count of 200 cells/mm3 
at 48 weeks). 
Last, Bekker and colleagues (Bekker et al. 2006) reported on 1139 
individuals initiated on HAART over three years in Guguletu South Africa, with an 
initiation rate of 58 patients/month in the last year of enrollment.  Their reporting of 
outcomes were quite limited, noting only that virologic suppression was assessed in 
those who were not dead or lost to follow up.  This cohort experienced relatively little 
loss to follow-up:  only 3% of patients were lost, compared to 7% who were 
confirmed dead.  In addition, they compared outcomes across all three years of 
enrollment using various non-modeling statistical techniques.  Compared to the first 
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two years of enrollment, during the third year fewer patients presented in WHO 
Stage IV and patients presented with higher median CD4 count, suggesting that 
patients were presenting earlier in disease course. 
Due to the paucity of methods and more-advanced outcomes presented, it is 
difficult to comment further on this report. 
Outcomes in rollouts:  reports from conference posters and abstracts. 
Very little information is available on methods used in any of these reports, due to 
their being derived from brief conference reports, from the 4th International AIDS 
Society Conference on HIV Pathogenesis, Treatment and Prevention and the 2007 
Conference on Retroviruses and Opportunistic Infections. 
El-Sadr and colleagues (El-Sadr et al. 2007) reported at the 4th International 
AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (2007) 
on 171259 patients enrolled at 151 sites throughout seven African countries 
(approximately 1100 individuals per site); unfortunately, because these results are 
only available in abstract form, a close evaluation of the methods used here are not 
available. In addition, the authors reported significant variation in results by country. 
Marlink et al. (Marlink et al. 2007) reported at CROI 2007 on 134120 people 
who initiated HAART in Côte d’Ivoire, South Africa, Tanzania, and Zambia 
(apparently including those who Stringer (Stringer et al. 2006) reported on below).  
After 28 months of follow-up, 93312 individuals remained in care, with 5% recorded 
deaths, 7% transferred or lost to follow-up, and 5% unknown.  There was little 
additional information given by Marlink et al. on methods or definitions. 
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Meloni et al. (Meloni et al. 2007) reported in a poster at CROI 2007 on 9070 
people who initiated HAART in six different sites Nigeria.  After 6 months of follow-
up, median CD4 had increased from baseline 128 cells/mm3 to 252 cells/mm3, and 
between 80 and 90% of patients were still in care (depending on site).  After 12 
months, median CD4 was 286 cells/mm3, and between approximately 73 and 92% 
of individuals were still in care.  The authors reported significant by-site 
heterogeneity of results. 
Mosoko et al. (Mosoko et al. 2007) reported on 2920 individuals in 
Cameroon, with fairly low rates of “alive and in care” outcomes at follow-up (see 
Table 1.2).  They found that age < 30, male gender, large distance (>150km) from 
clinic, and self-pay status for ARV drugs were associated with increased hazard of 
the combined dropout or death outcome.  However, HAART was not provided for 
free in this cohort. 
Outcomes in rollouts:  other peer reviewed reports (non-rollouts) 
The following reports are not from sub-Saharan African rollouts (though some are 
from sub-Saharan Africa, and some might arguably considered rollouts), but are 
helpful in assessing the wider context for this work. 
Calmy and colleagues from Médecins Sans Frontieres(MSF) (Calmy et al. 
2006) report outcomes of fixed-dose combination HAART (comprising d4T-3TC-
NVP) in 6861 patients at 21 MSF sites in Africa (~75%) and Asia (~25%).  They saw 
comparable proportions of deaths and individuals lost to follow up in a median of 4.1 
months of observations.  In the sub-cohort with at least 12 months of exposure, 
there was substantially more loss to follow up (from 4.8% overall to 9.3%).  The 
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authors caution against over-interpretation of their data due to short (median 18 
weeks) follow-up times overall. 
Calmy et al. used sensitivity analysis to ensure that their Kaplan-Meier 
estimates of risk factors were well-bounded.  They first used death as the outcome; 
and secondarily used death or lost to follow-up as an outcome, thus bounding the 
effect of loss to follow up on causal estimates of risk factors.  This approach has the 
advantage of giving us a worst-case estimate; but it does not help the reader assess 
what values are more likely within the range of best case to worst case scenarios.  It 
is unclear how much influence losses may have on accounting for those lost to 
follow-up.   
The ART-LINC collaboration (Antiretroviral Therapy in Lower Income 
Countries) is an international collaboration of treatment cohorts (Dabis et al. 2005).  
The goal of ART-LINC is  
to define the prognosis of HIV-1 infected patients treated with HAART in 
resource-limited settings; (ii) to compare the experience between different 
settings, delivery modes and types of monitoring; and (iii) to compare 
prognosis in resource-limited settings with that observed in industrialized 
nations. Importantly, both individual and programme level characteristics are 
of interest in this context.” (Dabis et al. 2005)   
 
They found an increased hazard of death in the first six months of HAART 
comparing low to high income countries (adjusted HR 4.3, 95% CI 1.6-11.8), and 
that in low-income countries the adjusted hazard ratio associated with free treatment 
compared to not-free treatment was 0.23 (95% CI 0.08-0.61). 
None of the developing world sites appeared to be rollout sites, which may 
limit generalizability to HAART rollout in sub-Saharan Africa. The authors used 
random-effects Weibull regression to model mortality with random effects accounting 
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for different treatment programs, with bootstrapped confidence intervals; this is a 
flexible proportional hazards model appropriate for highly stratified data (with strong 
heterogeneity between programs) (Carlin and Hodges 1999). 
In addition, the authors used multiple imputation techniques to fill in missing 
values of WHO disease stage, allowing them to use much more data than otherwise 
would have been available in a complete case analysis.  Last, the extremely strong, 
significant hazard ratio for death associated with free treatment compared with 
treatment-for-fee (0.23, 95% CI 0.08-0.61) in low income countries suggests that 
studies which do not either report or control for need to pay for HAART in rollouts will 
be difficult to interpret. 
Koenig, Léandre, and Farmer (Koenig, Leandre, and Farmer 2004) report 
on scaling-up directly observed HAART in rural Haiti, in which approximately 1050 
individuals were enrolled on HAART in the first year of scale-up.  Koenig et al. saw 
almost no mortality or loss to follow-up among the first 100 of the 1050 individuals 
receiving directly observed therapy (DOT)-HAART, and living in the area served by 
community health workers (also called accompagnateurs).  While these results are 
very impressive in light of substantially higher mortality seen in other scale-up 
efforts, several aspects of these data may limit their generalizability in both data and 
implementation practices.  First, while there was no mortality in this group, the 
background of malnutrition and co-infections may differ from Haiti to other 
developing world locations, and in particular may differ from conditions in Africa, 
where the scale-up is most important in terms of sheer numbers of individuals in 
need.  Second, Koenig et al. report that individuals who lived outside of the area 
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served by accompagnateurs were not eligible for DOT-HAART, but that 29 in 100 
evaluated patients in this group died in the first year.  This opens the question of 
whether a less personnel-intensive scale-up program – one that did not use 
accompagnateurs and DOT-HAART – might have reached more people and 
minimized deaths overall, or whether the accompagnateur-focused effort is useful in 
both ensuring good outcomes among those who start HAART and limiting onward 
transmission or the transmission of drug resistant HIV.  We conclude that at present 
the circumstances of the Haitian rollout are not easily generalizable to African 
rollouts. 
Severe and colleagues (Severe et al. 2005) reported on initiation and 
outcomes of HAART in 1004 individuals in Haiti beginning in March 2003 over 14 
months, a rate of approximately 71 individuals per month (Severe et al. 2005).  
Individuals were initiated on therapy when their CD4 counts were below 200 
cells/mm3, or if they had an AIDS defining illness, and were treated with AZT-3TC-
EFV, and d4T was sometimes substituted for AZT.  All clinical care, treatment, and 
antiretroviral drugs were provided free of charge.  CD4 tests were performed 
regularly, but viral load measurements were not available clinically.  Only 8% of adult 
and adolescent patients (hereafter, adult patients) had tuberculosis in this study, 
limiting this study’s generalizability to sub-Saharan Africa.  Analysis was intent-to-
treat and used straightforward regression methods such as Cox proportional 
hazards modeling for multivariable survival analysis. 
Severe et al. reported an overall one-year survival of 87% using a Kaplan-
Meier estimator.  Approximately 7% of individuals were lost to follow-up by analysis; 
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however, the authors report that individuals lost to follow-up most often because 
they returned to their villages from the urban center where the clinic was located, 
and did not differ from those not lost to follow up by any baseline characteristics 
including age, sex, CD4 T-cell count, body weight, or stage of HIV infection, 
suggesting that censoring these individuals will not seriously bias the results of this 
study. 
However, patients who return to their villages might be better classified as 
“transferred out” rather than “lost”, in that we indeed have information on them.  It is 
possible that individuals truly lost to follow up – a subset of those identified as “lost” 
in this study – have different outcomes, and that the mixing of the populations of 
truly lost and transferred out patients causes Severe to mistakenly conclude that 
those who are lost are more like those who are not lost than is truly the case.  
However, the overall percentage of those lost to follow up is relatively low, and so 
such an effect is unlikely to substantially change mortality estimates. 
Etard et al. (Etard et al. 2006) reports on 7-years of follow-up (median 199 
weeks of follow-up) in 404 patients.  This study is too small to be properly 
considered a rollout, and thus the methodological challenges of analysis are 
somewhat different.  Their follow-up was quite good (7 individuals lost to follow-up in 
the first year).  It is worth noting though, that Etard et al. took the same “sensitivity 
analysis” approach to loss to follow-up, assuming that the patients were dead to 
bound possible mortality estimates. 
One additional study worth noting here (not included in Table 1.3) is by Van 
Cutsem et al. (Van Cutsem et al. 2007), reviewing five years of follow-up in a public-
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sector antiretroviral clinic in Khayelitsha, Cape Town, South Africa.  They enrolled 
2565 patients (70% female) over the five years, or approximately 40 new patients 
per month (compared to 200 per month in Themba Lethu).  Six month mortality 
declined from 12.4% in 2001 to 5.4% in 2005; some of that may be attributable to 
loss to follow-up, which increased from none to 3% in that same time period – very 
low losses by rollout standards.  At 54 months, they estimated 78% (95% CI 74-82) 
of patients remained in care.  They do not report tuberculosis co-infection rates or 
rates of switching, and do not describe their methods in depth in this brief 
conference report. 
 Summary of literature review on outcomes of rollouts and other large 
HIV cohorts.  Many reports have indicated that rollouts can achieve significant 
success in improving laboratory markers and clinical outcomes of HIV disease 
status, even while rolling out HAART quickly and on a massive scale.  Despite 
widely varying estimates of mortality among studies, there is a qualitative consensus 
among these studies that low CD4 count, low BMI, poor adherence to HAART, and 
HAART-for-pay all contribute to early mortality.  Likewise, there is generally 
qualitative and quantitative agreement about median CD4 cells gained among 
individuals initiating HAART within six and twelve months and about percentage of 
individuals who can be expected to suppress virus within six months of initiation. 
Yet taken together, these studies suffer from serious flaws: they lack 
extensive documentation of outcomes after six months; they are frequently 
statistically and methodologically naïve, especially with regards to dealing with 
informative loss to follow-up, a major challenge in a rollout setting, and thus give 
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inaccurate pictures of mortality, other key outcomes, and of estimates of predictors 
of those outcomes; many reports ignore tuberculosis co-infection (see below); and 
while most of these studies achieve qualitative consensus as mentioned, there are 
serious disagreements among them as to the magnitude of effect measures relative 
to each other, due to differing methodologies, poor follow-up, and other issues. 
Our research on the Themba Lethu Clinical Cohort will remedy many of these 
shortcomings.  We have documentation of outcomes greater than 6 months, in some 
individuals as much as 3 years of follow-up.  Large sample size will allow us to 
control for many confounders of these outcomes simultaneously while maintaining 
good power.  And will deal with loss-to-follow-up in a methodologically more-
sophisticated way that will help us estimate mortality and relative influences on 
mortality both more accurately and more precisely. 
 
TUBERCULOSIS:  BIOLOGY AND TREATMENT IN THE CONTEXT OF HIV 
 
Mycobacterium tuberculosis.  Tuberculosis (TB) is the infection of the lungs 
(pulmonary TB) or other organs (miliary TB) with the aerobic bacterium 
Mycobacterium tuberculosis; here we will focus exclusively on pulmonary TB, 
hereafter TB.  TB is typically transmitted by direct inhalation of aerosolized droplets 
produced by an infectious individual, often through coughing.  Bacteria which reach 
the lungs of an exposed individual commence primary infection, which is contained – 
though not eliminated – by the immune system, particularly by alveolar 
macrophages, in about 95% of cases; the remainder develop active disease.  In the 
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majority of the remaining 95% of individuals, the mycobacteria remain contained by 
the immune system for the rest of the infected individual’s life, without incident. 
However, in about 5% of total individuals infected, TB will reactivate later in life, 
often at a time of immune compromise (such as older age) (Weinberger 2004; WHO 
2007).  In addition, TB can disseminate through the blood or lymph, and a small 
number of people develop TB in organs other than the lungs or miliary 
(disseminated) TB (Weinberger 2004), but these diseases are quite rare among non-
immunocompromised individuals.  However, in HIV-infected individuals, the 
probability of developing active TB of any sort is much higher, due to the attendant 
immunosuppression (Weinberger 2004; WHO 2007), with some estimates of annual 
incidence going as high as 15% per year (Meya and McAdam 2007). 
Clinically, TB presents with symptoms including coughing (and coughing up 
blood), weight-loss (hence the classical nickname, consumption), night-sweats, and 
general fatigue.  Diagnosis of TB is somewhat difficult; the purified protein derivative 
skin test (PPD) cannot distinguish active disease from previous exposure 
(Weinberger 2004). Chest x-rays are more useful, but can still be likewise non-
specific, failing to distinguish inactive from active disease.  Acid-fast staining of M. 
tuberculosis can also diagnose TB, but is non-specific to other Mycobacteria, and 
can be insensitive when the number of bacteria in the lungs is small.  Smear-positive 
diagnosis is useful for identifying the most-infectious cases of TB, but will not be able 
to find every clinically significant case.  Most sensitive, and indeed, definitive is to 
culture the TB bacterium itself, from sputum samples coughed up by a potentially 
infected individual, a process which requires appropriate laboratory infrastructure 
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and in addition takes six weeks to return results and can be difficult in very sick 
individuals (Weinberger 2004). 
Treating tuberculosis.  Drug susceptible TB is generally treated with a six to 
nine month course of antibiotics.  In South Africa, for existence, this course involves 
two months of rifampicin, isoniazid, pyrazinamide, and ethambutol (WHO 2007), 
followed by four months of rifampicin and isoniazid alone; in other settings in sub-
Saharan Africa, the drug course may include only rifampicin and isoniazid.  TB 
pharmacotherapy poses significant challenges when co-administered with HAART, 
for reasons of pill burden, adherence, and overlapping drug toxicities (Dean et al. 
2002; Subbaraman et al. 2007) (relevant issues of TB/HIV drug toxicites will be dealt 
with in literature review for Specific Aim 3, below).  In addition, especially in resource 
challenged settings such as South Africa, more and more cases of TB are resistant 
to these first-line TB drugs. Though the emergence of drug resistant TB (especially 
multiply-drug resistant, or MDR-, TB) is the immediate and direct consequence of 
the onward transmission of TB in individuals who did not complete their (arduous) 
course of medication, such emergence is perhaps more properly seen as the 
consequence and signal of a breakdown in public health systems and infrastructure 
(Van Rie and Enarson 2006).  The recent emergence of XDR-TB – resistant to 
fluoroquinolone and another, injectable second-line drug – makes treatment still 
more difficult (Van Rie and Enarson 2006). 
Tuberculosis and immune reconstitution inflammatory syndrome.  One 
potentially important complication of TB in patients initiating HAART is immune 
reconstitution inflammatory syndrome (TB-IRIS), in which tuberculosis paradoxically 
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worsens or is “uncovered” soon after initiating HAART due to an immune 
“dysregulation” and inflammatory response (McIlleron et al. 2007; Murdoch et al. 
2008; Murdoch et al. 2007).  While some investigators have reported incidence of 
IRIS (due to TB or other opportunistic infections) as high as 33% of patients in some 
cohorts and settings (Murdoch et al. 2007), a well-done prospective study in 
Johannesburg (and similar to the patient population of Themba Lethu Clinic in 
several significant ways) found a substantially lower incidence, of 10.4% total IRIS 
and 4% TB-IRIS by six months of follow-up (Murdoch et al. 2008). 
Incidence of TB-IRIS may be related to length of time from initiation of TB 
therapy to initiation of HAART (Murdoch et al. 2007; Navas et al. 2002).  It is partly 
for this reason that the SA National ARV Treatment Guidelines recommend waiting 
at least two weeks between initiation of TB and HIV therapies even in very sick 
patients (Republic of South Africa Department of Health 2004).  The only other 
strong risk factor for development of IRIS is of lower CD4 count at baseline and at 
IRIS diagnosis (Murdoch et al. 2008). 
While there are fears that IRIS may result in significant morbidity and 
mortality, preliminary reports of studies suggest that IRIS is more of a clinical 
nuisance than a life-threatening condition (Lawn 2008).  Indeed, the prospective 
clinical study referenced earlier noted that only two deaths were attributable to IRIS 
out of 22 cases, only 1 died (from Cryptococcal meningitis); given that individuals 
with IRIS had substantially lower CD4 counts than those without IRIS (median 79 vs. 
115), it is unlikely that IRIS would fall out of a multivariate model for mortality as an 
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independent risk factor.  It seems unlikely, therefore, that IRIS is an important risk 
factor for mortality. 
Clinical management of tuberculosis in South Africa.  There are four main 
drugs used in treatment of TB in South Africa, isoniazid, rifampicin, pyrazinamide, 
and ethambutol.  Isoniazid is most effective against metabolically active TB bacilli; 
rifampicin can kill semidormant bacilli; pyrazinamide kills bacilli inside cells such as 
macrophages; and ethambutol is bacteriostatic, and interferes with growth of the 
tuberculosis cell wall (WHO 2004).  Standard treatment for tuberculosis in SA is a six 
month course of chemotherapy, beginning with two months of isoniazid, rifampicin, 
pyrazinamide, and ethambutol, and then continuing with four months of isoniazid 
and rifampicin (WHO 2004).  If the patient has relapsed, defaulted, or failed 
treatment, streptomycin (which is typically injected into the muscle, which makes it 
painful and difficult to administer to severely wasted TB/HIV patients) is added to the 
combined drug regimen, which is repeated for a longer course (WHO 2004). 
In South Africa, presenting for TB treatment is often an HIV patient’s entry 
into the health care system; many patients therefore present for initiation of 
antiretroviral therapy having already initiated TB therapy.  This is in line the South 
African National ARV Treatment Guidelines, which state that a patient should delay 
two months (or a minimum of two weeks if the patient is extremely sick) between 
initiation of TB therapy and HAART, and warns further that patients may be at 
substantially higher risk several side-effects shared between TB and HIV therapies, 
that the high pill burden of the dual pharmacotherapy may cause problems with 
adherence to both regimens, and that immune reconstitution may be a problem 
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(Republic of South Africa Department of Health 2004).  However, as noted 
previously, TB-IRIS may be more of a clinical nuisance than serious complication of 
therapy. 
TB and HIV in the developing world.  Despite the fact that it is largely 
treatable, TB is the most common cause of death among HIV-infected individuals in 
the developing world (Meya and McAdam 2007).  Accordingly, a major component of 
the international effort to stop the spread of TB focuses co-infection issues (WHO 
2007).  The burden of pulmonary tuberculosis (TB) among HIV-positive individuals is 
extremely high in South Africa, rollout settings in general, and indeed worldwide. 
Despite the widely appreciated importance of TB in HIV-infected individuals 
and the relatively high prevalence of TB in areas which have seen HAART rollout in 
the last few years, some articles (e.g., (Bekker et al. 2006; Ferradini et al. 2006)) do 
not report TB prevalence at all, and fewer still have reported comprehensively on the 
relative contribution of prevalent TB to risk of death.  For instance Lawn(Lawn et al. 
2006) and Moore (Moore et al. 2007) both report only a crude estimate of the impact 
of tuberculosis on death, which, given the strong association reported in many 
studies between tuberculosis and low CD4 counts and low BMI, is not a useful 
measure.  Relatively few studies of rollouts have reported hazard or risk ratios for 
mortality (or other outcomes) on HAART given active TB at HAART initiation.  
Further, to our knowledge none have accounted explicitly for length of ongoing TB 
treatment at time of HAART initiation (an important modifier of the TB-death 
relationship, because most death from TB occurs early in TB treatment) and none 
have accounted explicitly for informative loss to follow-up in such as assessment; in 
 42 
situations where TB or factors associated with TB are predictive of loss to follow-up, 
analysis of risk factors for death that fails to explicitly account for loss to follow up 
may provide biased estimates of the impact of tuberculosis on death in individuals 
receiving HAART. 
 
 
TUBERCULOSIS AND MORTALITY IN THE CONTEXT OF TREATMENT FOR HIV 
 
The relatively few studies of rollouts that do report the impact of tuberculosis 
on mortality, controlled for important confounders, offer up somewhat mixed results. 
Studies that report at least TB prevalence among those initiating HAART are 
summarized in Table 1.4.  These studies, and a few additional studies, are 
discussed below. 
The report from Stringer et al. (Stringer et al. 2006) was notable in that, 
unlike many other sources, the authors found no effect of prevalent TB on risk of 
death.  They attribute this to two factors; first, that many patients have been on TB 
treatment for several weeks before HAART initiation, suggesting a selection bias for 
fewer TB-related deaths after the start of HAART.  Second, they note that incident 
TB after HAART initiation is not well measured in this cohort. 
Reports from Libamba (Libamba et al. 2006), Wools-Kaloustian (Wools-
Kaloustian et al. 2006), and Hawkins (Hawkins et al. 2007) all report from different 
regions of sub-Saharan Africa, and as such report widely variable TB prevalence at 
baseline, though all report more than 10% prevalence.  Given the high prevalence of 
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pulmonary TB in these cohorts and the well-recognized risk of death associated with 
the disease, none of these reports comment on either crude or relative hazard of 
death associated with prevalent or incident TB infection. 
Lawn et al. (Lawn et al. 2006) explored characteristics associated with 
tuberculosis (or concurrent TB treatment) at baseline, concluding “Although 
prevalent and incident TB were associated with greater than two-fold increased 
mortality risk, they did not compromise immunological and virological outcomes 
among survivors at 48 weeks” (Lawn et al. 2006).  Frustratingly, the two-fold 
increased mortality risk they reported was completely unadjusted for baseline 
covariates such as body mass index, CD4 count, and hemoglobin, to say nothing of 
length of TB therapy prior to HAART initiation. An earlier report from the same 
authors (Lawn et al. 2005) reported that tuberculosis was a “major attributed [cause] 
of death”, and reported results of a multivariate analysis of risks for early mortality in 
overlapping patients, but did not include tuberculosis in that analysis, reporting only 
on WHO stage (mortality rate ratio compared to stage I or II:  3.44, 95% CI 0.80-
14.85 for stage III, 5.93, 95% CI 1.36-25.89 for stage IV). 
The former paper by Lawn et al. (Lawn et al. 2006) reports on the impact of 
TB on CD4 and viral load outcomes in this cohort, in a complete case analysis, 
where the outcomes of those who died were apparently ignored (though this was not 
made explicit).  Multivariate risk analysis in this paper was performed using Poisson 
rate regression by follow-up interval, using GEE and robust standard errors to adjust 
properly for inter-individual correlation of CD4 cell counts and viral load 
measurements.  While this analysis is unbiased insofar as the outcome is well-
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defined, a full consideration of the impact of tuberculosis on outcomes may wish to 
also consider the impact of tuberculosis-related deaths on outcomes such as CD4 
count. This might imply a zero-inflated or “hurdle” model which incorporates a 
dichotomous survival model followed by a dichotomous outcome model.  
Additionally, there is the potential for bias to be introduced here in that CD4 cell 
counts may both confound the tuberculosis-CD4 exposure-outcome relationship in a 
time-dependent fashion, and in addition CD4 may be changed by the exposure of 
tuberculosis, and thus standard adjustment methods for assessing outcomes may 
return biased results (Cole et al. 2005; Hernan, Brumback, and Robins 2000; 
Robins, Hernán, and Brumback 2000). 
The ART-LINC study (Braitstein et al. 2006) was only able to control for the 
presence of an onsite TB clinic in the HAART clinic; however, they found a strong 
correlation (HR = 3.76, 95% CI 1.01-14.02) between the presence of such an onsite 
clinic and risk of death.  While it is tempting to claim that this ecological association 
is evidence of a relationship between TB infection at baseline and risk of death, such 
a claim requires us to both assume that the presence of such a clinic correlates with 
substantially higher prevalence of TB in those sites, and also that the TB-infected 
individuals are in fact dying earlier.  There is little evidence to suggest that either of 
these claims is true; indeed, we might equally well assume, on this evidence, that 
the easy availability of TB treatment accelerates time to death. 
Severe (Severe et al. 2005) reported an 8% prevalence of TB at HAART 
initiation in Haiti, and that 16% of deaths during follow-up were attributable to TB, but 
that there was no difference in risk of death between those with TB (who all received 
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TB treatment) and those without TB; however, this appeared to be a crude analysis 
and was not commented upon further.  Likewise, Etard (Etard et al. 2006) reported a 
baseline TB prevalence of 11.6% in Senegal, and that TB was the leading cause of 
death among their patients, but reported no relative effect of TB on risk of death. 
Zachariah et al. (Zachariah et al. 2006) studied 1507 individuals initiating 
HAART in Thyolo district, Malawi over two years, finding in multivariate logistic 
regression that TB was associated with a slightly reduced risk of mortality (OR = 0.7, 
95% CI 0.4-1.6).  This study appears to be well-done, and the result, while not 
statistically significant, is counterintuitive. 
López-Gatell et al. (Lopez-Gatell et al. 2007) studied the effect of incident TB 
on HIV-related death in the United States, finding a hazard ratio of 4 for women who 
had incident TB during follow-up in the WIHS Cohort from 1995-2002, a hazard ratio 
that was not affected by whether those women were on HAART or not (4.3 among 
HAART); this estimate was highly imprecise because of a very small number of 
women developing TB while on HAART (around 2% in all of follow-up).  In addition, 
the WIHS Cohort is based in the United States, and so the relevance of these results 
to the developing world is highly questionable.  
Moore et al. (Moore et al. 2007), reporting from Tororo, Uganda, found a 
prevalence of pulmonary TB of 7.2% among 1044 individuals initiating HAART, and 
an incidence of 3.9 cases/100 person-years during a median of 1.4 years of follow-
up.  37 of 75 TB-prevalent individuals were already receiving TB treatment (of an 
unknown duration) at HAART initiation; of the remaining half, 23 began HAART 
within 2 weeks starting TB treatment.  Individuals with TB accounted for 35% of 
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deaths within 18 months of HAART initiation, and the crude hazard ratio for TB for 
the outcome of death was 4.7.  The authors estimate that HAART reduced TB-
associated mortality by 52%.  However, the authors did not estimate the adjusted 
hazard of death associated with either incident or prevalent TB in this cohort; as 
prevalent TB is strongly associated with BMI < 18 (adjusted odds ratio 4.95, 95% CI 
2.95-8.31), a risk factor for death, a multivariate analysis would be very useful here. 
Several additional conference presentations focused on the issue of TB co-
infection and HAART outcomes.  One study from India (Patel et al. 2007), presented 
at IAS 2007, noted that individuals with TB at initiation of HAART, who received 
EFV-based HAART along with rifampicin-containing TB medications had no clinically 
meaningful differences in treatment outcomes compared with those who were not 
receiving TB medications.  However, they did experience higher rates of hepatitis, 
and did not monitor viral loads; as they report that TB may impact the 
pharmacokinetics of EFV in the body – reducing available EFV – viral load outcomes 
may be significant in this context.  In addition, they did not report on mortality or loss 
to follow-up; this, along with the fact that we should expect outcomes to be 
substantially different in India and sub-Saharan Africa, may limit the applicability of 
these results to our cohort. 
A report from a study performed from 1997-2001 in Botswana (Chideya 2007) 
observed that HIV positive individuals with CD4 counts below 200 (not receiving 
HAART) were more likely to have sub-therapeutic concentrations of rifampicin in the 
blood during TB therapy, though TB treatment failure itself did not appear to be 
associated with CD4 count among HIV-positive individuals.  However, low 
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pyrazinamide drug concentrations were associated with poor treatment outcomes 
and risk of death during follow-up, controlling for CD4 counts and HIV status.  While 
this study was done in a setting where there was no HAART provided, it does 
strongly reinforce the idea that TB/HIV co-infection may put patients at higher risk of 
death from each. 
Summary of literature review on tuberculosis and mortality.  In rollout 
settings, despite numerous reports of high prevalence of active, pulmonary 
tuberculosis at initiation of HAART throughout sub-Saharan Africa, and widespread 
acknowledgement of the large contribution of TB to HIV-related deaths in these 
settings, no reports from rollouts have rigorously assessed the relative contribution 
of prevalent TB at initiation of HAART to measures of mortality.  The few studies that 
assessed this measure at all both failed to account for losses to follow-up, nor did 
they account for length of TB treatment prior to initiation of HAART.  Finally, none of 
the studies appeared to assess interactions among strong confounders of the TB-
death relationship for interaction or effect measure modification, especially low BMI 
and low CD4 counts. 
The impact of TB on mortality after initiation of HAART is clearly important 
and essentially not yet evaluated to any rigorous degree.  Going forward, we will 
estimate the marginal relative hazard of death for the exposure of prevalent 
tuberculosis at baseline, accounting for length of TB treatment prior to HAART 
initiation.  In sub-analyses we will assess the potential for interactions with low BMI 
and low CD4 count. 
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ANTIRETROVIRAL DRUG TOXICITIES 
 
Antiretroviral drug toxicities and single-drug substitutions within first-
line HAART.  First, we will review background and literature on drug toxicities and 
drug substitution within first-line HAART in general and with regards to stavudine in 
particular, with special attention to reports of toxicity in rollout cohorts in sub-
Saharan Africa.  Then we will review the state of knowledge with regards to how 
current medication for tuberculosis (particularly with isoniazid) affects drug toxicities 
in general and stavudine toxicities and substitutions in particular. 
As suggested previously, drug toxicities may play a significant role in the 
success of a HAART regimen.  If a patient cannot tolerate her drugs, her adherence 
to the drug regimen may wane, leading to faster accumulation of resistance 
mutations (due to different half-lives of different antiretroviral drugs) and eventually 
to virologic, immunologic, or clinical failure of the drug regimen (Saag 2003).  For 
example, the management of stavudine toxicity frequently involves brief periods in 
which patients receive no HAART at all, followed by a re-start of HAART with a new 
drug – most often zidovudine (Boulle et al. 2007; Zachariah et al. 2005) – in place of 
stavudine, after which symptoms usually resolve and recurrences of toxicity are rare 
(Bolhaar and Karstaedt 2007; Llibre et al. 2006; Lonergan, Barber, and Mathews 
2003; Lonergan et al. 2004; Marceau et al. 2003; McComsey et al. 2005) and 
underlying metabolic pathologies appear to improve (McComsey et al. 2005).  Such 
inadvertent toxicity mediated drug holidays may put individuals at higher risk of 
death, as in one study that saw increased mortality during treatment interruption due 
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to the development of opportunistic infections among patients with low CD4 counts 
(Bolhaar and Karstaedt 2007); as well, these treatment interruptions appear highly 
likely to compromise virologic efficacy of HAART.  One study showed an HR of 22.5 
for developing an NNRTI resistance mutation that could compromise HAART after 
drug holidays (Parienti et al. 2004).  In addition, drug toxicities may themselves 
cause significant morbidity or mortality, e.g. (Currier 2007). 
Problems of drug toxicities and concomitant management of those toxicities 
are of particular public health concern in rollout settings for several reasons.  First, 
some of the drugs that compose first-line HAART in rollout settings – especially the 
NRTI stavudine – are associated with greater rates of toxicities than comparable 
NRTIs common to first-line HAART in the developed world (including AZT and TDF) 
(Bolhaar and Karstaedt 2007; Geddes et al. 2006).  Several reports have reported 
higher-than-expected rates of stavudine-related toxicities in developing world 
settings (Bolhaar and Karstaedt 2007; Geddes et al. 2006; Wester et al. 2007).  
There are typically fewer drug options in rollouts than in other settings; with fewer 
drug options, toxicities (especially serial toxicities) may be more difficult to manage 
clinically.  Last, greater demands on limited clinical personnel and resources intrinsic 
to the rollout setting, and less favorable clinician-to-patient ratios, may make clinical 
management of both toxicities and drug substitution significantly more difficult than 
in other settings, leading both to worse outcomes for individual patients, and worse 
outcomes for rollout cohorts as a whole, as clinical staff are stretched even further. 
For these reasons and others, a thorough assessment of risk factors for drug 
substitution within first-line HAART – particularly, substitution of stavudine, the most 
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frequently substituted drug in TLCC – may help lead to more-customized therapy 
regimens at the population level and thus save effort, clinic visits, and (hopefully) 
ensure longer durability of first- and second-line HAART, as well as lower costs, 
better care provisioning, and reduced drug-related morbidity.  This has been 
suggested by others; for instance, Currier suggests that it may be better to start 
women, and especially obese women, on TDF or AZT instead of d4T when those 
drugs are available (Bolhaar and Karstaedt 2007); the recommendation for TDF 
receives preliminary further support from a recent conference report on long-term 
safety of TDF in Central and South America (Madruga et al. 2007), which indicates 
little to no lipoatrophy after six years of TDF.  Both of these drugs have been shown 
to produce less direct biological toxicity than d4T (Birkus, Hitchcock, and Cihlar 
2002).  However, Currier appears to consider only the risk of symptomatic 
hyperlactatemia and lactic acidosis.  There are a number of other important 
stavudine-related toxicities, and decisions to customize initial HAART regimen by 
demographic characteristics might do better to consider other toxicities and reasons 
for substitution (or dose reduction) of stavudine. 
In particular, peripheral neuropathy and lipodystrophy are both common and 
serious stavudine toxicities (Boulle et al. 2007), and both can be an indication for 
stavudine substitution.  Despite this, risk factors for these two toxicities have not 
been well characterized, in part because they do not always present in a way 
serious enough to warrant drug substitution.  Peripheral neuropathy, in particular, is 
of specific concern in developing world settings because it is patients being treated 
concurrently for tuberculosis with the common anti-TB drug isoniazid (INH), which 
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itself can cause peripheral neuropathy (Breen, Lipman, and Johnson 2000; Moyle 
and Sadler 1998).  Nonetheless, few studies have rigorously examined the 
contribution of active tuberculosis pharmacotherapy (including isoniazid) on 
stavudine-related toxicities, and none have rigorously examined the impact of both 
prevalent and incident tuberculosis on time-dependent patterns of stavudine 
substitution. 
It is worth noting that other drugs key to first line HAART are substituted for 
reasons of toxicity (most notably NNRTIs for hepatotoxicity).  However, the majority 
of drug substitutions on first line HAART in TLCC (as well as in comparable cohorts) 
have been substitutions for stavudine (most often, with zidovudine); thus, we will 
concentrate on that substitution in this investigation. 
Here we will review reports from the literature that explore briefly the biology 
and epidemiology of major stavudine toxicities that are cause for substitution in 
rollout settings; and then we will review recent reports of risk factors for drug 
substitution, drug dose changes, and toxicity-related drug regimen discontinuation 
with a focus on tuberculosis as a main risk factor.  Finally, we will review additional 
literature on the impact of tuberculosis on stavudine toxicity and substitution. 
Stavudine toxicities of concern in the developing world.  Many of the 
most important drug toxicities on first-line HAART in the developing world are 
associated with the use of NRTIs in general (Wester et al. 2007), and with the use of 
stavudine (d4T) in particular (Subbaraman et al. 2007).  These toxicities are 
generally regarded as the result of NRTI-mediated inhibition of mitochondrial 
polymerase-gamma (White 2001), which results in malfunction of the process by 
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which mitochondria produce adenosine triphosphate (ATP), which is essential to cell 
function (Montaner et al. 2003; Pinti, Salomoni, and Cossarizza 2006; Wester et al. 
2007; Wohl et al. 2006).  The most important of these toxicities are symptomatic 
hyperlactatemia (SHLA) and lactic acidosis (LA); lipoatrophy and lipohypertrophy; 
dyslipidemia; and peripheral neuropathy (PN) (Colebunders et al. 2005; 
Subbaraman et al. 2007). 
Symptomatic hyperlactatemia and lactic acidosis occur when this 
mitochondrial toxicity results in anaerobic glycolysis (Wohl et al. 2006), of which 
lactate is a byproduct.  LA has a substantial mortality rate (as high as 57% in one 
review of the literature (Falco et al. 2002)), and SHLA and LA both result in 
significant morbidity, with non-specific but potentially significant symptoms including 
fatigue, nausea, vomiting, abdominal pain, weight loss, numbness, and 
lipodystrophy (see below) (Falco et al. 2002; Marceau et al. 2003; Wester et al. 
2007; Wohl et al. 2006).  Both conditions are relatively common in developing world 
settings, reaching 10.6 cases per 1000 patient-years in one South African cohort 
(Bolhaar and Karstaedt 2007) and 2% of all patients in an RCT in Botswana (Wester 
et al. 2007).  Risk factors for SHLA and LA are very similar, and include female 
gender, pregnancy, high BMI, DDI use, and duration of therapy (Bolhaar and 
Karstaedt 2007; Wester et al. 2007; Wohl et al. 2006).  
There is some evidence to suggest that – in absence of symptoms – elevated 
lactate levels are not clinically significantly, and that routine lactate monitoring may 
be of limited usefulness in surveillance for SHLA and LA (Currier 2007) in part 
because it is extremely difficult to measure lactate accurately in clinical settings 
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(Wohl et al. 2004).  One study found that when lactates were collected in a 
standardized fashion, 82 of 83 apparent cases of asymptomatic HLA resolved (Wohl 
et al. 2004).  Along these same lines, two European studies found no demographic 
characteristics predicting laboratory-diagnosed asymptomatic hyperlactatemia 
(Boubaker et al. 2001; Moyle et al. 2002), though in both cases the generalizability 
to developing world rollouts is questionable.  Nonetheless, the evidence suggests 
that in absence of solid evidence of SHLA, elevated lactate levels are not a cause 
for serious concern. 
Lipodystrophy is the re-distribution of body fat around the body, and takes two 
main forms.  Lipoatrophy is the loss of subcutaneous fat from one or more of several 
areas of the body, including the face, torso, or limbs (Wohl et al. 2006), and differs 
from so-called “AIDS wasting” in that it follows immune recovery rather than 
immunosuppression, and additionally that it does not typically involve loss of lean 
body mass, but only accumulated fat (Wohl et al. 2006).  In contrast, lipohypertrophy 
is increased fat accumulation in the abdomen, breasts, or the so-called “buffalo 
hump” (Heath et al. 2003).  Lipodystrophy in general is more common among older 
patients and lower CD4 counts prior to initiation of HAART (Wohl et al. 2006) and 
with increasing duration of HAART (Heath et al. 2003). 
Both forms of lipodystrophy are relatively common in many settings and 
populations; lipodystrophy affected 10% of patients in a South African rollout by 3 
years of follow-up (Boulle et al. 2007) and were a relatively common indication for 
regimen change in Botswana (Wester et al. 2007).  In Rwanda, at least some 
lipodystrophy was observed in 34% of 571 subjects receiving stavudine, including 
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70% of those who had received HAART for more than 72 weeks (Mutimura et al. 
2007).  It is common, as well, to see both lipoatrophy and lipohypertrophy in the 
same subject, as in (Aurpibul et al. 2007; Mutimura et al. 2007). 
Mitochondrial toxicity can result in dyslipidemia, the dysregulation of blood 
lipids that typically manifests as increased triglycerides, though less frequently will 
manifest as increased low-density cholesterol and/or decreased high-density 
cholesterol (Currier 2002; Heath et al. 2003).  Dyslipidemia is associated with 
duration of HIV infection, duration of NRTI-based therapy, lipoatrophy, and use of 
EFV (Parienti et al. 2007; Wohl et al. 2006).  
Peripheral neuropathy is a consequence of both HIV disease and HAART 
although it considered to occur more abruptly and be more painful (White 2001).  PN 
can be distinguished by bilateral, distal pain and numbness, particularly in the lower 
extremities (Moyle and Sadler 1998), as well as by “paraesthesia, numbness and 
tingling in a symmetrical pattern in the distal extremities, and signs of diminished 
sensation to pinprick and vibration, loss of ankle jerks, but preservation of joint 
position sense and motor function” (Breen, Lipman, and Johnson 2000). Major risk 
factors for drug-associated peripheral neuropathy include time on therapy, baseline 
CD4 count, prior alcohol use, malnutrition, history of disease-associated PN, and 
older age (Moore et al. 2000; Moyle and Sadler 1998; White 2001).  It is important to 
emphasize that because HIV disease can cause PN, it may be difficult to definitively 
identify PN as disease or HAART related; as well, other factors such infection with 
CMV, malnutrition and/or vitamin B deficiency, and (as previously noted) use of 
isoniazid for TB therapy (Colebunders et al. 2005; Moyle and Sadler 1998).  About 
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6% of individuals substituted a drug in first-line HAART for reasons of PN within 2 
years of initiating HAART in one large South African cohort (Boulle et al. 2007), and 
it is frequently cited as a main reason for stavudine discontinuation in other studies 
as well (e.g. (Amoroso et al. 2007; Hawkins et al. 2007)).  
All of these toxicities – common or otherwise – are cause for serious concern:  
they may cause significant morbidity or mortality, earlier virologic failure, or less 
time- and cost-efficient treatment of cohorts as a whole.  This serious concern has 
led to ongoing and sometimes acrimonious debate at the WHO and CDC.  
Stavudine is less expensive than its main alternative zidovudine ($80 difference per 
patient per year in low income countries (WHO 2007)) , so there is continuing 
pressure to use it in those countries; at the same time, the high level of toxicities 
makes an argument against the cost-effectiveness of that solution.  Regardless, the 
lower cost of stavudine makes it very likely that it will remain in use in the developing 
world for at least the next five and likely ten years, and thus that this research will 
remain relevant. 
Stavudine substitutions and toxicities.  Here we review several studies – 
rollouts, where possible – of rates of stavudine toxicities in sub-Saharan African 
HAART cohorts.  There are relatively few such reports, and so (below) we review 
additional studies from other locations as well; all data are summarized in Table 1.5.  
Discussions of TB are deferred to the next section. 
Boulle et al. (Boulle et al. 2007) reported on 2679 individuals receiving 
HAART for a median of 11 months, looking at cumulative probability of substitution 
of NVP, EFV, AZT, and d4T and risk factors for many of those substitutions.  By 
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three years, Kaplan-Meier estimation indicates that 21% of those who began on a 
d4T-based regimen would have substituted another drug for d4T.  They found that 
female gender and baseline weight of at least 75kg were strongly associated with 
substitution of d4T for reasons related to lactic acidosis or symptomatic 
hyperlactatemia (SHLA) (HR=10.7 95% CI 1.5-79.0 for female gender; HR=36.1, 
95% CI 10.6-122.8 for weight>75kg) and lipodystrophy (HR=10.0, 95% CI 1.3-74.5 
for female gender; HR=4.1, 95% CI 1.6-10.5 for weight>75kg); they also noted that 
early weight gain was a risk factor for discontinuation of d4T for reasons of SHLA. 
Risk of d4T discontinuation for reasons of peripheral neuropathy were not affected 
by weight or gender in their analysis, but increased slightly with age and ordinal 
WHO stage. 
A chief drawback of this analysis is that Boulle et al. are modeling based on 
relatively few actual switching events; though their Kaplan-Meier estimate of total 
switches by 3 years is 21%, they in fact saw only 125 stavudine substitutions in the 
entire cohort of 1996 individuals at risk in the cohort, a point which is not 
emphasized in their discussions.  This is likely the reason that their hazard ratio 
confidence intervals (above) are so large. 
Methodologically, Boulle et al. use a mix of naïve and more sophisticated 
techniques.  For example, in the former category, their control for weight was 
undoubtedly biased because they controlled only for weight, and not for weight-for-
height or BMI; this is of particular concern in modeling risk of LA/SHLA, because 
men typically weigh more than women, but women are at higher risk of the toxicity.  
Lack of control for height, and lack of control for interaction between gender and 
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weight (or BMI) may produce biased results in this context.  After this, however, 
Boulle et al. report results from multivariate Cox models of risk factors for each major 
area of stavudine toxicity separately, the results of which are properly interpretable 
as hazard ratios and which are controlled for a number of important baseline factors. 
Boulle et al. do not account for losses to follow-up in this analysis, but as only 
5% of those who entered into care at their site in South Africa were lost, their 
complete case approach to the data is unlikely to result in substantial bias.  In 
addition, they note that “associations with each toxicity-mediated substitution could 
therefore potentially be biased by censored observations (related to stopping 
stavudine for other toxicities)”, and “explored estimating the associations jointly 
across all three toxicity-related reasons for stopping stavudine” in a competing risks 
framework, and said that “the results from this exercise were consistent with those 
presented here”, though they did not give further detail. 
Despite these methodological and substantive drawbacks, however, Boulle et 
al. present comprehensive, useful data which addresses a number of important 
points and elucidates risk factors for stavudine substitution.  Though not a final word 
on the subject, this report helps move us forward in our own investigation. 
A conference report from the same site by Osler et al. (Osler et al. 2007) 
noted a referred rate of approximately 10 cases/1000 person-years of severe SHLA, 
presenting at a median of 10 months post-HAART initiation and the vast majority 
presenting within 18 months, with an acute mortality rate of 15%.  86% of cases 
were receiving stavudine; 95% were female compared to approximately 66% of the 
overall cohort.  In univariate analysis, co-morbidity with peripheral neuropathy and/or 
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lipodystrophy were both common.  Case-control analysis indicated that those with 
SHLA were more likely to have higher baseline weight (with referent weight < 60 kg:  
OR 5, 95% CI 1.6-15.4, for 60kg ≤ weight < 75kg and OR 19.3 95% CI 4.8 – 77.1 for 
weight ≥ 75kg), female gender (OR 44.2, 95% CI 6.4 – 303.8), decreasing CD4 nadir 
(OR 1.1, 95% CI 1.1-1.25 per 10 cells) and increasing WHO stage (OR 1.9, 95% CI 
0.9-3.7 per stage). 
These results suggest overlap in risk factors for several important stavudine 
related toxicities.  However, the imprecision of the results combined with 
methodological shortcomings of this report (no description of control sampling 
procedures; claims that the study was a “matched” case-control study without any 
description or indication of what they matched on), makes these estimates difficult to 
interpret. 
Bolhaar and Karstaedt (Bolhaar and Karstaedt 2007), report a high 
incidence of LA and SHLA among 1735 individuals receiving HAART in the 
Baragwaneth Hospital in Johannesburg; the great majority of toxicity was among 
women (63% of the cohort) receiving stavudine. Overall, they saw a rate of 10.6 
cases of LA per 1000 patient years of follow-up, and 20.2 cases of SHLA per 1000 
patients years.  Replacement with zidovudine after a median ~8 weeks treatment 
interruption resulted in no recurrences of LA or SHLA in a mean follow-up time of 9.6 
months among 56 patients.  Their findings suggested that high BMI (>30) might well 
be a risk factor for developing both conditions.  However, these findings were largely 
descriptive, because a small number of total outcomes (23) precluded extensive 
multivariate modeling. 
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Hawkins et al. (Hawkins et al. 2007) studied 1286 patients in Kenya, 59.1% 
of whom were female, on d4T-3TC-NVP, with a median time on HAART of 350 days.  
These patients experienced a cumulative incidence of toxicity-related drug 
substitution estimated at 40.6% at 12 months, with 26.5% of their patients actually 
experiencing such a toxicity during follow-up.  Any drug substitution was predicted 
by older age (≥40), AIDS symptoms at baseline, male gender, and lower baseline 
CD4 count (≤ 100 cell/mm3); toxicities in particular were predicted only by lower 
CD4 count and older age.  Peripheral neuropathy was common in this cohort, with 
20.7% of patients experiencing PN in follow-up; PN accounted for two-thirds of 
observed toxicities.  The authors report that this toxicity was attributable to 
stavudine, though they do not explain adequately how they attributed PN to 
stavudine in particular.  Interestingly, the authors do not report any symptomatic 
hyperlactatemia or lactic acidosis in this cohort, a lack-of-finding they do not 
comment on.  
Forna et al. (Forna et al. 2007) studied 1029 adult patients on d4T-3TC-NVP 
(96%) and d4T-3TC-EFV in rural Uganda, finding a rate of 4.47 toxicities per 100 
patient-years (median follow-up time 11.2 months).  The vast majority of toxicities 
found were peripheral neuropathy (322 of 411 total toxicities, having excluded those 
with evidence of disease-associated PN), which was found to be associated with 
older age (≥35) and tuberculosis treatment at baseline (severe PN only); they drew 
attention to this latter association as a matter of serious concern in the developing 
world.  222 toxicity-related single drug substitutions were made in this cohort, for any 
reason; 178 patients replaced zidovudine with stavudine (and four of those had an 
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anemia toxicity).  The authors estimated that 24% of those who began on stavudine 
would substitute for stavudine by 18 months.  The authors saw a single case of lactic 
acidosis, but did not look for symptomatic hyperlactatemia as a potential toxicity. 
Wester et al. (Wester et al. 2007) reported rates of 2% of SHLA and 1% of 
LA during follow-up of 659 adults (69% female) in a randomized controlled trial in 
Botswana in 2 years of follow-up; in crude analysis, the major predictors of both 
conditions included female gender, BMI > 25 kg/m2, and older age (>40 years).  No 
multivariate modeling was done in this study.  The authors report that individuals 
who were survived their toxicity were switched onto a completely new drug regimen. 
There is only one conference abstract worth reviewing in depth. Amoroso 
and colleagues (Amoroso et al. 2007) reported on 6520 patients treated in 
PEPFAR programs in Uganda, Kenya, and Zambia, of whom 1164 experienced a 
toxicity driven drug substitution in a maximum of 20 months of follow-up.  The 
population as a whole was 68% female, while those who experienced a toxicity 
driven substitution were 67% female.  Of 2149 patients treated with stavudine, 24% 
required a substitution in a median of 141 days; by far the most common reason for 
these substitutions was peripheral neuropathy (53.0%), followed by lipoatrophy 
(7.5%), lactic acidosis (2.4%), and pancreatitis (0.7%); 36% did not have a 
documented reason.  Because they do not specify the median follow-up time, it is 
difficult to extrapolate from these reported switching probabilities to rates if the full 
cohort were followed up for a year (for example).  Nonetheless, these results confirm 
what we have seen in several other large African cohorts. 
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Additional conference abstracts (not listed in Table 1.5) report similar findings.  
A Nigerian study indicated that rate of drug substitution was three times higher for 
d4T-based regimens compared with AZT- and TDF-based regimens, though they do 
not specify who, in particular, required those substitutions (Shepherd et al. 2007).  A 
study in Cambodia found that 75% of drug substitutions were for reasons of toxicity, 
and went as far as to recommend that a programmed switch from d4T at 6 months 
might be appropriate (Hing et al. 2007).  A retrospective review from a Kenyan 
cohort showed that while only 16% of individuals required drug regimen changes 
within four years of follow-up (median follow-up not specified), approximately 81% of 
those switches were due to stavudine toxicity, primarily lipodystrophy, SHLA and LA, 
and PN (Kocholla et al. 2007).  A study in India found that 27% of subjects initiated 
on HAART experienced a serious adverse event within a median of 48 weeks, most 
of those attributable to stavudine, primarily SHLA and PN (Abraham et al. 2007).  
Finally, a London study (Davidson et al. 2007) estimated an “observed toxicity switch 
rate (OTSR)” for stavudine of 304(95% CI 174 to 495) per 1000 patient years, but 
also a high OTSR for zidovudine (224(180 to 276) per 1000 p-y). 
Several additional studies (not included in Table 1.5) are worth noting here.  
Forna (Forna et al. 2007) reported the effects of substitution of AZT for stavudine in 
261 of the 1029 patients noted above and followed up for a median of 17.3 months.  
The authors found that risk of leukopenia (a key zidovudine toxicity) was higher 
among those with a history of more than six months of d4T before substitution of 
AZT (HR = 2.63, 95% CI 1.51-4.60), suggesting that earlier switching to AZT might 
alleviate risk of some AZT toxicities in a population of people who experienced 
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stavudine toxicities.  This, in turn, provides limited support for replacing d4T with 
AZT in initial HAART regimen among people most likely to have d4T toxicities. 
Kumarasamy et al. (Kumarasamy et al. 2006) studied 1443 individuals 
initiating HAART in India from 1996-2004, 72% of them on d4T-containing regimens.  
183 of those individuals had a drug substitution due to a toxicity in a median of 40 
days, and an additional 27 patients discontinued first-line HAART due to a toxicity in 
a median of 49 days.  Only 27 of the total patients (about 1.8%) modified their 
HAART for reasons of d4T-related toxicities; this is much lower than in other studies 
(such as Boulle et al., above).  This may be in part due to the much higher 
proportion of men in this cohort (82%, compared to 29% in Boulle et al.). 
Dieleman et al., writing for the ATHENA Cohort in the Netherlands (Dieleman 
et al. 2002), studied the causes of subsequent drug substitution among individuals 
who substituted a drug on first-line HAART.  They did not analyze risk factors for first 
substitution, noting only that 1573 of 2096 individuals at risk experienced some drug 
substitution between 1998 and 2002 (though there are varying lengths of follow-up 
among individuals in the cohort) and that the most frequent indication for substitution 
was toxicity.  Risk factors for toxicity-driven second substitutions of antiretroviral 
drugs included female gender, toxicity-driven (rather than virologic failure or 
contraindication-based) first-substitution, and not switching underlying NRTIs while 
switching a PI during first substitution.  Risk of toxicity-driven second substitutions 
fell with calendar time.  They saw no influence of BMI or duration of first HAART on 
risk of toxicity-driven second substitutions.  This cohort largely comprised men with 
relatively high CD4 counts, and additionally the HAART regimens used were mostly 
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PI-based on first line, and it is unclear how many used stavudine; thus, it is difficult 
to generalize these results to a developing world rollout situation.  Nonetheless, we 
view these results as hypothesis generating of the possibility that previous toxicity-
driven drug substitution may act as a risk factor for subsequent toxicity-driven drug 
substitutions; this would be an additional motivation to avoid drug substitutions by 
customizing baseline HAART. 
Summary of findings on stavudine toxicities and substitution.  As we 
noted above, there is ongoing controversy surrounding use of stavudine and support 
from WHO for moving away from use of the drug.  Several reports allude to the need 
for increased drug regimen options – for instance, Forna et al. (Forna et al. 2007) 
conclude their 2007 paper by saying: 
Our findings indicate the need to expand drug formularies in resource-limited 
settings, because the large number of patients experiencing toxicity and 
requiring drug substitution shows that programs need to have alternate drugs 
available to switch to if toxicity occurs. In resource-limited settings, toxicity 
from ART regimens containing stavudine or nevirapine is manageable but 
more tolerable regimens are needed. 
 
Nonetheless, as we noted above, stavudine is $80 less expensive per patient per 
year than the next cheapest alternative, zidovudine (WHO 2007), in developing 
countries.  While WHO recognizes the prevalence of stavudine toxicities and as a 
consequence “now recommends zidovudine as one of the preferred NRTI options to 
be considered by countries” (WHO 2006), stavudine is not likely to disappear from 
use in the developing world due to price considerations.  As WHO notes, price 
considerations for these drugs will remain central to the choices made in national 
programmes.” (WHO 2006).  Unfortunately, therefore, the proposed work will remain 
useful for some time to come. 
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Stavudine toxicity is an important concern in both developed and developing 
world settings; while a number of papers have explored frequency of and reasons for 
stavudine substitution within first-line HAART, there are still several outcomes that 
have not been rigorously examined – among them risk factors for time to all-cause 
stavudine substitution.  All-cause stavudine substitution is of particular interest in 
rollout settings, in fact, because in rollouts we are often concerned not only with 
effect of (for instance) peripheral neuropathy on patient quality of life and (therefore) 
on the patient’s drug adherence, but also about the optimal use of already-
overworked clinician resources and drug supplies.  By the same token, if peripheral 
neuropathy is not serious enough to justify stavudine substitution, then perhaps the 
clinical event is of lower interest in terms of drug regimen management.  Thus, 
focusing on all-cause stavudine substitution therefore may be more appropriate in 
many ways than assessing risk factors for individual drug toxicities in the context of 
large scale public health rollouts. 
In the next section, we will review literature which examines the contribution 
of tuberculosis pharmacotherapy containing isoniazid to risks of all-cause stavudine 
substitution and peripheral neuropathy.  First, however, we will briefly review the 
standard treatment plan and pharmacological regimen for TB in South Africa. 
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TUBERCULSOSIS DRUG TOXICITIES IN THE CONTEXT OF TREATMENT FOR 
HIV 
 
Side effects of isoniazid and other TB drugs. Each of these drugs has 
side-effects, some serious, and many which overlap with side-effects and toxicities 
of anti-retroviral drugs.  While the rest of this review will focus on isoniazid, it is worth 
noting at this point that there is a growing literature on interactions between 
rifampicin and nevirapine.  Because rifampicin induces the cytochrome p450 
enzyme, results in reduced pharmacoavailability of nevirapine (Colebunders et al. 
2005; Zachariah et al. 2005).  This appears to be a less-serious concern with 
efavirenz (Manosuthi et al. 2005; Patel et al. 2004), hence the strong 
recommendation that patients on TB pharmacotherapy be placed on EFV-containing 
regimens when at all possible (Republic of South Africa Department of Health 2004). 
The most common side-effect reported with the common and highly potent 
anti-TB drug isoniazid is peripheral neuropathy (Lawn, Edwards, and Wood 2007; 
Subbaraman et al. 2007), also a well-known and common side-effect of stavudine 
(Lawn, Edwards, and Wood 2007).  Despite the fact that these overlapping toxicities 
have been recognized for 10 years (Lawn, Edwards, and Wood 2007; Moyle and 
Sadler 1998), there are few published reports of the effect of isoniazid on stavudine 
toxicity:  a Medline search for “tuberculosis stavudine” returns only 17 matches, not 
all of them relevant, and a search for “isoniazid stavudine” returns only 3.  We review 
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the relevant literature here, beginning with reports reviewed in the previous section, 
on stavudine toxicities more generally. 
Isoniazid for tuberculosis, stavudine-related toxicities, and drug 
substitution.  Here we will re-examine literature already reviewed above for content 
regarding the particular problem; then we will review other relevant literature. 
Forna et al. (Forna et al. 2007) observed a strong association between 
receiving TB pharmacotherapy (including isoniazid) at baseline and experiencing 
severe peripheral neuropathy (n=83 events) during follow-up was 2.35 (95% CI 1.18-
4.68).  They found no association with non-severe peripheral neuropathy, and the 
association between TB and any severe toxicity was also attenuated at 1.7 (95% CI 
0.97-2.98), and in their discussion specifically suggested that this increased risk 
might be due to co-medication of isoniazid and stavudine. 
In contrast to the report by Forna, no other report of toxicities reviewed 
previously specifically addressed issues of tuberculosis and stavudine toxicity or 
substitution. Hawkins et al. (Hawkins et al. 2007) reported that 28% of the observed 
drug substitutions in their cohort were due to TB-HAART drug interactions, but imply 
that these were proactive drug regimen modifications to avoid rifampicin/nevirapine 
interactions.  Although 40.6% of their observed drug substitutions were caused by 
drug toxicity, and 2/3 of those were caused by peripheral neuropathy, they do not 
mention TB as an independent risk factor for substitution or peripheral neuropathy (it 
is not clear whether this is because it was not significant in the model or because 
they did not check for it).  Kumarasamy et al. (Kumarasamy et al. 2006) 
concentrated on the interaction of rifampicin and nevirapine, which in their study was 
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shown to elevate risks of adverse events as the cause of first-line HAART 
modification, and made no mention of TB-stavudine drug interactions.  Boulle et al. 
(Boulle et al. 2007) mentions the same issue in passing. 
Very few other studies shed light on interactions between concurrent use of 
stavudine and pharmacotherapy for tuberculosis including isoniazid.  A very small 
study of 28 individuals receiving d4T in the UK, Breen et al. (Breen, Lipman, and 
Johnson 2000) found an significant increase in cases of peripheral neuropathy 
among those who were also receiving isoniazid.  Patel et al. (Patel et al. 2004) 
studied 255 patients with and without TB in India, most of them receiving stavudine 
for HIV, and found no increase in incidence of peripheral neuropathy with 
combination of stavudine and isoniazid, although their numbers of total cases of 
peripheral neuropathy were small in both groups (7 among TB, 4 among non-TB).  
However, they did find that rates of hepatitis were greatly increased in patients 
receiving anti-TB medications, from 0 cases in the non-TB group to 17 cases in the 
TB group.  It is unclear how to apply these Indian findings to a sub-Saharan African 
context; the very small numbers of cases of peripheral neuropathy suggest that the 
results indeed may not be generalizable.  Dean et al. noted that among English 
patients receiving isoniazid, those who also received stavudine were at 1.7 times the 
risk of peripheral neuropathy (p=0.07) (Dean et al. 2002). 
Summary of research on tuberculosis and stavudine-related toxicities 
and stavudine substitution.  While there is a substantial body of research 
examining particular stavudine toxicities and particular reasons for stavudine 
substitution, and despite the clear importance of tuberculosis to HIV treatment 
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outcomes in the developing world, there are no reports which rigorously examine the 
confounding-adjusted population-level impact of ongoing or incident tuberculosis 
pharmacotherapy on the risk of stavudine substitution during first-line HAART. 
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Table 1.1.  Major outcomes of rollout studies published 2003-2007. 
Mortality CD4 gain 
Study Location n 6  
mo 
12 
mo 
Lost to 
follow-
up 
6  
mo 
12 
mo 
(Stringer et al. 2006) Zambia 16,198 
16 / 100 
person-
years  
21% 155
* 
175
* 
(Libamba et al. 2006) Malawi 13,183 n/r 8% 8% n/r n/r 
(Fairall et al. 2008) ‡ South Africa 3,619 5% 10% n/r 90 170 
(Wools-Kaloustian et al. 
2006) Kenya 2,059 5.4% 24.5% n/r 
160
* 
(Ferradini et al. 2006) Malawi 1,308 
19% at 
median 36 
weeks 
follow-up 
7% 138# 
176
# 
(Hawkins et al. 2007) Kenya 1,286 
1.1% at 
median 350 
days follow-
up 
33.8% 169
* 
208
* 
4.4% 7% 
(Bekker et al. 2006; Lawn, 
Badri, and Wood 2005; Lawn 
et al. 2006, 2006; Lawn et al. 
2006; Lawn et al. 2005) 
South 
Africa 1,139 
12/100 
person-
years in 563 
person-
years at risk 
≤3% 116# 
164
# 
n indicates number reported as initiating HAART.  n/r = not reported.  * indicates 
mean values, # indicates median values. ‡ Mortality and CD4 count gains estimated 
from Figures in article. 
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Table 1.2.  Major outcomes from conference reports of HAART rollouts. 
Mortality CD4 gain 
Study Location n 6  
mo 
12 
mo 
Lost to 
follow-
up 
6  
mo 
12 
mo 
(El-Sadr et al. 2007) Multiple 171,259 n/r n/r 
119
# n/r 
(Marlink et al. 2007) Multiple 134,120 
5% total 
recorded 
during 
follow-up 
7-12% 101
* 
n/r 
(Meloni et al. 2007) Nigeria 9,070 
Alive and in care:  80-
90% at 6 months; 73-
92% at 12 months. 
124
# 
158
# 
(Mosoko et al. 2007) Cameroon 2,920 
Alive and in care:  
66% at 6 months; 58% 
at 12 months; 47% at 
24 months 
189
# 
233
# 
n indicates number reported as initiating HAART.  * indicates mean values, # 
indicates median values. 
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Table 1.3.  Major outcomes from additional studies relevant to study of sub-Saharan 
African HAART rollouts. 
Mortality CD4 gain 
Study Location n 6  
mo 
12 
mo 
Lost to 
follow-
up 
6  
mo 
12 
mo 
(Calmy et al. 2006) 21 sites, global 6,861 
14.2 / 100 
person-
years 
n/r 102# 
144
# 
(Braitstein et al. 2006) Africa, Asia, Brazil 4,810 n/r 6.4% 
15% 
(year 1) 
106
# n/r 
(Koenig, Leandre, and 
Farmer 2004) Haiti 1,050 0% 0% n/r n/r n/r 
(Severe et al. 2005) Haiti 1,004 10% 13% 7.8% 128# 
163
# 
(Etard et al. 2006) Senegal 404 
6.3/100 
person-
years 
<1% 104# n/r 
n indicates number reported as initiating HAART.  n/r = not reported.  # indicates 
median values. 
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Table 1.4. Prevalence and impact on risk of death of pulmonary tuberculosis in 
selected large cohorts.  No study controlled for length of tuberculosis treatment. 
Study n 
Baseline 
TB 
prevalenc
e 
Hazard 
ratio of TB 
for death 
Notes 
(Stringer et al. 2006) 16,198 11% 
No 
significant 
difference 
Post-hoc estimated 
80% power to 
detect HR of 1.26 
at α=0.01 
(Libamba et al. 2006) 13,183 11% n/r 
Lower than 
expected 
prevalence; 
suggest due to drug 
interactions and 
structural issues 
(Wools-Kaloustian et al. 2006) 2,059 <27%  (see Notes) n/r 
27% of cohort 
received treatment 
in median 40 weeks 
follow-up 
(Hawkins et al. 2007) 1,286 34.3% n/r 11.4% first-year incidence of TB 
(Lawn et al. 2006) 944 25% Crude >2 High early incidence of TB 
(Braitstein et al. 2006) 4,810 
11 sites of 
18 
had TB 
clinic 
onsite 
3.76  
(95% CI 
1.01-14.02) 
Purely ecological 
analysis;  
HR is for death in 
HAART clinics with 
onsite TB clinic 
(Severe et al. 2005) 1,004 8% 
No 
significant 
difference 
16% of deaths 
attributed to TB 
(Etard et al. 2006) 404 11.6% 
“Leading 
cause of 
death” 
Prevalence is from 
% receiving anti-TB 
drugs at baseline 
(Lopez-Gatell et al. 2007) 1,412 n/r 4.3 (0.9-22.0) 
HR is incident TB 
(2% incidence); 
study conducted in 
the United States 
(Moore et al. 2007) 1,044 7.2%  4.7 (crude) Incidence 3.9/100 person-years 
This table includes all studies in Tables 1.1, 1.2, and 1.3 which reported at least TB 
prevalence; in addition, this table includes two studies not included previously.  n/r, 
not reported. 
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Table 1.5. Incidence of lactic acidosis, peripheral neuropathy, and stavudine 
substitution in large cohorts from sub-Saharan Africa.   
Incidence 
Study n 
Lactic acidosis 
or  
symptomatic 
hyperlactatemia 
Peripheral  
neuropath
y 
Lipo-
dystrop
hy 
d4T 
substituti
on 
(Boulle et al. 2007) 2,679 4.7%#  6.2%# 9.0%# 20.8% in  3 years 
(Osler et al. 2007) 
7,080 
p-y in 
28 
months 
LA: 10 / 1000 p-y n/r n/r n/r 
(Bolhaar and 
Karstaedt 2007) 1,735 
LA:  10.6 / 1000 p-
y 
SHLA: 20.2 / 1000 
p-y 
n/r n/r n/r 
(Hawkins et al. 
2007) 1,286* n/r 20.7% 2.2% 
40.6% by 
350 days 
(median 
follow-up) 
(Forna et al. 2007) 1,029 LA: 1 case SHLA: n/r 
~3.5/100 p-
y n/r 
18% by 1 
year 
(Wester et al. 2007) 659 
LA: 1% in 2 years 
SHLA: 2% in 2 
years 
n/r n/r n/r 
(Amoroso et al. 
2007) 2,149 
LA: 0.6% 
SHLA: n/r 13.0% 1.9% 
24.6% in 
median 
141 days 
P-y is patient-years. # incidence measured only in events which led to drug 
substitution. 
 
 
 
 
 
 
 
  
 
 
 
CHAPTER 2 
STATEMENT OF THE SPECIFIC AIMS 
 
SPECIFIC AIMS AND JUSTIFICATIONS 
 
Specific aim 1.  To assess outcomes among patients who initiated HAART in 
the Themba Lethu Clinic in Helen Joseph Hospital, Johannesburg, South Africa, 
between 1 April 2004 and 31 March 2007. 
Justification.  Rapid rollout of ART is necessary to achieve the largest 
possible number of patients on ART. Concerns have been raised of the quality of 
such large programs, with fears of poor adherence and poor outcome. We will 
assess the outcomes of survival, “alive and still in care”, viral suppression, and CD4 
gain among 7587 patients who presented for care in the first 3 year of rollout.  We 
will use maximum-likelihood regression modeling to explore the impact of baseline 
characteristics including gender, age, CD4 count, tuberculosis status at baseline, 
and WHO stage on these outcomes. 
Specific aim 2.  To estimate the effect of currently treated baseline 
pulmonary tuberculosis on survival after the initiation of HAART among patients in 
the Themba Lethu Clinic.  
Justification. Tuberculosis is a key predictor of mortality among individuals 
initiating HAART, especially in South Africa, but few studies have been able to 
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provide good estimates of the hazard ratio associated with the condition in a rollout 
setting.  We will use inverse probability weighted marginal structural discrete time 
hazard models to estimate the marginal effect of TB on mortality, as well as perform 
an analysis which estimates the effect of time lag between start of TB 
pharmacotherapy and HAART initiation.  In secondary analysis, we will examine 
interactions of TB with key confounders for effect measure modification to identify 
subpopulations of individuals with TB who may be at differential risk of death.  We 
will adjust for both confounding and informative censoring using inverse probability 
weights to obtain accurate and precise estimates of hazard attributable to TB in this 
cohort, results which (given the assumption of no uncontrolled confounding) will 
approximate those that would be observed if we were to perform a randomized trial 
of ‘assigning’ TB to individuals at random. 
Specific aim 3.  To estimate the effect of treatment for tuberculosis on 
hazard of stavudine substitution within first line HAART among patients in the 
Themba Lethu Clinic.   
Justification.  Stavudine is a key component of first line HAART throughout 
sub-Saharan Africa, but many individuals require a substitution for stavudine due to 
toxicities within relatively short windows of follow-up; many of those same toxicities 
are exacerbated by concurrent TB pharmacotherapy.  We will use inverse probability 
weighted history adjusted marginal structural models to estimate the marginal effect 
of TB on the outcome of all-cause stavudine substitution, controlling for time since 
initiation of TB pharmacotherapy.  We will adjust for both confounding and 
informative censoring using inverse probability weights to obtain accurate and 
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precise estimates of hazard attributable to TB in this cohort, results which (given the 
assumption of no uncontrolled confounding) will approximate those that would be 
observed if we were to perform a randomized trial of ‘assigning’ TB to individuals at 
random. 
 
RATIONALE 
 
The HIV/AIDS pandemic continues to claim lives at an astounding pace in all 
corners of the developing world; this is especially true in sub-Saharan Africa, where 
the World Health Organization (WHO) estimates that nearly 2 million individuals died 
of HIV-related causes in 2006 alone (UNAIDS/WHO 2006).  Timely treatment with 
antiretroviral therapy (ART) has enormous potential to reduce the morbidity and 
mortality of AIDS.  Despite efforts such as the WHO/UNAIDS 3x5 initiative (WHO 
2005), many more people need ART than currently receive it; in South Africa, for 
instance, it is estimated by the WHO that only 20% of the one million individuals in 
need of ART are receiving the therapy (WHO 2007). 
Meeting the UNAIDS goal of universal access to HAART by 2010 (WHO 
2006) will require very large scale “public-health style” rollouts of HAART, in which 
thousands or tens of thousands of individuals are initiated on ART over a very short 
period of time.  Rollouts of this sort have been a major part of expanding access to 
treatment throughout sub-Saharan Africa, where hundreds of thousands of 
individuals have initiated HAART in the last several years.  Because of the immense 
scale of such rollouts, monitoring and sound evaluation of HAART outcomes 
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including survival, and virologic and immunologic status, predictors of those 
outcomes, and assessment of issues surrounding antiretroviral drug toxicity are both 
challenging and extremely important to ensure that a high quality of care is 
delivered. 
Pulmonary tuberculosis is a particular concern among people suffering from 
HIV in South Africa and throughout the developing world (WHO 2004), even in the 
presence of HAART.  The prevalence of TB among people presenting for HAART is 
as high as 25% in some locations (Lawn et al. 2006); an estimated 50 to 80% of TB 
patients are HIV positive in southern Africa (South African National AIDS Council 
2007).  In addition, there are serious concerns about possible interactions between 
components of first-line HAART and standard TB pharmacotherapy (Subbaraman et 
al. 2007).  Nonetheless, the contribution of TB to both mortality and durability of first-
line HAART remain uncharacterized in a methodologically rigorous way.  Indeed, 
many previous reports of HAART rollouts ignore issues of TB entirely. 
Thus, despite numerous reports in the literature, serious gaps remain in our 
knowledge about outcomes in the context of rapid scale-up and delivery of HAART 
in the developing world, especially as relates to tuberculosis co-infection and co-
medication. 
Taken together, these three specific aims will describe the impact of TB on 
the outcomes of the ongoing HAART rollout at the Themba Lethu Clinic, adding to a 
growing body of results from other rollouts; these results will contribute to the 
literature both substantively and methodologically, and will provide essential 
evidence for rational clinical decision making and policy changes.  In particular, 
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proper evaluation of the HR associated with death among individuals with TB in this 
cohort may contribute to policy around patient care and follow-up immediately after 
HAART initiation.  Similarly, a thorough understanding of the impact of TB on risk of 
stavudine substitution within first-line HAART may help guide decisions to initiate 
certain individuals on alternative drugs (such as zidovudine or tenofovir), leading to 
better outcomes and lower costs and burden of care overall. 
 
HYPOTHESES TO BE TESTED 
 
Specific aim 1.  No hypotheses to be tested. 
Specific aim 2.  A.  Is the effect of current treatment for pulmonary 
tuberculosis on all-cause mortality among individuals initiating HAART different than 
the null?  B.  Does the effect of current treatment for pulmonary tuberculosis on all-
cause mortality among individuals initiating HAART differ by the time lag between 
initiation of treatment for tuberculosis and initiation of HAART? 
  Specific aim 3.  Does current treatment for pulmonary or extrapulmonary 
tuberculosis increase the hazard of substitution of the antiretroviral drug stavudine 
for any reason? 
 
 
 
 
  
 
 
 
CHAPTER 3 
METHODS 
 
STUDY SETTING AND CLINCAL PROCEDURES 
 
Overview of study setting.  The rollout of HAART in South Africa provides 
an excellent resource to perform the analyses proposed in this dissertation.  In 
particular, this dissertation concentrated on a central site for the South African 
rollout, the Themba Lethu Clinic in Helen Joseph Hospital, Johannesburg, Gauteng 
Province, South Africa (Clinical HIV Research Unit 2005).  The Themba Lethu (“Our 
hope”) Clinic (TLC) is the single largest clinic providing HAART to HIV-infected 
adults drugs in South Africa, with over 10000 individuals in care in January of 2008, 
all of whom were enrolled since the start of the so-called “government era” of 
HAART availability in April of 2004. 
Along with Johannesburg General Hospital and Chris Hani Baragwanath 
Hospital (Bara), TLC is one of the three major centers for where HAART is provided 
within Johannesburg.  Patients are referred to TLC through voluntary counseling and 
testing clinics, hospitals, prenatal care facilities, and by self-referral.  Unlike Bara, 
which is located in the township of Soweto, TLC is relatively far from the areas 
where TLC patients live and work.  TLC is a joint project of Right to Care, a South 
African non-profit organization dedicated to providing HAART (Right To Care 2005), 
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and the South African government through the CCMT initiative; TLC is funded by the 
Gauteng Province Department of Health and the President’s Emergency Plan for 
AIDS Relief (PEPFAR), and works closely with the Clinical HIV Research Unit of the 
University of Witwatersrand. 
The effort to initiate large numbers of patients on HAART at TLC is part of the 
larger effort to fight HIV and AIDS in South Africa, which has one of the largest 
unmet needs for HAART in the world (WHO 2007).  The widespread scale-up of 
HAART in South Africa is important not only because of the lives it will save, but also 
because of the political statement it makes in a country with a tangled political 
history around AIDS (AVERT.ORG 2007) and whose leader has sown considerable 
doubt about the fact that HIV is the cause of AIDS (Smith and Novella 2007). 
Study population and enrollment.  Patients were enrolled upon initiation of 
HAART in TLC between 1 April 2004 and 31 March 2007.  In all analyses, patients 
were excluded if they had a history of HAART before 1 April 2004; if they had 
missing or incomplete information on initial HAART regimen; or if they initiated a 
non-HAART ART regimen.  There are approximately 7500 patients who meet 
inclusion criteria for baseline analyses, though there were fewer individuals for some 
analyses due to missing data or inadequate opportunity for follow-up.  Specific aim 3 
considered only patients on one of three main HAART regimens (see Antiretroviral 
therapy regimens, below). 
All patients in TLCC receive antiretroviral medications (ARVs) free of charge; 
until 1 October 2006 patients paid 35 Rand (less than $5 US) per visit to clinic.  We 
accounted for this change in policy in analysis with an indicator variable for date. 
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Antiretroviral therapy regimens.  Following the South African national ARV 
treatment guidelines, first line HAART regimens in this cohort were most frequently 
stavudine (d4T), lamivudine (3TC), and either efavirenz (EFV) or nevirapine (NVP) 
(Regimens 1a and 1b, respectively).  Some individuals received Kaletra® (lopinavir 
boosted with ritanovir, LPVr) in place of NVP or EFV, and zidovudine (AZT) replaced 
d4T in some cases.  Second-line HAART regimens included AZT, didanosine (DDI), 
and LPVr. 
For purposes of these analyses, drug substitution was defined as the 
substitution of one or two drugs within a single drug class (for instance, substituting 
AZT for D4T), or switching between NVP and EFV.  A drug regimen switch (or 
switch) was defined as a change between any WHO-approved first line HAART 
regimen to any WHO-approved second line HAART regimen.  Collectively, all 
changes to drug regimen (including drug substitutions, drug regimen switches, the 
addition or subtraction of a drug to a drug regimen, or the adjustment of a dose of a 
drug within an established drug regimen), were referred to as drug regimen 
changes.  Drug regimens were assumed to be continued until termination date given 
in the database.  If a drug regimen was discontinued for more than 30 days and then 
subsequently restarted, it was deemed a treatment interruption (TI). 
Other medications, including TB medications.  A large number of other 
medications and treatments are provided to individuals receiving antiretroviral 
therapy including a wide variety of antibiotics and vitamins.  TLC is not recognized 
as a TB treatment clinic.  Patients with TB are referred in to TLC or referred out to 
TB clinics, thus making perfect ascertainment of adherence to and completion of TB 
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therapy difficult for most patients.  The non-integration of TB and HIV treatment 
services is widely acknowledged as a serious barrier to optimal treatment in South 
Africa. 
Clinical procedures; collection of laboratory and clinical measurements.  
Patients attended TLC at initiation (month 0), and at months 4, 10 and every 6 
months thereafter.  Patients attend additional visits at months 1, 5, 11 and every 6 
months thereafter to receive test results, and come to clinic in the intervening 
months to pick up drugs from the pharmacy, or if they become sick or experience 
drug side effects.  Patients who had not suppressed virus by month 4 were 
scheduled for monthly visits until viral suppression was achieved; patients who 
experienced drug toxicities or other health problems were seen as required.  In 
addition to clinical visits, patients also visited the TLC pharmacy monthly or bi-
monthly to receive antiretroviral drugs and other prescription medications (including 
tuberculosis drugs and other antibiotics).  A typical clinical visit involved an 
assessment by a nurse, evaluation by a doctor or nurse-practitioner, a pharmacy 
visit, additional adherence counseling if the nurse, doctor, or pharmacy deemed it 
necessary; individual or group wellness counseling if desired, and a blood draw if 
necessary. 
Patient demographics were taken at baseline; patient weight and other basic 
measurements were taken at every visit to the clinic (though not at pharmacy-only 
visits).  Patient viral load, CD4 count, hemoglobin, liver enzymes, and other lab 
values were evaluated at every scheduled visit; viral loads were not taken at 
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baseline.  All laboratory assays were performed by the Auckland Park Regional Lab 
of the South African National Health Laboratory Service at Helen Joseph Hospital. 
Adherence.  Adherence data was not routinely or systematically collected in 
TLC.  Records of pharmacy visits by the patients, which indicate when they picked 
up their ARV drugs and their next scheduled visit, have been used by other cohorts 
to ascertain adherence (reference).  Using these data, adherence can be measured 
in two ways:  first, as the proportion of intervals between two consecutive visits in 
which the patient was no more than 2 days late for the latter visit; and second, as the 
days captured in the pharmacy when the patient had drugs available to them.  These 
adherence values constitute an upper bound on possible adherence, in that patients 
cannot be adherent on days when they have insufficient drugs; in contrast, patients 
can be non-adherent on days on which they have sufficient drugs. 
These adherence measures are problematic for other reasons.  First, they are 
more likely to be missing among those who become lost to follow-up very early, and 
second, they give high adherence scores to individuals with fewer opportunities to 
miss visits.  For instance, an individual who shows up to their first visit on time and 
then dies before the next scheduled visit would have perfect adherence.  This may 
suggest that high adherence causes death, and especially early death. 
We did not control for adherence, but instead for successful suppression of 
viral load by month 6.  As virologic suppression of virus is a direct result of 
adherence to therapy, we assumed that in this way, we have controlled the majority 
of any confounding due to adherence. 
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Loss to follow up and patient tracing.  Individuals who did not return to 
TLCC in the 90 days after next scheduled visit were automatically flagged as 
potentially lost.  These patients were called at least three times at telephone 
numbers provided at entry to the cohort; patients who could not be contacted in this 
way were visited by the home-based care team (HBCT) at the address they 
provided.  If the HBCT failed to locate the patient, the patient was declared 
“confirmed” lost to follow-up. 
In time to event analysis in which multiple imputation or inverse probability 
weighting was not used to deal with informative censoring, individuals lost to follow 
up were censored midway between the last recorded visit and the next scheduled 
visit; and potential lost to follow up patients were analyzed as confirmed lost to 
follow-up. 
 
DEFINITIONS 
 
Laboratory and clinical definitions for analysis.  In general, we defined 
baseline covariates as those collected closest to time of initiation of HAART, and no 
more than four months before initiation of HAART.  If no value was available 
previous to the initiation of HAART, we used values collected up to one month post 
HAART initiation only for those variables not likely to be substantially affected by the 
first month of HAART.  Thus, while a value of BMI or CD4 count from two weeks 
post HAART initiation might be included, as these values rise only somewhat during 
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the first month, viral load measurements were never included if taken after the 
initiation of HAART. 
Other variables were defined as follows. 
Sex was coded dichotomously. 
Age was coded categorically five-year exclusive increments, as <25, 25-30, 
30-35, 35-40, 40-45, 45-50, 50-55, and ≥55. 
Ethnicity was coded as African or otherwise. 
Employment status was coded dichotomously as employed, student, or 
retired; or otherwise. 
Virologic suppression was defined as viral load ≤ 400 copies/ml; patients 
were considered to have experienced initial virologic success if they achieved 
virologic suppression at any point within seven months of HAART initiation. 
WHO disease stage was coded categorically as 1 or 2; 3; and 4, although we 
modeled all four categories separately in some analyses.  In analyses that include 
tuberculosis as a main exposure, we controlled only for WHO stage IV, because TB 
is WHO stage III defining and thus there is substantial co-linearity between the 
exposure and WHO stage (WHO 2005). 
Body mass index (BMI) was coded as a linear predictor or categorically as 
indicator variables as in the WHO classification as Underweight (<18.5kg/m2), 
Normal (18.5-24.99kg/m2), Overweight (25-29.99kg/m2), and Obese (>30kg/m2) 
(WHO 2008).  Where height was missing but weight was present (n=28), we imputed 
height as the median height by gender.  When both height and weight were missing 
(n=20), we imputed median BMI by gender. 
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Low hemoglobin was defined as a hemoglobin (Hb) value below 13.0 g/dl 
(men), 12.0 g/dl (women), or 11.0 g/dl (pregnant women) (WHO 2001).  However, 
Johannesburg is at an elevation of 1753 meters (Wikipedia 2008) (higher than 
Denver, Colorado), and thus measured hemoglobin counts must be adjusted for 
altitude (Beutler and Waalen 2006; Cook et al. 2005; Ruiz-Arguelles 2006).  Thus, 
the final cutoffs for low hemoglobin were 12.35, 11.35, and 10.35 g/dl, respectively. 
History of antiretroviral therapy (ART) is rare in this cohort, with a total of 231 
individuals (about 3% of the cohort) reporting any history of ART at all, including 
mono-, dual-, or triple-therapy.  As such, we coded history of ART as a simple 
dichotomous indicator. 
Initial HAART regimen was classified simply as efavirenz-containing, 
nevirapine-containing, Kaletra-containing.  
CD4 count was included as both a categorical and a linear predictor in most 
models.  Categories were widely accepted clinical categories of <50 cells/mm3, 50-
199 cells/mm3, 200-349 cells/mm3, and >350 cells/mm3 (Badri et al. 2001; 
Churchyard et al. 2000; Mermin et al. 2004; Mocroft et al. 2003; Schim van der Loeff 
et al. 2002; van der Sande et al. 2004; Whalen et al. 2000; WHO 2005). 
Pulmonary TB status at baseline was coded dichotomously, with the 
understanding that everyone recorded as having TB in this cohort was also being 
treated for TB.  Thus, the exposure of pulmonary TB should be understood as the 
exposure of prevalent, treated, pulmonary TB. 
Baseline pregnancy status and baseline complaint of peripheral neuropathy 
were both coded dichotomously. 
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Year of enrollment was coded as a three-category/two-indicator variable, 
measuring from first day of follow-up (April 1 2004) to April 1 in subsequent years. 
 
DATA QUALITY 
 
Data were entered into the TherapyEdge™ (TherapyEdge Inc., USA) clinical 
database.  This database system is comprehensive, in that it has fields for every 
laboratory test imaginable in a clinical HIV context, as well as some advanced 
patient-monitoring display tools.  The TherapyEdge system is unfortunately 
somewhat needlessly complicated for a rollout setting:  it is somewhat too 
comprehensive, as well as not designed intuitively  (though the design of data entry 
forms changed in small ways many times throughout the enrollment period, and in a 
substantive way at least once).  As a result, there have been serious backlogs of 
data entry over the three years of enrollment.  Due to these backlogs, as well as 
because of very high patient load – and thus high volume of data collected and 
entered into the database – double entry of data was not an option in this database 
(although it occurred inadvertently – see below). 
One additional complicating factor in this database is that many laboratory 
values which are key to analyses were not entered directly into the database, but 
instead were provided to the data management team in the form of flat text files from 
the Auckland Park Regional Lab of the NHLS, mentioned above, without unique 
identifiers that could be traced back to our database directly.  These values were 
matched with unique ids within the TherapyEdge database by means of two 
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independently computer programs written by data management personnel, which 
matched values between the two files by first initial, last name, date of birth, and 
gender.  Because there were a number of misspellings as well as confusion over 
names (misspellings of last names are common; and in addition many black South 
Africans have two first names, and may report their first name differently depending 
on a number of cultural and interpersonal factors), we could not reject imperfect 
matches as necessarily incorrect.  Thus, each computer program ranked matches by 
quality based on closeness of match, and included flags for whether the last name 
matched; to what degree, if any, the last name was mismatched (by both leftmost 
mismatched character, and the Levenshtein edit distance, the latter with the SAS 
complev function); whether the date of birth matched; and whether the sex matched.  
The two ranked lists of definite and possible matches were sent to me.  I integrated 
only those observations ranked highly on both lists into the existing database. 
Thus, there are undoubtedly at least some incorrect laboratory values in the 
database for analysis.  However, some of the laboratory values in the NHLS data 
had already been entered into the TLCC database for lab results most essential to 
the clinic, especially for CD4 count.  After merging the two sets of data by unique ID 
and month in which CD4 count was performed (because recorded days are often 
one day apart in the two databases), we compared CD4 counts from the unintended 
double entry database.  Comparison of the 22645 doubly entered CD4 counts (out of 
37116 total CD4 counts available for analysis) indicated that 22063 (97.43%) were 
identical, while the remaining 582 had CD4 counts that were divergent.  Among 
those 582 divergent CD4 pairs, 192 were labs recorded within 1 day of each other; 
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71 of the 192 CD4 count pairs are within 20 CD4 cells of each other.  Of those 
“mismatches” recorded between 2 and 10 days apart (n=224), 128 pairs are within 
20 CD4 cells of each other.  Of those where labs were taken more than 10 days 
apart (n=166), 112 were within 50 CD4 cell counts.  Thus of the 582 mismatches, 
there are 311 plausible values; we therefore judge the prevalence of badly entered 
or mismatched CD4 counts to be approximately 1.2% comparing those values 
already in the Therapy Edge database to those that matched those values from 
outside values.  Matching by week of CD4 instead of month indicates a 98.83% 
perfect matching percentage among CD4 counts; 95 of the 246 mismatched CD4 
counts differed by less than 20 CD4 cells, indicating a 99.5% plausible match rate.  
We therefore believe that data quality is very high in this database. 
 
STATISTICAL METHODS FOR CHAPTER 4 
 
The purpose of Chapter IV was to address Specific aim 1, by characterizing 
outcomes over three years of a rollout of antiretroviral therapy in the Themba Lethu 
Clinical Cohort.  We have previously described the study site, enrollment, eligibility, 
treatment, clinical procedures, data capture and quality ascertainment, and covariate 
definitions.  Here we will concentrate on statistical analyses. 
Baseline demographics were characterized using standard descriptive 
statistics.  Chi-square tests were used to compare categorical variables and 
Wilcoxon rank-sum tests for continuous variables by category.  Crude rates were 
estimated from simple Poisson models.  Risks were estimated from simple 
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proportions.  Risks and rates of drug toxicities were characterized using simple 
descriptive statistics, crude rates and rates controlled for sex using Poisson 
regression.  Poisson regression was implemented in all cases using proc genmod in 
SAS with link=log and dist=Poisson.  The Poisson model is formally stated as: 
 
ln(rate of death | X=x) = β0 + βj * xj + e 
 
where outcome is rate of death, e is distributed as Poisson, β0 is the intercept, βi is a 
vector of j modeled parameters, and xi is a vector of j observed covariates.  As is 
customary in the Poisson model, rate of death will be broken out into an indicator 
variable for death (yes/no), and the log of person-time follow-up for each individual 
will be included as the “offset” variable. 
We examined four main outcomes in this study: initial virologic success, 
death, combined death or LFTU, and CD4 gain during follow-up.  Analyses were 
intent-to-treat with regards to HAART, ignoring treatment interruptions and drug 
substitutions in time to event analyses. 
Virologic outcomes.  Initial virologic success was evaluated using 
descriptive statistics including risk of virologic suppression by six months by baseline 
HAART regimen and (separately) history of ART, evaluated by the chi-square test. 
Mortality and loss to follow-up.  Risk of death and combined risk of death 
or LTFU was evaluated using descriptive statistics and Kaplan-Meier curves 
stratified by baseline CD4 counts and examining twelve month mortality risk 
stratified by both baseline CD4 count and WHO stage (four separate categories). 
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We then evaluated multivariate hazard ratios for both outcomes using Cox 
proportional hazards model.  Predictors in these models included gender, age, 
ethnicity, employment status, and baseline measurements of BMI, hemoglobin, 
WHO stage, CD4 count, pulmonary tuberculosis (TB) status, history of ART, 
pregnancy status, initial HAART regimen, and peripheral neuropathy at baseline.  
We used univariate log-log-survival plots to examine the univariate proportional 
hazards assumption (PHA) for each variable included in Cox models and examined 
linear and plausible categorical time interactions with each covariate using chi-
square tests at an alpha of 0.10. We used time-stratified Cox models to estimate 
hazard ratios in the presence of violations of the PHA.  The form of the Cox model to 
be used is: 
  
h(t | X=x) = h(t | X=0) * eβjxj  
 
for all t, where (as above) βj is a vector of estimated parameters, and xj is a vector of 
observed covariates.   
In the time-varying case with a categorical time interaction, this model is 
extended to 
 
h(t | X=x) = h(t | X=0) * eβj1*xj1+ βj2*xj2(t) 
 
where xj2(t) is a function of xj1 such as xj2(t) = x1j * I(month>3). 
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Where we are modeling the hazard at time t as a function of covariates X and 
as a fraction of the underlying (unspecified) hazard function h(t | X=0) such that 
hazard ratio at time t is constant and thus 
  
HR(t) = hx(t)/h0(t) = eβx 
 
which in the time-varying case is extended to  
  
HR(t) = eβj1*xj1+ βj2*xj2(t). 
 
All the above models for mortality were complete case analyses with regards 
to missing data.  Because baseline CD4 count was missing for approximately 650 
individuals at baseline, we performed a sensitivity analysis to establish the impact of 
complete case analysis on multivariate estimates of mortality for baseline CD4 
count.  We created 10 datasets (using SAS proc mi) in which missing baseline CD4 
values were imputed based on other variables in the model (WHO stage, BMI, sex, 
age, and hemoglobin count).  Then we compared the effect of baseline CD4 count 
on hazard of death during follow-up in the complete-case and multiple imputation 
scenarios. 
In addition, because we were concerned by the large ratio of recorded LTFU 
to recorded deaths, we used baseline inverse probability of censoring weights to 
estimate the effect of loss to follow-up on total crude incidence of death.  The 
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implementation of IPCW is described in the next section (General statistical methods 
used in chapters IV and V). 
CD4 gain on antiretroviral therapy.  CD4 gain over time was first assessed 
using simple dichotomous measures at four months of follow-up, using t-tests to 
assess the crude effect of baseline CD4 on four-month CD4 gain. Mean and median 
CD4 count during follow-up for the entire cohort were estimated non-parametrically 
by month. 
Mean CD4 count and CD4 count gain during follow-up was estimated by 
initial CD4 count category using two separate static change-point generalized 
estimating equations (GEE) models with an independent correlation matrix.  In the 
first model, we included the main variable of months since HAART initiation, 
indicator variables for baseline CD4 count, and static change points at months 4, 10, 
and every 6 months thereafter until 28 months (5 changepoints) to allow the slope of 
CD4 increase to change in time (Chu et al. 2005).  These changepoints were 
selected because they were the scheduled appointment times for regular follow-up 
visits; thus data at these time points should have been least affected by selection 
bias, whereas data at other time points was typically generated as a result of 
patients who arrived for care for specific reasons and thus may have been less 
representative of the cohort as a whole. 
The second model included all terms from the first model, as well as 
interaction terms between all baseline CD4 count categories and continuous time as 
well as all changepoints (total 24 interaction terms), to allow slope to change in time 
and by initial CD4 count.  Last, we performed one GEE analysis which controlled for 
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sex, age, and virologic success after month 6 among only those patients with a 
measure of virologic success at that time point. 
The need to control for within-patient correlation suggests that either a 
generalized estimating equations (GEE) model or a general linear mixed model 
(random effects model) is necessary for this modeling.  The former provides a 
population average parameter, while the latter provides subject-specific estimates; 
however, when estimating a collapsible linear outcome (CD4 count), these two 
quantities converge to the same estimate given large sample size.  Since we have 
large sample size in this investigation, we conclude that either model is acceptable.  
Because we are using GEE models to implement marginal structural models for 
Chapters IV and V, we will use GEE models here for simple consistency. 
The general form of the GEE model is 
 
S(β) = Σi=1 to n (dµi/d βi)*Vi-1 (yi – µi) = 0 
 
where there are n subjects (i=1 to n) and t time points (j=1 to t), yi is the vector of 
outcomes for individual i at t times points, µi is the vector of E(yi) for t time points, Vi-1 
is the matrix estimating the variance-covariance structure over time, the heart of 
which is the correlation matrix R(α).  We will have thousands of clusters even if we 
stratify the model completely by initial CD4 count, which will help ensure the 
robustness property of GEE using R(α); we will initially use the Unstructured 
correlation matrix specification, and examine estimated pairwise correlations to see 
if a more efficient correlation matrix is appropriate. 
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We should note here that the main disadvantage of the GEE model compared 
with random effects models is that the latter have implicit assumptions of missing at 
random rather than the implicit assumption of GEE models that missingness is 
completely at random (MCAR).  Missing CD4 counts in this analysis are likely 
informative in this analysis, because low CD4 counts are a risk factor for death.  
Thus, because we are modeling only CD4 count by time, the missing at random 
(MAR) assumption of random effects models would imply that missingness is at 
random (and in particular, independent of the missing value) given time alone, which 
is not likely.  As such, both models are likely to be biased when considering the 
unconditional estimate of CD4 gain among all individuals who initiated HAART in this 
cohort. 
However, the overall goal of this analysis is to allow clinicians to understand 
where a particular, observed patient falls in the spectrum of observed CD4 gain at a 
particular time point.  As such, we are interested in explicitly estimating CD4 gain 
contingent on remaining in the cohort.  Under this interpretation, we can ignore 
missingness (or rather, assume that missingness is MCAR); either model will 
provide an unbiased estimate of this contingent outcome.  Furthermore, this 
approach is typical of published approaches taken to the problem of estimation of 
CD4 gain (e.g. (Stringer et al. 2006)), and so – while clearly not ideal – we feel that it 
is an appropriate compromise position for this investigation.   
If we were interested in the unconditional estimate of CD4 gain, we could take 
one of two approaches:  first, we could implement a “hurdle model”, in which we first 
model probabilities of death and/or loss to follow-up, and then model the linear 
 96 
outcome contingent on the outcome of the first model.  Separately, we could use 
inverse probability weighting (see next section) to allow observations to “stand-in” for 
missing observations. 
 
INTRODUCTION TO METHODS USED IN CHAPTERS V AND VI 
 
Chapters V and VI both make extensive use of marginal structural models.  
Here we describe marginal structural models (MSM) briefly, and explain the ideas 
behind inverse probability weighting, which is used to estimate MSM. 
What are marginal structural models?  Marginal structural models (MSM) 
are a necessary methodology for assessing outcomes in longitudinal settings in 
which confounders are both time-varying and affected at later time points by the 
exposure (e.g., confounders of interest are on the causal pathway) (Hernán, 
Brumback, and Robins 2000; Robins, Hernán, and Brumback 2000). 
For instance, consider a study of the relationship between receipt of 
antiretroviral therapy (ART) and death.  CD4 count may cause the initiation of ART, 
and a low CD4 count is a risk factor for death; thus, at time of initiation of ART, CD4 
is a confounder.  But, as Figure 3.1 below, the receipt (or not) of antiretroviral 
therapy at time 0 affects subsequent CD4 count (at time 1), which in turn confounds 
the relationship between antiretroviral therapy (at time 1) and death at some later 
time point.  As a result, CD4 count is on the causal pathway between ART (at Time 
0) and Death (at Time 2). 
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Traditional regression analysis – a so-called ‘stratification’ approach - will 
control for CD4 count as it changes over time; but because CD4 is on the causal 
pathway, the resulting estimate of effect will be biased (Hernán, Brumback, and 
Robins 2000).  Marginal structural models avoid this problem by using 
standardization rather than stratification, not dissimilar to the approach implicitly 
taken when we report age-standardized mortality rates. 
There are at least two additional advantages of a marginal structural 
approach compared to more traditional regression analyses.  First, given several 
important assumptions (Cole et al. 2003), the results of a marginal structural model 
are interpretable as the result we would have seen had we conducted a randomized 
controlled trial (RCT) of the exposure on the outcome.  The assumptions that must 
hold true for this interpretation to be valid include the assumptions that we have 
correctly measured all variables, that we have sufficient covariate information to 
control for confounding, that we have correctly specified all models (Hernán, 
Brumback, and Robins 2000), and that the positivity condition holds (Hernán, 
Brumback, and Robins 2002; Hernán and Robins 2006).  Positivity states that there 
is a non-zero probability that those who were exposed could have been unexposed, 
and that those who were unexposed could have been exposed.  This condition 
intuitively holds true when we actually assign an exposure to individuals at random 
(as in an RCT) but it is not always true in observational settings.  Intuitively, then, if 
the two groups were so different from each other that they were not comparable, we 
would have non-positivity.  If these conditions hold, however – and many of them are 
no more heroic than assumptions commonly made in observational studies (Hernán, 
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Brumback, and Robins 2000), MSM can be used to construct (that is to say, 
estimate) post-hoc RCTs of exposures which were not – or could never be – 
randomized, such as tuberculosis infection or pregnancy. 
Second, marginal structural models are fit with inverse probability weights 
(Robins, Hernán, and Brumback 2000), which are a general tool to ameliorate 
biases to missing information, such as is imparted by selection and information bias, 
as well as confounding; thus, a MSM approach lends itself easily to simultaneous 
control of multiple types of systematic error (e.g., (Hernán, Brumback, and Robins 
2000)).  This is a specific reason that MSM might be useful in a situation in which 
exposure and/or confounding are only important at baseline. 
What are inverse probability weights?  Inverse probability weights are a 
generalized methodology for controlling both confounding and selection bias.  We 
will here concentrate on inverse probability of treatment weights, which control the 
confounding of a treatment-outcome relationship by (a vector of) covariates Z.  We 
note without further comment here that “exposure” can substitute for “treatment” in 
all the following explanations. 
Properly then, an individual’s inverse probability of treatment weight (IPTW) is 
defined as exactly equal to 1 / P(T=t | Z=z), that is, the inverse of the probability that 
the individual received the treatment she actually received, given her covariates.  
Ideally, the vector of covariates Z=z includes all possible confounders of the 
relationship between treatment; in reality, the IPTW is calculated based on only 
observed data (whereas an RCT controls confounding by all factors, observed and 
unobserved).  While IPTW can be estimated non-parametrically (and we will do so 
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below), in reality they are typically estimated using parametric maximum likelihood 
regression.  The estimation of IPTW is exactly analogous to the estimation of 
propensity scores, and is therefore a rich area for the application of recursive 
portioning algorithms (Breiman 2001; D'Agostino 1998; Glynn, Schneeweiss, and 
Sturmer 2006; McCaffrey, Ridgeway, and Morral 2004).  This is not our concern at 
present, however. 
Intuitively (and in some cases, mathematically (Hernán and Robins 2006)) 
inverse probability weights (IPW) are equivalent to standardization, a common basic 
epidemiologic technique for controlling confounding.  When used in the context of 
marginal structural models, IPW are used to control confounding and also to control 
selection bias induced by loss to follow-up.  While any attempt here to explain IPW 
will fall far short of the superlative explanation given by Hernán and Robins (Hernán 
and Robins 2006), the basics of IPW can be illustrated with a series of simple 2x2 
tables. 
In Tables 3.1a and 3.1b we show crude stratified 2x2 tables for an exposure-
outcome relationship that is confounded by Z (only).  Issues of sample size aside, 
the crude relationship of 3.000 is substantially different than the estimate adjusted 
for confounding by the Mantel-Haenszel method. 
To apply inverse probability of treatment (exposure) weights to these data, we 
first estimate the conditional probability of observed exposure given value of Z, and 
the inverse of that quantity.  Note that P(E=1 | Z=1) is calculated simply as 300 / 
(300+200) = 0.600; the results of these calculations are shown in Table 3.1c below.  
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The far right column of Table 3.1c is the inverse of P(E=e | Z=z); that is, exactly the 
inverse probability of treatment weight for this analysis. 
Then the original populations are multiplied by their respective weights to 
construct pseudopopulation in which exposure and Z are independent (Table 3.1d).  
In this simple example, this step is equivalent to standardizing exposure to the 
distribution of Z in the whole population (Hernán and Robins 2006; Sato and 
Matsuyama 2003). 
Note in Table 3.1d that the conditional probability P(E=e | Z = z) is now equal 
to 0.5 in both strata of Z; this demonstrates the independence of E and Z in the 
calculated pseudopopulation.  Because E and Z are (now) independent, the crude 
estimate of the effect of the exposure on the outcome in the pseudopopulation will 
be unbiased with respect to Z. The last step of this analysis, therefore, is to combine 
the two populations back into a single population and calculate the crude risk ratio 
(Table 3.1e). 
Note that the IPTW-risk ratio of 2.370 is very close to the MH-risk ratio of 
2.375.  Thus, we have shown how IPTW can control for confounding.  Similar 
arguments apply to inverse probability of censoring weights. 
Basic implementation of time-to-event marginal structural models using 
IPW.  Generally speaking, the implementation of a marginal structural model for 
time-to-event data is as follows, assuming we are trying to estimate the effect of a 
Treatment on an Outcome given a set of k covariates Z measured as z.  Assuming 
this, the MSM will attempt to estimate the quantities 
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 P(Outcome | set T=1)  and 
P(Outcome | set T=0) 
 
where we borrow “set T=1” terminology from Sato and Matsuyama (Sato and 
Matsuyama 2003) to indicate the situation had everyone in the target population (the 
whole population) were exposed, compared with everyone in the target population 
having been unexposed.  This terminology implies the positivity assumption holds; 
that is that it is (at least probabilistically) sensible to talk about setting the exposure 
status of everyone in the population to one exposure or another.  Our IPTWs are 
therefore attempting to estimate the conditional probability P(T=t | Z=z). 
First, the data analyst constructs a discrete time hazard model (DTHM) for the 
data, such that each person-time-unit of experience is a separate observation.  
When analyzed using pooled log-binomial regression the DTHM will approximate 
proportional hazards regression, and with infinite sample size the two models are 
equivalent as the size of the person-time-unit approaches zero (or rather, the point 
where each person-time-unit is small enough that each contains only a single event).  
While DTHM for MSM are often analyzed using logistic regression (e.g. (Hernán, 
Brumback, and Robins 2000)), the use of logistic regression means that the model 
will estimate the hazard odds ratio rather than the hazard ratio itself (Muthén and 
Masyn 2005); the hazard odds ratio, in turn, should approximate the hazard ratio 
under the same conditions as the odds ratio will estimate the risk ratio:  that is, when 
prevalence of the outcome is low. 
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Then the data analyst estimates weights for each person-time-unit in the 
DTHM (a process which is computer intensive and may well be a limiting factor on 
the size of the time-unit used in the DTHM).  Probability of treatment (which is then 
trivially transformed into weights, see Appendix of (Hernán, Brumback, and Robins 
2000)) are typically estimated using simple or polytomous logistic regression to 
predict the treatment, in a model such as: 
 
logit(treatment) = β0 + βj * zj  
 
where treatment is (typically) categorical and often binary, logit is the log-odds 
transformation of risk, and i goes from 1 to k.  (Continuous treatments are more 
difficult to deal with, and we do not address them in this dissertation, so discussion 
will be deferred.)  If treatment is time-varying (as in Figure 3.1) then this model will 
contain both baseline and time-updated covariates. 
If we also wish to estimate the effect in absence of censoring, then the causal 
effect being estimated is: 
 
 P(Outcome | set T=1 & set C=0)  and 
P(Outcome | set T= 0 & set C=0) 
 
As a result, our weights must control for P(T=t & C=0 | Z=z).  Using symbolic logic, 
we find that this statement is equivalent to P(T=t | Z=z) * P(C=0 | T=t, Z=z).  Thus, in 
estimating the inverse probability of censoring weights, we use the model 
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ln(uncensored) = β0 + β1 * Ti + βj * xj  
 
IPTW and IPCW can be combined by simple multiplication; at this point, every 
observation of person-time has its own weight. Then a weighted GEE is used to 
implement the crude structural model 
  
ln(pr(Outcomejk=1 | Outcomej(k-1)=0) = β0 + β1 * Ttk 
 
where Outcomejk is the outcome for patient j at time k, and Tjk is the treatment (or 
exposure) for patient j at time k.  In the case where the exposure violates the 
proportional hazards assumption, this generalizes to: 
 
ln(pr(Outcomejk=1 | Outcomej(k-1)=0) = β0 + β1 * Ttk + β2 * Ttk * ft(k) 
 
where ft(k) is some function of current time k, such as I(k>3 months).  These general 
models were adapted from Cole et al.(Cole et al. 2007). 
 
EXTENSIONS OF MARGINAL STRUCTURAL MODELS 
 
With simple IPTW (and IPCW, but here restricting discussion to IPTW for 
simplicity; all arguments apply analogously to IPCW), occasionally we will estimate a 
weight which is extremely large.  As Robins says, “These few subjects will contribute 
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a very large number of copies of themselves to the pseudopopulation and thus will 
dominate the weighted analysis, with the result that our IPTW estimator will have a 
large variance and will fail to be approximately normally distributed.” (Robins, 
Hernán, and Brumback 2000).  Experience shows that this is especially true when 
including factors in the IPTW model which are strongly associated with exposure but 
only weakly associated with outcome.  
We can stabilize by multiplying our weights by the unconditional probability of 
the treatment received (Robins, Hernán, and Brumback 2000), P(T=t), which has the 
effect of forcing the mean of weight to equal 1 and reducing the variance of the 
IPTW.  However, stabilization by unconditional probability of treatment received may 
not sufficiently stabilize weights – and this, unfortunately, is where the 
implementation of IPTW becomes as much an art as a science.  In this dissertation, 
we have chosen to use a traditional regression backwards-elimination strategy (in a 
non-weighted preliminary analysis) to determine which risk factors for exposure are 
true confounders of the outcome, and therefore which ought to be included in weight 
models, but other strategies are possible (and perhaps more desirable).  For 
instance, van der Laan et al. have used recursive partitioning algorithms with 
multiple potential interaction and polynomial terms to search the space of possible 
model specifications, a method which makes fewer assumptions than the 
backwards-elimination method used here; however, their approach uses custom 
software and is neither well-documented nor independently well-validated. 
Typically and more generally, when examining a time-varying exposure, 
covariates measured at baseline are used in both the stabilization (numerator) and 
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weighting (denominator) components of IPTW, while time-varying covariates are 
included only in the denominator.  Note that this implies that the limit as time-varying 
covariates become randomized with respect to the exposure in this model (that is, 
are not predictive of exposure), stabilized IPTW will converge to 1.  In general, a 
factor which is included in both the numerator and denominator of IPTW will not be 
fully controlled for in the structural model.  Thus, true confounders of the exposure-
outcome relationship must be included in the structural model as well, which 
transforms the structural model into the following: 
 
 ln(Outcomeij | xi0) = β0 + β1 * Tij + βj * xj0  
 
where xij is the observed covariates for person i measured at time 0 – that is, 
baseline covariates (again, formula adapted from Cole et al.(Cole et al. 2007)).  Note 
that in this model – which is common in the MSM literature (Cole et al. 2007; Cole et 
al. 2005; Cole et al. 2003; Hernán, Brumback, and Robins 2000; Lopez-Gatell et al. 
2007) – the effect being estimated is no longer purely marginal, but is instead a 
marginal effect conditional on baseline covariates.  This point is often lost in 
discussions in the literature.  Additionally, according to Cole it is acceptable to 
include non-confounding variables in both the numerator and denominator of IPTWs 
to improve stabilization (i.e., bring variance of weights down) (Cole 2008). 
While most published examples of MSM assume that the proportional 
hazards assumptions holds, there is no bar to relaxing the PHA by – for instance – 
including a time-interaction term in the main model; an example can be found in 
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Cole et al. (Cole et al. 2007).  However, if MSM are applied to baseline exposure 
only, the analyst must include a time-interaction variable in the structural model to 
ensure a hierarchically well-specified model.   
Finally, we note that in relaxing the PHA we face the same potential for 
selection bias as is faced in RCTs which evaluate outcomes in a subset of 
individuals selected after randomization.  In either case, selection bias occurs when 
evaluating the effect of baseline covariates on the effect of a baseline exposure on 
an outcome which is conditional on not having had an earlier outcome.  For 
example, if we are examining an outcome from months 0-2 and then from 3 
onwards, the only individuals who will be at risk of the outcome at month 3 are those 
who did not experience the outcome by month 2.  As a result, there is a selection for 
those at risk of the outcome in months 3 and onward; due to this selection bias, 
randomization is not guaranteed to hold after baseline (Shepherd et al. 2006). 
 
METHODS AND DEFINITIONS SPECIFIC TO CHAPTER V 
 
This section will concentrate on statistical methods, with references to the 
previous sections on MSM and IPTC weights.  A directed acyclic graph-causal 
diagram (DAG) for the investigation in Chapter V is shown in Figure 3.2.  We 
examined the effect of prevalent, treated, pulmonary TB at the time of HAART 
initiation on hazard of mortality during follow-up. 
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We described differences in baseline exposure category using descriptive 
statistics including chi-square tests to compare categorical variables, t-tests to 
compare means, and the Wilcoxon rank-sum test to compare medians.   
We assessed the proportional hazards assumption for the exposure variable 
in univariate and multivariate analysis through visual inspection of survival curves, 
log-survival, and log-log-survival plots, as well as Cox tests of both continuous and 
categorical time interactions. 
The first main analysis (model 1) examined the marginal effect of any TB at 
time of initiation of HAART on all-cause mortality during follow-up, adjusting for 
baseline confounders.  The second analysis (model 2) examined the effect of time 
lag between initiation of TB therapy and initiation of HAART on mortality on HAART, 
where time lag was categorized in approximate quartiles of duration of TB treatment 
prior to initiation of HAART: >120 days, 60-120 days,  30-60 days, and <30 days. 
Both models were implemented using IPTC weighted-MSM as described 
above, using log-binomial discrete time hazard model with one observation per 
person-month and an “independent” correlation matrix (Hernán, Brumback, and 
Robins 2000).  We performed an equivalent analysis using one observation per 
person-week to ensure that one observation per person-month did not lose 
important information; person-months were found to be adequate. 
In model 1, IPTW were estimated using simple logistic regression and 
stabilized with the unconditional prevalence of observed exposure (TB).  In model 2, 
IPTW were estimated using polytomous logistic regression and stabilized similarly.  
We considered the following as predictors for both the weight and censoring models: 
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gender, ethnicity, employment status, age, history of antiretroviral therapy, history of 
TB; and baseline measures of pregnancy, peripheral neuropathy, hemoglobin 
(adjusted for sex, pregnancy status, and altitude), BMI, CD4 cell count, and WHO 
stage (IV or other), year of enrollment (measuring years starting at baseline), and 
whether treatment was initiated after October 2006 (when all fees for treatment were 
eliminated).  In addition, time-varying censoring models accounted for time-updated 
measures of hemoglobin, CD4 count, and BMI, as well as for month of follow-up with 
both a linear month and cubic spline terms for month of follow up (derived using the 
SAS macro RCSPLINE(Harrell 2004), with knots at the approximate 5th, 25th, 50th, 
75th and 95th percentiles of survival time (Fairall et al. 2008; Hernán, Brumback, and 
Robins 2000)).  
We did not control for HAART adherence, successful virologic suppression, or 
initial HAART regimen (NVP vs. EFV) because these factors either occur during 
follow-up or may be affected by the exposure (and would therefore be part of the 
causal mechanism of the exposure on the outcome). 
If patients initiated TB therapy outside of the HAART clinic and then died 
before starting HAART, they would never enter the study (i.e., they would be left-
truncated), and thus the mortality attributable to TB could have been 
underestimated.  Consequently, our results must be interpreted conditionally - given 
that an individual who initiated TB therapy survived until initiating HAART, there was 
no effect of being on treatment for TB on mortality on HAART.  At the same time, 
however, many (if not most) individuals initiate HAART because of the diagnosis of 
an opportunistic infection such as pneumonia or Cryptococcal meningitis; deferring 
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therapy among such individuals can markedly increase risk of death or progression 
to AIDS (Zolopa et al. Abstract 142 CROI 2008).  Thus, it is unlikely that left 
truncation due to TB would bias these results unless left truncation due to TB acted 
differently than left truncation due to these other indications.  To the extent that left-
truncation remains a problem in this analysis, other have proposed inverse 
probability weighting approaches to left truncation-like problems (e.g. (Cole et al. 
2004)); unfortunately, we did not have the data in this cohort to take such an 
approach and instead dealt with this in sensitivity analysis. 
A related problem is that we may have adjusted for intermediates on the 
causal pathway between TB and mortality, thus biasing the effect estimate towards 
the null.  If TB treatment, initiated 120 days ago, affects key risk factors for death 
(e.g., CD4 count or BMI) then controlling for baseline risk factors amounts to 
controlling for a factor on the causal pathway. We hypothesized that if this effect 
were significant, we would see evidence of increasing bias with increasing lead time; 
this was examined in the study. Similarly, in sensitivity analysis we limited exposure 
to recent TB only and to recent and early incident TB only, situations which should 
not suffer from this bias. 
Another limitation of the study resulted from the lack of data on culture- or 
smear-confirmation of TB in most cases and likewise no information on drug 
resistance; as a result, there may have been misclassification of the exposure.  We 
investigated the possibility of a sensitivity analysis using only those TB cases on 
which we had smear results, but the numbers were too small to enable such a sub-
analysis.  Thus, this is a limitation of the study to be discussed. 
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Sensitivity and secondary analyses. We performed seven sensitivity 
analyses.  To limit the potential effects of individuals dying between initiation of PTB 
treatment and initiation of HAART (i.e., left-truncation), we restricted PTB to cases 
who initiated HAART within 30 days of start of PTB treatment (S1) and separately to 
cases who initiated PTB treatment 30 days before or after initiation of HAART (S2). 
To assess the effect of PTB on early mortality, we restricted follow-up to the first four 
months of HAART (S3).  To determine the effect of the exposure among the 
exposed, we calculated the weighted standardized mortality ratio for PTB (S4).(Sato 
and Matsuyama 2003)  We used a traditional proportional hazards regression 
approach (with adjustment rather than reweighting) (S5).  To ascertain the extent of 
bias due to LTFU, we examined the main effect estimate without censoring weights 
(S6).  Last, to ensure that the effects of this study were not limited to PTB, we 
repeated analysis 1 using both pulmonary and extrapulmonary tuberculosis as the 
exposure category (S7). 
Last, we performed a secondary analysis to examine effect measure 
modification of PTB by key baseline risk factors for mortality in people living with 
HIV, including severe immunosuppression (CD4≤50 cells/mm3 or WHO stage IV 
disease), malnutrition (underweight, BMI<18.5 kg/m2), and anemia. 
 
METHODS AND DEFINITIONS SPECIFIC TO CHAPTER VI 
 
This specific aim requires several specific definitions, after which we will 
describe the statistical methods used in this analysis.  A DAG for the baseline 
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analysis is shown in Figure 3.3, and a simplified DAG showing only components of 
the time-varying analysis are shown in Figure 3.4.  Figures 3.2 and 3.3 are similar, 
largely because (a) the exposures in the two figures are very similar (though not 
identical), and (b) the outcome of stavudine substitution is related to issues of 
toxicities and virologic failure, which are in turn closely related to and causal of 
mortality.  
The key differences between the exposure in this study and the previous 
study is that while in the previous study we examined treated pulmonary TB at time 
of HAART initiation, here we examine the exposure of TB treatment (for pulmonary 
and/or extrapulmonary TB) at both time of HAART initiation and during follow-up. 
Study site, clinic procedures, data collection.  This study was conducted 
on the Themba Lethu Clinical Cohort, a prospective cohort of adults initiating 
HAART.  The clinic is located in Helen Joseph Hospital, Johannesburg, South Africa, 
and funded by the South African Government, Gauteng Province SA, PEPFAR, and 
USAID, and operated as a collaborative project with the Clinical HIV Research Unit 
of the University of the Witwatersrand and the non-profit Right To Care.  Themba 
Lethu is one of the largest single clinics providing HAART in South Africa and has 
initiated patients on HAART at a rate of approximately 200 per month since April 
2004.  After initiating HAART, patients are scheduled for monthly pharmacy visits 
and clinical visits to Themba Lethu Clinic at 4 months and every 6 months thereafter. 
Clinical data as well as CD4 counts, hemoglobin, and other laboratory diagnostics 
are collected at all visits, except for viral loads which are not collected at baseline.  
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All data were stored in the TherapyEdge™ (TherapyEdge Inc., USA) database, and 
analyzed in SAS v9.1.3 (SAS Institute, NC, USA). 
Therapy for TB is usually initiated outside of Themba Lethu Clinic.  The 
standard course of TB treatment in South Africa is six months:  two months of 
isoniazid, rifampicin, pyramizade, and ethambutol followed by four months of 
isoniazid and rifampicin (Republic of South Africa Department of Health 2004).  The 
course of therapy is longer if the patient does not respond to treatment, has 
relapsed, or has drug resistant TB.  Vitamin B6 (pyridoxine) is commonly prescribed 
at time of initiation of TB treatment.  Amitriptyline  is commonly prescribed for 
individuals experiencing peripheral neuropathy (Saarto and Wiffen 2007) in the 
Themba Lethu Clinic. 
Definitions.  Patients were eligible for this study if they initiated a stavudine-
containing HAART regimen at Themba Lethu Clinic between April 1 2004 to March 
31 2007 (Republic of South Africa Department of Health 2004). 
The exposure of interest for the main analysis was TB treatment, defined as 
therapy for pulmonary or extrapulmonary TB which included isoniazid.  There were 
three specific exposure categories:  ongoing TB treatment at time of HAART 
initiation; recent initiation of TB treatment; and incident TB treatment during HAART.  
Ongoing TB treatment was defined as TB treatment started at least two weeks 
before initiation of HAART.  A two-week cutoff was chosen based on the South 
African National ARV Guidelines recommendation to wait at least two weeks 
between initiation of TB treatment and HAART.  Recent initiation of TB treatment 
was defined as initiation of TB treatment 0 to 14 days before initiation of HAART.  
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Last, incident TB treatment was defined as any TB treatment which began after 
initiation of HAART.  A schematic diagram for these exposure categories is shown in 
Figure 6.1 in Chapter 6. 
In analyses of ongoing and recent TB treatment, patients were censored at 
time of incident TB.  In the analysis of incident TB treatment, individuals who had 
ongoing or recent TB treatment became eligible for incident TB one month after the 
recorded completion of their previous course of TB treatment, or nine months after 
the initiation of the previous course of therapy, if no end date was available.  When 
these patients became eligible for the incident TB analysis, they were marked as 
having a history of TB treatment (just as patients with ongoing or recent TB 
treatment might have such a history).  Individuals who experienced multiple 
episodes of incident TB were censored at the second episode. 
The outcome of all-cause d4T substitution was defined as the event of 
substitution of a single drug (most often zidovudine [AZT]) for d4T while the rest of 
the regimen remained unchanged.  Patients were still at risk during treatment 
interruptions and after drug substitutions for drugs other than d4T.  Drug substitution 
events in which d4T and other drugs were substituted simultaneously (multi-drug 
substitutions) were considered competing events and cause for censoring in the 
main analysis, but were included as outcomes in a sensitivity analysis. 
Statistical analyses. There were three main analyses, corresponding to the 
three exposures defined above.  In all analyses, we controlled for confounding and 
censoring using inverse probability of treatment and censoring (IPTC) weights (Cole 
et al. 2007; Hernán, Brumback, and Robins 2000; Robins, Hernán, and Brumback 
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2000).  Analyses were implemented as discrete time hazard models, and evaluated 
using log-binomial generalized estimating equations models, which controlled for 
within-individual correlation using an “independent” correlation matrix for robust 
standard errors in the presence of repeated observations (Hernán, Brumback, and 
Robins 2000). 
Stabilized weights for TB treatment were estimated using ordinary logistic 
regression, and histograms of multivariate treatment weight models were examined 
to ensure that the positivity assumption (see Appendix) was met (Hernán and 
Robins 2006). The estimation of stabilized censoring weights was complicated 
because of the issue of competing risks (Matsuyama and Yamaguchi 2007) of multi-
drug substitution, death, and lost to follow-up, all of which may be informative with 
respect to the outcome of stavudine substitution.  In a marginal structural model, the 
most intuitive solution to this problem is to extend IPTC weights to encompass 
multiple causes of censoring (Matsuyama and Yamaguchi 2007).  Because initial 
analysis showed little change in estimates and confidence intervals when modeling 
outcomes of lost to follow-up and death separately, we estimated a single weight for 
both outcomes and a separate weight for the competing risk of multi-drug 
substitution (except in sensitivity analysis). 
Possible predictors for both the weight and censoring models were gender, 
ethnicity, employment status, age, history of antiretroviral therapy, previous history 
of TB treatment; and baseline measures of pregnancy, peripheral neuropathy, 
hemoglobin (adjusted for sex, pregnancy, and altitude), BMI, CD4 cell count, and 
WHO stage (IV or other), calendar date, and whether treatment was initiated after 
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October 2006 (when all consultation fees were eliminated by the Department of 
Health).  In addition, time-varying censoring models accounted for time-updated 
measures of hemoglobin, CD4 count, BMI, and initial virologic success (measured at 
month 6), as well as for month of follow-up as both a continuous and categorical 
variable.  Predictors were removed from weight models if they were not found to 
confound the outcome in traditional proportional hazards regression using 
backwards elimination (with an alpha of 0.10 for removal).  Some of these variables 
were subsequently added back to both the weight and stabilization models to 
increase the stability of the final IPTC weights. 
We did not account for administrative (right) censoring (AC) in our IPCW.  
This is in contrast to some reports of MSM in the literature (e.g. (Hernán, Brumback, 
and Robins 2000)) but in concert with others (e.g. (Cole et al. 2007)).  Because all 
observed person-time is included for analysis in this cohort, to introduce selection 
bias AC would have to act such that (for instance) a first person-month of 
observation which took place from March 1 to March 31 2007 (the month before AC) 
was not exchangeable with a first person-month of observation which took place 
from April 1 to May 1 2004 (the first possible month of observation), conditional on 
the observed covariates.  For this bias to be significant, then, there would need to be 
at least one important unmeasured confounder, the effect of which changes 
substantially in time.  We believe that this situation is relatively unlikely, and that to 
the extent that it is possible, controlling for year of enrollment and for whether or not 
all clinical treatment was free of charge at time of HAART initiation, in addition to a 
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large number of demographic and clinical factors, makes it unlikely that AC will 
introduce significant selection bias into this investigation. 
The components of the final treatment model for all three exposures are 
shown in Table 3.2, and further detail for these models are given in Appendix III.  
Note that the final model for incident TB included baseline factors in the final 
structural model, which was not true of the ongoing/concurrent weight models.  As 
such, while the estimates from the ongoing and concurrent models can be 
interpreted as purely marginal estimates of effect, the estimate from the incident 
model must be interpreted as conditional on baseline covariates included in the final 
model. 
Proportional hazards assumption in this analysis.  Preliminary analysis 
indicated that the effect of TB treatment on hazard of stavudine substitution 
decreased markedly with time and thus violated the proportional hazards 
assumption.  We therefore we included a categorical time-interaction term (Cole et 
al. 2007) to allow the hazard ratio (HR) to change at the beginning of the third month 
of concomitant TB treatment and HAART.  We included an additional time-
interaction term for months 3-6, as TB treatment lasts 6 months except in cases of 
drug resistance or retreatment (Republic of South Africa Department of Health 
2004). 
Thus, in this framework, the effect estimate for “7+ months” estimates the 
combined effect of (a) TB therapy from month seven onwards and of (b) the effect of 
having completed TB therapy (after a standard course of six months). 
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Secondary and sensitivity analyses. For each of the three main models, we 
performed several sensitivity analyses.  We included multi-drug substitutions 
(excluding switches to second-line HAART) as outcomes (S1); we replaced the 
treatment portion of the IPTC weights with simple adjustment for confounding (S2); 
we truncated IPTC weights to the 99th and 1st percentile to ensure that no individual 
observations contributed excessively to effect estimates (S3); we estimated the 
relative effect of the exposure among the exposed (the standardized morbidity ratio) 
for each group (Sato and Matsuyama 2003) (S4); and we restricted the referent 
group to those without recorded history of TB (S5) to ensure that lingering peripheral 
neuropathy from previous drug exposures did not bias the results. 
We performed one additional sensitivity analysis (S6) for ongoing TB 
treatment only, stratifying results by length of TB treatment prior to initiation of 
HAART in two categories chosen based on treatment guidelines (Republic of South 
Africa Department of Health 2004): 2 weeks to 2 months after initiation of TB 
treatment (15-60 days), and after two months (the continuation phase of TB 
treatment, 61+ days). 
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3.1a-e. Step-by-step example of how inverse probability of  treatment weights work 
in a 2x2 table 
 
Table 3.1a.  Crude example 2x2 table. 
Crude Disease No disease Total Risk Risk ratio 
Exposed 120 280 400 0.300 
Not exposed 40 360 400 0.100 3.000 
 
Table 3.1b.  Table 3.1a stratified by confounder Z. 
Z=1 Disease No disease Total Risk Risk ratio 
Exposed 110 190 300 0.367 
Not exposed 30 170 200 0.150 2.444 
Z=0 Disease No disease Total Risk Risk ratio 
Exposed 10 90 100 0.100 
Not exposed 10 190 200 0.050 2.000 
Mantel-Haenszel estimate 2.375 
 
Table 3.1c.  Calculation of conditional probability of exposure. 
Z=1 Disease No disease Total P(E=e | Z=1) 
1 / P(E=e | 
Z=1) 
Exposed 110 190 300 0.600 1.667 
Not exposed 30 170 200 0.400 2.500 
Z=0 Disease No disease  P(E=e | Z=0) 
1 / P(E=e | 
Z=0) 
Exposed 10 90 100 0.333 3.000 
Not exposed 10 190 200 0.667 1.500 
 
Table 3.1d.  Application of inverse probability weights from Table 3.3. 
Z=1 Disease No disease Total P(E=e | Z=1) 
Exposed 183.33 316.67 500 0.500 
Not exposed 75.00 425.00 500 0.500 
Z=0 Disease No disease Total P(E=e | Z=0) 
Exposed 30.00 270.00 300 0.500 
Not exposed 15.00 285.00 300 0.500 
 
Table 3.1e.  Crude risk ratio in combined pseudopopulation. 
ALL Z Disease No disease Total Risk Risk ratio 
Exposed 213.33 586.67 800 0.267 
Not exposed 90.00 710.00 800 0.113 2.370 
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Table 3.2.  Variables included in final IPTW models for three exposures. 
Ongoing and 
concurrent Incident Covariate 
Weight Stabilization Weight Stabilization Marginal 
Female √  √ √ √ 
Ethnicity √ √ √ √  
Employment √ √ √ √  
Age √  √ √ √ 
History of TB √ √ √ √  
History of ART √  √ √ √ 
Pregnant √  √ √ √ 
Baseline PN √  √ √ √ 
Hemoglobin      
Baseline √ √ √ √  
Current   √   
BMI      
Baseline √* √* √ √ √ 
Current   √   
CD4      
Baseline √ √ √ √  
Current   √   
WHO stage √ √ √ √  
Year/enrollment √ √ √ √ √ 
Free treatment √ √ √ √ √ 
Month/follow-up √  √ √  
Virologic failure √  √ √  
* indicates that this variable was coded differently (different referent groups) in the two models.
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Figure 3.1.  Directed acyclic graph for an analysis for which a marginal structural 
model is indicated. 
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Figure 3.2.  Directed acyclic graph of conceptual causal model for the effect of 
prevalent therapy for pulmonary TB at time of HAART initiation, and subsequent risk 
of mortality. 
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Figure 3.3.  Directed acyclic graph of conceptual causal model for the effect of 
ongoing or concurrent TB therapy and risk of subsequent substitution of stavudine. 
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Figure 3.4.  Simplified directed acyclic graph of conceptual causal model for the 
effect of incident TB therapy and risk of subsequent substitution of stavudine.  This 
diagram is simplified in that it includes only time-varying confounders; baseline 
confounders of the relationship are shown in Figure 3.3. 
 
 
 
 
  
 
 
 
CHAPTER 4 
OUTCOMES OVER THREE YEARS OF ANTIRETROVIRAL THERAPY SCALE-UP 
IN JOHANNESBURG, SOUTH AFRICA:  THE THEMBA LETHU CLINICAL 
COHORT 
 
 INTRODUCTION 
 
Infection with human immunodeficiency virus (HIV) affects over 33 million 
people globally (UNAIDS/WHO 2007).  Although global access to highly active 
antiretroviral therapy (HAART) has increased dramatically, the majority of those in 
need remain untreated, especially in sub-Saharan Africa.  In response, the World 
Health Organization (WHO) has set the goal of universal HAART access by 2010 
(WHO 2006). Large scale HAART rollouts using a public health approach are 
essential to meet this goal. Several reports from sub-Saharan Africa have confirmed 
the success of these rollouts and have provided evidence that HAART can save the 
lives of countless people living with HIV/AIDS (Bekker et al. 2006; Ferradini et al. 
2006; Hawkins et al. 2007; Lawn, Badri, and Wood 2005; Lawn et al. 2006, 2006; 
Lawn et al. 2006; Lawn et al. 2005; Libamba et al. 2006; Stringer et al. 2006; Wools-
Kaloustian et al. 2006). 
Despite the success of these programs, much of current need for HAART 
remains unmet, a situation exemplified by the Republic of South Africa (SA).   With 
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more than five million individuals living with HIV and AIDS, SA has the single largest 
population of HIV-infected individuals in the world (Kapp 2007; UNAIDS/WHO 2007).  
In August 2003, the South African Cabinet made a commitment to provide HAART in 
the public Health sector and an Operational Plan on Comprehensive HIV and AIDS 
Care, Management and Treatment for SA was published in November 2003. 
Unfortunately, although South Africa has the largest number of people receiving 
HAART in the world (South African National AIDS Council 2007), scale-up of 
HAART has been slower than anticipated, and the so-called treatment gap in South 
Africa remains in excess of 500000 individuals. 
Extremely rapid expansion and rollout of HAART is required to meet the need 
in SA and throughout sub-Saharan Africa; however, the published literature still 
lacks comprehensive, rigorous assessments of outcomes of HAART in such 
situations.  To this end, we describe clinic procedures, enrollment characteristics, 
and basic outcomes of individuals initiating HAART over three years of rollout and 
treatment in the Themba Lethu (“Our Hope”) Clinic in Johannesburg, SA. 
 
METHODS 
 
Study site.  The Themba Lethu Clinic (TLC), located in Helen Joseph 
Hospital in urban Johannesburg, is the single largest clinic providing HAART to HIV-
infected adults in Africa, with over 10000 individuals in care by January of 2008.  
TLC is a joint project of the South Africa Department of Health Provincial HIV and 
AIDS Comprehensive Care Management & Treatment program, and Right to Care, a 
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non-profit organization dedicated to providing HAART and receives additional 
funding from the Gauteng Province Department of Health, United States PEPFAR, 
the United States Agency for International Development.  TLC is supported by 
researchers and clinicians from the Clinical HIV Research Unit of the University of 
Witwatersrand.  Patients were referred to TLC from voluntary counseling and testing 
clinics, hospitals, prenatal care facilities, and by self-referral. All patients in TLC 
received antiretroviral medications free of charge. Patients paid 35 Rand (about $5 
US) per clinic visit prior to October 2006, after which all fees were eliminated. 
Treatment and clinical care.  As per the South African national guidelines, 
the majority of first-line HAART regimens given in the TLC included stavudine (d4T), 
lamivudine (3TC), and either efavirenz (EFV) or nevirapine (NVP) (Regimens 1a and 
1b, respectively).  Some individuals – mostly pregnant women – received Kaletra® 
(lopinavir boosted with ritanovir, LPVr) in place of EFV or NVP; a small number of 
individuals initiated zidovudine (AZT) instead of d4T.  Second-line HAART typically 
included AZT, didanosine (DDI), and LPVr. 
Patients visited TLC at time of HAART initiation (month 0); regular follow up 
visits were scheduled at months 4 and every six months thereafter. A typical clinic 
visit involved initial assessment by a nurse, evaluation by a doctor or nurse-
practitioner, pharmacy visit, blood draw, and adherence counseling if necessary; in 
addition, patients could opt to receive individual or group wellness counseling. 
Patients also visited the clinic one month after each assessment visit to receive test 
results and adjust medications. Patients who had not suppressed HIV by month 4 
were scheduled for monthly visits until viral suppression was achieved, and patients 
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who experienced drug toxicities or other health problems were seen as required.  In 
addition to clinical visits, patients visited the pharmacy monthly or bi-monthly to 
receive prescription medications. 
Patient demographics and clinical measurements were recorded at every 
clinic visit; laboratory measures including viral load, CD4 count, and hemoglobin 
were collected at baseline (except viral load) and at each regular follow-up visit. All 
laboratory assays were performed by the South African National Health Laboratory 
Service (NHLS). 
Data capture and quality.  Throughout the three years, data from clinical 
records were entered into the TherapyEdge™ (TherapyEdge Inc., USA) database. 
Results were regularly quality controlled by a senior nurse or data quality assurance 
manager.  Some laboratory values (CD4 counts, viral loads, and hemoglobin) were 
integrated into existing data from an NHLS database.  The duplicate entry of a 
subset of laboratory values in both TherapyEdge and the NHLS database served as 
a de facto validation study of quality of data entry into TherapyEdge. 
Definitions. Patients who did not show up for a scheduled appointment 
(including pharmacy visits) were categorized as defaulters; patients more than three 
months late were categorized as lost to follow-up (LTFU). LTFU designations were 
considered confirmed LTFU if the follow-up team was unable to locate the patient 
after three phone calls and a home visit.  LTFU patients were censored midway 
between the last recorded visit and the next scheduled visit if available, or at last 
recorded date of receipt of therapy. 
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Collectively, drug regimen changes comprised both individual drug 
substitutions (e.g., the substitution of AZT for d4T), or drug regimen switches, from 
first to second line HAART.  Virologic suppression was defined as viral load ≤ 400 
copies/ml, and initial virologic success was defined as virologic suppression within 
six months of HAART initiation.  Body mass index (BMI) was categorized as 
underweight (< 18.5 kg/m2), normal (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), 
and obese (≥30 kg/m2) (WHO 2008). Anemia was defined as a hemoglobin (Hb) 
value below 13.0 g/dl (men), 12.0 g/dl (women), or 11.0 g/dl (pregnant women) 
(WHO 2001).  Because Hb increases with elevation (Cook et al. 2005; Ruiz-
Arguelles 2006; WHO 2001) and Johannesburg is 1753 meters above sea level 
(Wikipedia 2008), Hb values were down-adjusted by 0.65 g/dl (WHO 2001).  
Baseline covariates were those collected closest to time of initiation of HAART, and 
no more than four months before initiation of HAART or one month after initiation. 
Statistical analysis.  Patients who initiated HAART at TLC between 1 April 
2004 and 31 March 2007 were eligible for the analysis. Patients were excluded if 
they had missing or incomplete information on initial HAART regimen or initiated a 
non-HAART ART regimen in TLC.  Baseline demographics were characterized using 
standard descriptive statistics.  Chi-square tests were used to compare categorical 
variables and Wilcoxon rank-sum tests for continuous variables by category.  Rates 
were estimated from crude Poisson models; risks were estimated from simple 
proportions. 
We examined four main outcomes in this study: initial virologic success, 
death, combined death or LFTU, and CD4 gain during follow-up.  Analyses were 
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intent-to-treat with regards to HAART, ignoring treatment interruptions and drug 
substitutions in time to event analyses.   
Initial virologic success was evaluated using descriptive statistics.  To 
examine risk of death and combined risk of death or LTFU, we created Kaplan-Meier 
curves stratified by baseline CD4 counts and examined mortality risk stratified by 
both baseline CD4 count and WHO stage. In addition, we used Cox proportional 
hazards models to estimate hazard ratios for predictors of death and combined 
death or LFTU; predictors in these models included gender, age, ethnicity, 
employment status, and baseline measurements of BMI, hemoglobin, WHO stage, 
CD4 count, pulmonary tuberculosis (TB) status, history of ART, pregnancy status, 
initial HAART regimen, and peripheral neuropathy at baseline. We used univariate 
log-log-survival plots to examine the proportional hazards assumption (PHA) for 
each variable included in Cox models and examined linear and plausible categorical 
time interactions with each covariate using chi-square tests at an alpha of 0.10. We 
used time-stratified Cox models to estimate hazard ratios in the presence of 
violations of the PHA. 
CD4 gain over time was assessed using two linear generalized estimating 
equations (GEE) models with an independent correlation matrix.  In the first model, 
we included the main variable of months since HAART initiation, indicator variables 
for baseline CD4 count, and static change points at months 4, 10, and every 6 
months thereafter until 28 months (5 changepoints) to allow the slope of CD4 
increase to change in time (Chu et al. 2005).  These changepoints were selected 
because they were the scheduled appointment times for regular follow-up visits; thus 
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data at these time points should have been least affected by selection bias, whereas 
data at other time points was typically generated as a result of patients who arrived 
for care for specific reasons and thus may have been less representative of the 
cohort as a whole (see Discussion).  The second model included all terms from the 
first model, as well as interaction terms between all baseline CD4 count categories 
and continuous time as well as all changepoints (total 24 interaction terms), to allow 
slope to change in time and by initial CD4 count. 
Sensitivity analysis and missing data.  In a small number of individuals 
missing baseline height (n=48) or weight (n=20), median height and weight for 
gender was assigned for the missing value.  Where baseline CD4 counts (N=639) or 
outcomes were missing, complete case analysis was performed.  We tested the 
validity of complete case analysis for CD4 counts by performing a sub-analysis in 
which we used multiple imputation (n=10) to fill in values of baseline CD4 count 
based on other variables in the model (including WHO stage, BMI, sex, age, and 
hemoglobin count), and compared the effect of baseline CD4 count on hazard of 
death during follow-up in the complete-case and multiple imputation scenarios.  Last, 
because we were concerned by the large ratio of recorded LTFU to recorded deaths, 
we used baseline inverse probability of censoring weights to estimate the effect of 
loss to follow-up on total crude incidence of death. 
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RESULTS 
 
Enrollment and baseline characteristics.  Between 1 April 2004 and 31 
March 2007, a total of 7583 or approximately 210 patients per month initiated first-
line HAART in TLC. Data from 7519 patients were available for analysis; 40 were 
excluded due to missing demographic information, and 24 were excluded because 
of errors in recorded dates of therapy.  Baseline characteristics of the 7519 
individuals are summarized in Table 4.1.  Two-thirds (66.5%) of patients were 
women; mean age at start of HAART was 35.4 years in women and 38.7 years in 
men (p < 0.0001). More than half (56%) were unemployed.  At time of ART initiation, 
18.4% had a BMI < 18.5. Median CD4 count at ART initiation was 88 (IQR 31-158); 
34.4% of individuals initiating HAART had CD4≤50, 55% had CD4≤100 and 88% 
had CD4 < 200. 
Therapy initiation and durability of first-line HAART.  The majority 
(78.1%) of patients initiated d4T-3TC-EFV; smaller numbers initiated d4T-3TC-NVP 
(7.8%) and d4T-3TC-LPVr (8.2%), and 5.9% initiated other regimens.  Those 
initiating LPVr regimens were more likely to be pregnant women (unadjusted OR 
147.8, 95% CI 114.0-191.4). 
During 99008 person-months follow up (mean 13.2 months per patient, 
median 11 months), 1888 (25.1%) patients experienced any change in their drug 
regimen, at a median of 273 (IQR 141-431) days of therapy.  The crude rate of drug 
regimen change was 28.5 (95% CI 27.2 – 29.8) per 100 person-years, and women 
were twice as likely to experience a drug change than men (HR for change 2.08, 
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95% CI 1.86-2.33).  172 patients (2.3%) patients were switched to second-line 
HAART, a rate of 2.1 (95% CI 1.8-2.5) drug regimen switches per 100 person-years.  
Among those who switched to second line therapy, median time on first drug 
regimen was 336 days (IQR 236-553). 
Viral suppression.  Among individuals who had viral load measured within 
six months of HAART initiation (n=5077), 4502 (88.7%) had suppressed virus to < 
400 copies/ml.  Patients on d4T-3TC-NVP suppressed virus at slightly lower rates 
than patients on other first-line regimens (85.7% vs. 88.9%, chi-square p=0.05).  In 
addition, a smaller proportion of patients with any history of anti-retroviral therapy 
previous to initiation of HAART in TLC suppressed virus (no vs. yes, 85.2% vs. 
88.8%, chi-square p=0.15). 
Survival and loss to follow-up.  7519 individuals were available for survival 
analysis. 298 (4.0%) patients died during follow-up; 111 (37.3%) within 60 days and 
(cumulatively) 204 (68.5%) within 180 days of initiating HAART.  1425 patients 
(19.0%) were lost to follow up, 382 (26.8%) of those within 30 days and 
(cumulatively) 878 (61.1%) of those within 180 days.  The crude rate of death over 
all of follow-up in this cohort was 3.6 deaths per 100 person-years (95% CI 3.2-4.1) 
over all of follow-up; in the first three months of follow-up crude mortality rate was 
8.6 (7.3-10.2) per 100 person-years; in first six months of follow-up, crude mortality 
rate was 6.8 per 100 person-years (95% CI 6.0-7.8).  Crude mortality rate rose to 7.3 
(95% CI 6.3-8.5) per 100 person years in the first six months when we accounted for 
LTFU using baseline IPMWs.  Kaplan-Meier curves for survival and combined 
outcome of alive and in care, stratified by CD4 count, are shown in Figure 4.1.  In 
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addition, crude twelve month risk of death stratified by WHO stage and CD4 count is 
shown in Figure 4.2. 
In univariate proportional hazards analysis, several baseline characteristics 
were associated with increased risk of mortality, including male gender, older age, 
low BMI, low hemoglobin, WHO stage 3 or 4, low CD4 count, prevalent TB, and 
receiving EFV-based HAART (compared to LPVr- or NVP-based HAART). 
Pregnancy and history of ART were protective.  Estimated univariate hazard ratios 
for the same risk factors were similar but attenuated (closer to the null) in analysis 
for the combined outcome of death or LTFU (not alive or not in care); exceptions 
were pregnancy and use of LPVr, both of which were both associated with increased 
LTFU. 
Hazard ratios from multivariate Cox proportional hazards models for the 
outcomes of death and death or LTFU are summarized in Table 4.2.  Key predictors 
of death included age > 55 (HR 2.36, 95% CI 1.41-3.94), CD4 count ≤ 50 compared 
to 50<CD4≤200 (HR 2.54, 95% CI 1.94-3.32), and WHO stage 3 (HR 1.47, 95% CI 
1.10-1.97) or 4 (1.96, 95% CI 1.37-2.80),  compared to WHO stages 1 and 2.  
Hazard ratios were similar but generally closer to the null in a model for the 
combined outcome of death or LTFU; however, pregnancy at baseline was 
associated with twice the risk of death or LTFU (HR=2.03, 95% CI 1.54-2.68), but 
not death alone (HR=0.84, 95% CI 0.27-2.59).  Hazard ratios for these risk factors 
on death alone are reported separately for first three months of follow-up and the 
remainder of follow-up in Table 4.3. 
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CD4 response. A “four month” measurement of CD4 count was available for 
5199 patients after a median of 118 days (IQR 110-137 days, range 61-213 days); 
median and mean CD4 count at four months were 205 and 226 cells/mm3, 
respectively, and 23.9% of patients with a CD4 measurement at four months had 
gained fewer than 50 CD4 cells/mm3 at this time.  Four-month CD4 gain differed by 
baseline CD4 count: individuals with a baseline CD4 count of ≥200 gained a mean of 
73 CD4 cells/mm3 while those with CD4<200 gained a mean of 123 CD4 cells/mm3 
(p<0.0001).  Mean and median CD4 count during follow-up for the entire cohort was 
estimated non-parametrically by month and is shown in Figure 4.3.  Mean CD4 
count and CD4 count gain during follow-up was estimated by initial CD4 count 
category using a static change-point generalized estimating equations model; these 
estimates are given in Tables 4.4a and 4.4b.  The predicted mean CD4 counts for 
the whole population at baseline and at four months from this model are 111 and 
228 cells/mm3 respectively, very close to the observed means of 109 and 226 
cells/mm3.   
Mean gain in CD4 cell count at six months was estimated at 134 (95% CI 
130-138) cells/mm3 and 188 (95% CI 183-193) cells/mm3 at twelve months.  
Patients who suppressed virus within six months experienced substantially greater 
CD4 count gains at six months compared to those who did not suppress virus.  In a 
model for the entire cohort that that controlled for baseline CD4 count, sex, and age, 
the estimated mean CD4 gain was 43 (95% CI 34-52) cells/mm3 higher at six 
months post HAART initiation among those who achieved virologic success 
compared to those who did not. 
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Major drug toxicities.  845 individuals experienced incident peripheral 
neuropathy after a median of 173 days (IQR 88-329) of HAART, corresponding to a 
rate of 11.6 cases per 100 person-years of follow-up (95% CI 10.8-12.4). Women 
experienced a slightly lower rate of this toxicity than men (incidence rate ratio 0.80, 
95% CI 0.69-0.92). 
404 individuals experienced incident lactic acidosis (n=203) or symptomatic 
hyperlactatemia (n=201), after a median of 378 days (IQR 302-519), corresponding 
to an overall rate of 5.1 (95% CI 4.6-5.6) per 100 person-years.  Women 
experienced this toxicity at 2.91 times the rate of men (95% CI 2.20-3.85).  
367 individuals experienced incident lipodystrophy, after a median of 477 
days (IQR 322-614), corresponding to a crude rate of 4.6 (4.1-5.1) cases per 100 
person-years. Women experienced lipid disorders at 4.36 (95% CI 3.09-6.16) times 
the rate of men. 
Data quality and sensitivity analysis.  We evaluated the laboratory values 
entered by hand into TherapyEdge to those matched by patient id and date from the 
NHLS databases; laboratory values matched between the two databases in 98.8% 
of cases evaluated.  In sensitivity analysis, the crude estimates of effect for baseline 
CD4 category on hazard of death did not change after multiple imputation analysis 
for missing baseline CD4 (results not shown). 
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DISCUSSION 
 
Rapid scale-up of HAART is essential to confronting the HIV/AIDS epidemic 
in South Africa and throughout the world, but will only succeed if that scale-up does 
not come at the cost of a high level of care.  These results demonstrate that a high 
level of clinical care can consistently be delivered in a rollout setting.  This is 
particularly significant given the very high enrollment rates seen at TLC, which 
initiated an average of 210 new patients on HAART every month over the period of 
this study; this rate of enrollment is nearly 4 times higher than the estimated 50-60 
patients/month/clinic initiation rate that can be calculated from comparable, 
published reports (Bekker et al. 2006; Ferradini et al. 2006; Hawkins et al. 2007; 
Lawn, Badri, and Wood 2005; Lawn et al. 2006, 2006; Lawn et al. 2006; Lawn et al. 
2005; Libamba et al. 2006; Stringer et al. 2006; Wools-Kaloustian et al. 2006). 
Our results show relatively low mortality, below 5% during three years of 
follow-up, suggesting that HAART can be extremely effective at reducing mortality in 
resource poor settings with very high rates of enrollment. However, sensitivity 
analysis by inverse probability weighting suggests true incidence of death is likely to 
be moderately higher than our observed rate of death.  This is because, while the 
TLC staff undertook great efforts to track down individuals who became LTFU in this 
cohort, it is highly likely that at least some deaths were mistakenly classified as 
LTFU in this analysis. This misclassification is likely to be non-differential with regard 
to predictors of this outcome; thus, predictors in Tables 4.2 and 4.3 are likely slightly 
biased towards the null.  Use of IPMWs increased the overall estimate of death rate 
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in the first six months only slightly from 6.8 to 7.3 per 100 person-years, suggesting 
that the magnitude of bias is likely to be small.  However, the IPMWs will only correct 
bias due to missing data to the extent that there are no unmeasured predictors of 
missingness, an unverifiable assumption. 
As with comparable studies, we found that the majority of both deaths and 
LTFU occur early (Braitstein et al. 2006; Ferradini et al. 2006; Lawn et al. 2005; 
Stringer et al. 2006),  Extending the results of other studies, we found several 
variables affected risk of death differently in early and later follow-up, violating the 
proportional hazards assumption. In particular, we found that while the effect of 
baseline CD4 count and low BMI did not appear to change over time, the effect of 
older age and WHO stage were both more strongly associated with risk of death in 
the first three months of follow-up. 
Our estimates of CD4 gain over time are concordant with other estimates 
from the literature, suggesting that these results are generalizable to other situations 
and may therefore be of use to clinicians seeking guidance on what CD4 response is 
“normal” over several years of HAART.  However – as with other models of CD4 
gain in the literature – these results must be considered conditionally, keeping in 
mind that they are representative only of those individuals who remained alive and in 
care and had CD4 counts measured.  However, as clinicians typically want to apply 
such estimates of CD4 count to exactly those patients who remain alive and in care, 
this limitation should not affect the usefulness of these data. 
Despite potential limitations of these data, however, these results are in 
accord with other key reports of HAART scale-up in the literature, and extend 
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previous findings in several key ways.  This report describes results on the most 
rapid scale-up of HAART yet reported in the literature, and demonstrates that even 
with a rate of HAART initiation approximately four times that previously reported, 
high quality of care can be maintained in resource challenged settings. 
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Table 4.1.  Baseline characteristics of 7,543 individuals enrolled in Themba Lethu 
Clinical Cohort (TLCC) from 1 April 2004 to 31 March 2007. 
 
Count (%) by sex Characteristic, lab value, condition Female (n=5015) Male (N=2528) P-value 
Age (Median and IQR) 
  
 Mean (SD) 35.4 (8.4) 38.7 (8.4) 
 Median (IQR) 34.0 (29.4-40.2) 37.2 (32.8-43.3) 
<0.0001 
Ethnicity 
  
 African or black 4817 (96.1) 2378 (94.1) 
 Coloured 167 (3.3) 97 (3.8) 
 Asian, White, or Missing 31 (0.6) 53 (2.1) 
<0.0001 
Employment 
  
 Employed, student, retired 1650 (32.9) 1086 (43.0) 
 Unemployed 2977 (59.4) 1263 (50.0) 
 Unknown or missing 388 (7.7) 179 (7.1) 
<0.0001 
BMI 
  
 < 18.5 796 (15.9) 642 (25.4) 
 18.5 – 24.9 2593 (51.7) 1543 (61.0) 
 25.0 – 29.9  1064 (21.2) 280 (11.1) 
 ≥ 30 550 (11.0) 55 (2.2) 
 Missing 12 (0.2) 8 (0.3) 
<0.0001 
Hemoglobin* 
  
 Normal 2496 (49.8) 1202 (47.6) 
 Low  2463 (49.1) 1297 (51.3) 
 Missing 56 (1.1) 29 (1.2) 
0.1892 
WHO stage 
  
 I 2372 (47.3) 1012 (40.0) 
 II 631 (12.6) 286 (11.3) 
 III 1558 (31.1) 929 (36.8) 
 IV 454 (9.1) 301 (11.9) 
<0.0001 
CD4 count 
   
 Median (IQR) 94 (37-164) 74 (23-146) <0.0001 
 Mean (95% CI) 114 (111-118) 98  (94-102) <0.0001 
 <50 1423 (28.4) 953 (37.7) 
 50 – 99 976 (19.5) 453 (17.9) 
 100 – 199 1569 (31.3) 703 (27.8) 
 200 – 349 459 (9.2) 169 (6.7) 
 ≥ 350 135 (2.7) 61 (2.4) 
 Missing 453 (9.0) 189 (7.5) 
<0.0001 
Pulmonary tuberculosis 700 (14.0) 504 (19.9) <0.0001 
History of ART 146 (2.9) 78 (3.1) 0.3224 
Pregnant 574 (11.5) NA NA 
Peripheral neuropathy (at baseline) 177 (3.5) 143 (5.7) <0.0001 
All figures are expressed as number (% total).  Marital status, age, ethnicity, employment status, 
residency, education, referral status, alcohol, and smoking are by self-report.  P-values are by chi-
square test of general association across all categories by sex (all variables are categorical).  *Lower 
limit of normal hemoglobin is 12.9 g/dl for men; 11.5 g/dl for non-pregnant women; and 10.5 g/dl for 
pregnant women. 
 140 
Table 4.2:  Multivariate hazard ratios for baseline risk factors for outcomes of 
mortality and mortality or LTFU (combined outcome) 
 
Outcome of mortality 
(only) 
Outcome of mortality or 
LTFU (combined) Baseline risk factor 
HR 95% CI HR 95% CI 
Male gender 1.13 0.88-1.45 1.27 1.14-1.42 
Age > 55 vs. age ≤ 55 2.31 1.38-3.86 1.24 0.94-1.63 
African ethnicity vs. other 0.81 0.48-1.37 0.94 0.75-1.18 
Employed vs. other 0.98 0.76-1.28 0.87 0.78-0.97 
Body mass index 
    
 BMI < 18.5 1.80 1.39-2.33 1.38 1.22-1.56 
 BMI >18.5 and BMI < 30 Reference 
 BMI ≥ 30 0.87 0.45-1.66 0.92 0.75-1.14 
Hemoglobin low vs. normal 1.60 1.21-2.10 1.34 1.20-1.49 
WHO stage 
    
 I or II Reference 
 III 1.53 1.15-2.05 1.10 0.98-1.25 
 IV 2.01 1.41-2.88 1.29 1.09-1.52 
CD4 count 
    
 CD4 ≤ 50 Reference 
 50 < CD4 ≤ 100 0.46 0.33-0.65 0.72 0.63-0.83 
 100 < CD4 ≤ 200 0.35 0.25-0.49 0.74 0.65-0.84 
 CD4 > 200 0.28 0.15-0.55 0.84 0.70-1.01 
Pulmonary tuberculosis 0.89 0.66-1.20 0.88 0.77-1.02 
History of ART 0.71 0.26-1.98 0.57 0.39-0.82 
Pregnancy 0.84 0.27-2.59 2.03 1.54-2.68 
Baseline HAART regimen 
  
  
 Contains efavirenz Reference 
 Contains nevirapine 0.62 0.34-1.14 0.90 0.73-1.10 
 Contains lopinavir-ritanovir 0.65 0.25-1.70 1.03 0.79-1.35 
Peripheral neuropathy 1.09 0.67-1.77 1.00 0.80-1.27 
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Table 4.3.  Hazard ratios (HRs) for baseline risk factors for outcomes of early (≤3 
months) and late (>3 months) mortality. 
 
Early mortality  
(within 3 months) 
Late mortality  
(more than 3 months) Baseline risk factor 
HR 95% CI HR 95% CI 
Male gender 1.13 0.79-1.61 1.14 0.80-1.61 
Age > 55 vs. age ≤ 55 2.93 1.47-5.84 1.81 0.84-3.92 
African ethnicity vs. other 0.77 0.35-1.65 0.84 0.41-1.73 
Employed vs. other 1.02 0.70-1.49 0.95 0.66-1.36 
Body mass index 
    
 BMI < 18.5 1.76 1.22-2.54 1.84 1.28-2.66 
 BMI >18.5 and BMI < 30 Reference 
 BMI ≥ 30 0.41 0.10-1.70 1.22 0.58-2.57 
Hemoglobin low vs. normal 1.61 1.07-2.42 1.60 1.10-2.32 
WHO stage (vs. stage I or II) 
    
 I or II Reference 
 III 2.00 1.29-3.10 1.23 0.83-1.83 
 IV 3.03 1.83-5.01 1.36 0.81-2.31 
CD4 count 
    
 CD4 ≤ 50 Reference 
 50 < CD4 ≤ 100 0.47 0.29-0.76 0.46 0.29-0.73 
 100 < CD4 ≤ 200 0.31 0.18-0.51 0.39 0.25-0.60 
 CD4 > 200 0.12 0.03-0.48 0.43 0.20-0.90 
Pulmonary tuberculosis 0.77 0.50-1.18 1.04 0.69-1.58 
History of ART Not estimable due to small 
sample size 1.21 0.43-3.37 
Pregnancy 0.27 0.03-2.32 1.86 0.54-6.42 
Baseline HAART regimen 
  
  
 Contains efavirenz Reference 
 Contains nevirapine 0.41 0.13-1.28 0.76 0.37-1.58 
 Contains lopinavir-ritanovir 1.41 0.47-4.24 0.25 0.06-1.04 
Peripheral neuropathy 1.21 0.63-2.31 0.92 0.45-1.90 
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Tables 4.4a and 4.4b.  Mean (SD) estimated CD4 count (4a) and gain (4b) in the 
Themba Lethu Clinical Cohort from two linear generalized estimating equations 
models. 
 
Months post HAART initiation Baseline CD4 count N 0 4 6 12 18 24 36 
Total population 6880 111 (1) 228 (2) 245 (2) 300 (3) 348 (4) 383 (5) 469 (33) 
 
        
CD4 ≤ 50 2369 22 (1) 143 (3) 166 (3) 235 (4) 295 (6) 334 (9) 359 (43) 
50 < CD4 ≤ 100 1423 76 (1) 205 (4) 221 (3) 267 (5) 304 (7) 335 (9) 482 (63) 
100 < CD4 ≤ 200 2266 149 (1) 277 (3) 290 (3) 334 (4) 378 (6) 418 (8) 303 (48) 
CD4 > 200 822 317 (6) 367 (8) 393 (8) 451 (10) 485 (12) 524 (16) 782 (116) 
 
Months post HAART initiation Baseline CD4 count N 0 4 6 12 18 24 36 
Total population 6880 N/a 116 (2) 134 (2) 188 (3) 237 (4) 272 (5) 358 (33) 
 
        
CD4 ≤ 50 2369 N/a 121 (3) 144 (2) 213 (4) 273 (6) 312 (9) 336 (43) 
50 < CD4 ≤ 100 1423 N/a 129 (4) 145 (3) 191 (5) 228 (7) 259 (9) 406 (62) 
100 < CD4 ≤ 200 2266 N/a 128 (3) 141 (3) 185 (4) 229 (6) 270 (8) 154 (48) 
CD4 > 200 822 N/a 49 (8) 76 (7) 133 (9) 167 (12) 205 (16) 464 (115) 
 
Model for total population values (CD4 model 1) included changepoints at 4 months and every 6 
months thereafter.  Model for by-strata estimates (CD4 model 2) includes all variables in CD4 model 
1 and interaction terms for each CD4 category and continuous time, and each CD4 category and 
each changepoint term (total 34 terms in model). 
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Figures 4.1a and 4.1b.  Kaplan-Meier plots of survival (4.1a) and combined outcome 
“alive and in care” (4.1b), by strata of CD4 count.  For readability, graphs have 
different X and Y axes. 
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Figure 4.2. Twelve month risk of death by CD4 count category and WHO stage at 
baseline. 
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Figure 4.3.  Predicted mean CD4 gain from baseline with 5% and 95% confidence 
bands for all individuals.  Values are conditional upon being alive and in care. 
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CHAPTER 5 
EFFECT OF PULMONARY TUBERCULOSIS ON MORTALITY IN PATIENTS 
RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY 
 
INTRODUCTION 
 
 Pulmonary tuberculosis (PTB) is a leading cause of death among HIV-
infected individuals in sub-Saharan Africa and throughout the world.(WHO 2004)  
PTB is of particular concern in South Africa, where an estimated 44% of new adult 
PTB cases arise among HIV-positive individuals.(WHO 2008)  Prior to the 
introduction of highly active antiretroviral therapy (HAART), PTB in HIV-positive 
individuals was identified as a leading cause of death even among those receiving 
PTB treatment.(Badri et al. 2001; Mukadi, Maher, and Harries 2001; Nunn et al. 
1992)  Access to HAART for individuals with HIV-PTB co-infection reduces both 
mortality(Dean et al. 2002; Dheda et al. 2004; Manosuthi et al. 2006; Meya and 
McAdam 2007) and incidence of PTB.(Badri, Wilson, and Wood 2002; Meya and 
McAdam 2007) 
Whether there are differences in prognosis between patients with PTB 
initiating HAART and patients free of active PTB when initiating HAART remains 
unresolved.  Several studies have identified PTB as a leading cause of death among 
people receiving HAART.(Etard et al. 2006; Lawn et al. 2005) A study in Uganda 
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found that among individuals receiving HAART, those who had prevalent or incident 
PTB died at 4.7 times the rate of those without PTB, although the authors 
acknowledge that the relationship was likely confounded by body mass index (BMI) 
and CD4 cell count.(Moore et al. 2007)  In contrast, a large study in Zambia reported 
no difference in mortality rates by PTB status(Stringer et al. 2006), but these results 
may have been affected by the substantial numbers of patients lost to follow-up 
(LTFU). 
Controversy also remains over the effect of time between initiation of PTB 
treatment and initiation of HAART on the risk of death.  The South African National 
Comprehensive Care, Management and Treatment Guidelines for HIV and AIDS 
recommend waiting two weeks to two months to initiate HAART, (Republic of South 
Africa Department of Health 2004; WHO 2007) because of concerns of drug-drug 
interactions, pill burden, adherence, and immune reconstitution inflammatory 
syndrome (IRIS) (McIlleron et al. 2007)  However, the WHO suggests separately 
that while it may be safer to defer the initiation of HAART, concurrent initiation of 
HAART and PTB treatment may be necessary in patients at high risk of death.(WHO 
2004) 
In this study of the Themba Lethu Clinical Cohort, a large (>7500 patients) 
Department of Health HAART treatment site in Johannesburg, South Africa, we used 
state of the art methods (inverse probability of exposure and censoring weighted 
marginal structural models) to control for both confounding and LTFU to 
comprehensively assess the impact of PTB and the treatment for PTB at the time of 
HAART initiation on subsequent all-cause mortality, both overall and by length of 
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delay between initiation of PTB treatment and initiation of HAART. In addition, we 
assessed the impact of the combined presence of PTB and other risk factors for 
mortality on survival during HAART. 
 
METHODS 
 
Study site, clinic procedures, data collection.  The Themba Lethu Clinical 
Cohort is a prospective clinical cohort of adults initiating HAART at the Helen Joseph 
Hospital in Johannesburg, South Africa. The program is funded by the South African 
Government, Gauteng Province, PEPFAR, and USAID.  Themba Lethu has initiated 
over 10,000 patients on HAART since April 2004 and is the largest single clinic 
providing HAART in South Africa, and one of the largest antiretroviral clinics in the 
world.  HAART-eligible patients attend educational and adherence sessions, and are 
assessed by a physician prior to initiating treatment.  After HAART initiation, patients 
are scheduled for monthly pharmacy visits and clinical visits at month 4 and every 6 
months thereafter and whenever needed clinically.  Clinical and laboratory (including 
CD4 count, viral load and hemoglobin) data are collected at all scheduled visits, 
except for viral load which is not collected at baseline.  All data were stored in the 
TherapyEdge™ (TherapyEdge Inc., USA) database, and analyzed in SAS v9.1.3 
(SAS Institute, NC, USA). 
South African national policy for the treatment of PTB follows the DOTS 
strategy.  Patients with PTB typically receive treatment at primary health care clinics 
(outside of Themba Lethu); data on treatment adherence was therefore not available 
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for the majority of patients.  Date of initiation of PTB treatment is by patient self-
report. 
Study eligibility and definitions.  Patients were eligible for this study if they 
initiated HAART at Themba Lethu Clinic between April 1 2004 and March 31 2007.  
The main exposure was prevalent, treated PTB (hereafter, PTB) at the time of 
HAART initiation; the main outcome for analysis was all-cause mortality.  Individuals 
more than three months late for a scheduled clinic appointment and who could not 
be located by the follow-up team after three phone calls and a visit to the last known 
address were classified as LTFU.  These patients were censored midway between 
the last recorded visit and the next scheduled or at the last recorded date of receipt 
of therapy. 
Statistical analyses.  Descriptive analyses were performed using chi-square 
tests to compare categorical variables, t-tests to compare means, and Wilcoxon rank 
sum test to compare medians.  We assessed the proportional hazards assumption 
for PTB in univariate and multivariate analysis through visual inspection of survival 
and log-log-survival curves, as well as Cox tests of continuous and categorical time 
interactions. 
Analysis 1 examined the effect of PTB at time of initiation of HAART on all-
cause mortality during follow-up.  Analysis 2 examined the effect of time lag between 
initiation of PTB treatment and initiation of HAART on subsequent mortality, where 
time lag was categorized by approximate quartile of duration of PTB treatment prior 
to initiation of HAART: >120 days, 61-120 days,  31-60 days, and ≤30 days. 
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In both analyses we controlled for confounding and LTFU using inverse 
probability of exposure and censoring weights.(Cole et al. 2007; Hernán, Brumback, 
and Robins 2000; Robins, Hernán, and Brumback 2000) Analyses were 
implemented as discrete time hazard models with one observation per person-month 
and time-updated covariates.  Models were evaluated using log-binomial 
generalized estimating equations, controlling for within-individual correlation using 
an “independent” correlation matrix for robust standard errors in the presence of 
repeated observations. Log-binomial regression was preferred to logistic regression 
because the former directly estimates the hazard ratio (HR) rather than the hazard 
odds ratio.(Muthén and Masyn 2005) 
In both analyses, stabilized weights were estimated separately for exposure 
and censoring using ordinary (Analysis 1) or polytomous logistic regression 
(Analysis 2). We considered the following factors as predictors for both the weight 
and censoring models: gender, ethnicity, employment status, age, history of 
antiretroviral therapy, history of PTB, baseline measures of pregnancy, peripheral 
neuropathy, hemoglobin (adjusted for sex, pregnancy status, and altitude), BMI, 
CD4 cell count, and WHO stage (IV or other), year of enrollment (measuring years 
starting at baseline), and whether treatment was initiated before or after October 
2006 (when consultation fees of ranging between $2-$5 per consultation were 
eliminated by the Department of Health). In addition, the time-varying censoring 
model accounted for time-updated measures of hemoglobin, CD4 count, and BMI, 
as well as for month of follow-up with both a linear month and cubic spline 
terms(Harrell 2004) for month of follow up with knots at the approximate 5th, 25th, 
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50th, 75th and 95th percentiles of survival time.(Fairall et al. 2008; Hernán, Brumback, 
and Robins 2000). 
We did not control for HAART adherence, successful virologic suppression, or 
initial HAART regimen (NVP vs. EFV) because these factors either occur during 
follow-up or may be affected by the exposure and therefore would be part of the 
causal mechanism of the exposure on the outcome.  Full descriptions of the 
components and validation of the stabilized weight models for both exposure and 
censoring are given in the Appendix. 
Sensitivity and secondary analyses. We performed seven sensitivity 
analyses.  To limit the potential effects of individuals dying between initiation of PTB 
treatment and initiation of HAART (i.e., left-truncation), we restricted PTB to cases 
who initiated HAART within 30 days of start of PTB treatment (S1) and separately to 
cases who initiated PTB treatment 30 days before or after initiation of HAART (S2). 
To assess the effect of PTB on early mortality, we restricted follow-up to the first four 
months of HAART (S3).  To determine the effect of the exposure among the 
exposed, we calculated the weighted standardized mortality ratio for PTB (S4).(Sato 
and Matsuyama 2003)  We used a traditional proportional hazards regression 
approach (with adjustment rather than reweighting) (S5).  To ascertain the extent of 
bias due to LTFU, we examined the main effect estimate without censoring weights 
(S6).  Last, to ensure that the effects of this study were not limited to PTB, we 
repeated analysis 1 using both pulmonary and extrapulmonary tuberculosis as the 
exposure category (S7). 
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Last, we performed a secondary analysis to examine effect measure 
modification of PTB by key baseline risk factors for mortality in people living with 
HIV, including severe immunosuppression (CD4≤50 cells/mm3 or WHO stage IV 
disease), malnutrition (underweight, BMI<18.5 kg/m2), and anemia. 
Ethics approval.  This study was approved by the human subjects review 
boards of both the University of the Witwatersrand and the University of North 
Carolina at Chapel Hill. 
Role of the funding sources.  The funding sources had no involvement in 
the design of the study, in the collection, analysis, or interpretation of the data, in the 
writing of this report, or in the decision to submit this report for publication. 
 
RESULTS 
 
There were 7,512 individuals included in this study, who contributed a total of 
106,795 person-months to this analysis.  Of these patients, 1,197 (15.9%) were 
being treated for PTB at the time of HAART initiation.  Individuals who had PTB at 
baseline were more likely to be male, unemployed, and underweight, and had more 
severe immunosuppression (lower CD4 counts, more WHO stage IV) than those 
without PTB at baseline (Table 5.1a).  The risk of death during follow-up was higher 
in individuals receiving PTB treatment at time of HAART initiation than in individuals 
not receiving PTB treatment at HAART initiation (6.2% vs. 3.6%, chi-square 
p<0.0001). Similar proportions of LTFU were observed in the two populations 
(19.5% and 18.8% respectively, p=0.6150). 
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Of the 1,197 individuals with PTB at baseline, 254 (21.2%) had been 
receiving PTB treatment for more than 120 days, 320 (26.7%) for 61-120 days, 289 
(24.1%) for 31 to 60 days, and 334 (27.9%) for 30 days or less.  Key differences in 
baseline characteristics by amount of lead-time are summarized in Table 5.1b. 
Patients with shorter lead time had more advanced disease, including lower CD4 cell 
counts, hemoglobin, and BMI. 
As there was no evidence of violation of the proportional hazards assumption 
(Figure 5.1a), we summarized the effect of PTB at time of HAART initiation on 
mortality as a single estimate. In the overall crude (unweighted and unadjusted) 
analysis (Table 5.2), individuals with PTB at baseline were more likely to die during 
follow-up than those without PTB (crude HR for death 1.71; 95% CI 1.31-2.23).  The 
crude HRs by lead time ranged from 1.34 for those with 60-120 days of lead-time, to 
2.02 for those with <30 days of lead-time, but all 95% CIs were relatively wide and 
there were no discernible trends by lead-time.  Crude survival curves comparing 
individuals with PTB to those without PTB are shown in Figure 5.1a.  HRs in Figure 
5.1 differ slightly from those presented in Table 5.2 because the figure required the 
use of weighted Cox proportional hazards models.(Cole and Hernán 2004) 
In models which adjusted for confounding and LTFU using inverse probability 
of exposure and censoring weights, the HR comparing risk of death in those with 
PTB to risk of death in those without PTB at baseline was 1.06 (95% CI 0.75-1.49).  
The results were again similar when stratified by lead-time category, with adjusted 
HRs ranging from 0.89 to 1.27 and confidence intervals including the null (Table 
5.2). Semi-parametric survival curves adjusted for confounding (but not censoring) 
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with inverse probability of exposure weights(Cole and Hernán 2004) are shown in 
Figure 5.1b. 
Results of sensitivity and secondary analyses.  Analyses S1-S7 yielded 
estimates of effect similar to the results of analysis 1, and none yielded an adjusted 
estimate of effect different from the null (Figure 5.2). 
In the secondary analysis in which interaction terms were included in the 
model, we found several subpopulations in which PTB appeared to increase risk of 
death.  First, this analysis showed that the HR for PTB on mortality among 
individuals who had CD4>50, BMI≥18.5, normal hemoglobin, and were not in WHO 
stage IV was 1.70 (95% CI 0.83-3.49), suggesting a raised hazard due to PTB 
among these otherwise relatively “healthy” individuals.  Second, the estimates of the 
HR for PTB on mortality for individuals who had both PTB and a BMI<18.5, and 
individuals who had both PTB and CD4≤50 differed when interaction terms were 
considered.  The HR for PTB and BMI<18.5 increased from 2.06 (95% 1.37-3.11) to 
4.43 (95% CI 1.91-10.27) when interactions were added to the model; likewise, the 
HR for PTB and CD4≤50 increased from 2.91 (95% CI 1.95-4.37) to 4.01 (95% CI: 
2.09-7.72).  These results suggest a synergistic effect of PTB and other risk factors 
for death. 
 
DISCUSSION 
 
In a large urban clinic providing HAART in South Africa, we have shown that 
treatment for PTB at the time of HAART initiation does not put patients at increased 
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risk of death during follow-up. Additionally, we have shown that among those eligible 
for HAART, the period of time between initiation of PTB treatment and initiation of 
HAART does not change the relationship between prevalent PTB and risk of death 
on HAART. Our approach to the problem of LTFU makes it highly unlikely that these 
results can be explained by differential, informative LTFU among PTB patients.  
Instead, the increased risk seen in the unadjusted models is due to the fact that PTB 
patients are more likely than others to have severe immunosuppression (low CD4 
counts, WHO stage IV illness), low BMI, and anemia. 
In addition, we have shown that the overall lack of effect of PTB on mortality 
persists when we restrict our model to those who started PTB within only 30 days of 
HAART initiation, and also when we restrict follow-up to the first four months of 
HAART, a period in which the majority of deaths occur in our clinic.  Taken with the 
main analysis, these results suggest strongly that starting HAART soon after 
initiation of PTB treatment will not put patients at higher risk of death. 
While it is tempting to conclude from these results that length of time between 
initiation of PTB treatment and initiation of HAART does not affect risk of death, our 
findings must be interpreted cautiously.  Patients in South Africa most often initiate 
PTB treatment outside of HAART clinics, and may die before starting HAART (in 
analytic terms, they would be left-truncated).  The mortality attributable to PTB could 
therefore have been underestimated.  Consequently, our results must be interpreted 
conditionally - given that an individual who initiated PTB treatment survived until 
initiating HAART, there was no effect of current PTB treatment on mortality. 
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However, the size of this potential left-truncation bias is likely to be small.  
Results from a recent randomized controlled trial of time between treatment for 
opportunistic infections (chiefly Pneumocystis carinii pneumonia, Cryptococcal 
meningitis, and pneumonia; the trial excluded all tuberculosis) showed that deferring 
HAART among such co-infected individuals can significantly increase risk of death 
or progression to AIDS (Zolopa et al. 2008).  As is suggested by universally low CD4 
counts and high prevalence of WHO stage III and IV disease in this cohort, many 
patients in our cohort initiate HAART with an acute opportunistic infection. Unless 
left truncation due to PTB acted differently than left truncation due to other 
opportunistic infections, then, it is unlikely that left truncation due to PTB would 
substantially bias these results.  Additionally, if left-truncation created substantial 
bias, we would expect individuals with shorter lead-time to be at higher overall risk of 
death from PTB.  We saw no trends in hazard of death with changing lead-time, nor 
did we observe a significant effect of PTB on mortality among the patients with the 
shortest lead-time (S1), again suggesting that the effect of left-truncation bias in this 
study is likely to be modest. 
 Another limitation of the study resulted from the lack of culture- or smear-
confirmation of PTB in most cases, reflecting a high rates both of diagnoses made 
on clinical suspicion and of patient referral with previous PTB diagnosis. As a result, 
there may have been misclassification of the PTB status, which would likely lead to a 
bias towards the null.  However, even if smear microscopy were available, the 
problem of misclassification would remain due to the low sensitivity of smear 
microscopy among HIV-positive individuals.(Tsiouris et al. 2006)  PTB drug-
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resistance status was also not available to this study; the inclusion of cases of drug-
resistant PTB among individuals being treated for PTB would likely raise the effect of 
PTB on death and bias the results away from the null. 
One additional limitation of this work is that we did not consider diagnoses of 
extrapulmonary TB in the main analysis.  Although a finding of extrapulmonary TB is 
sufficient for a diagnosis of WHO stage IV disease(WHO 2005), there is a wide 
range in the severity of extrapulmonary TB from lymph node TB to TB meningitis.  
As such, a summary estimate for the effect of extrapulmonary TB on mortality would 
likely be misleading.  Nonetheless, the sensitivity analysis which included both 
pulmonary and extrapulmonary TB (S7) showed no independent effect on risk of 
death in the population as a whole.  In addition, we did not control for adherence to 
either HAART or treatment for PTB in these analyses. 
Key risk factors for death after HAART initiation include advanced disease 
with severe immunosuppression, poor nutritional status and anemia(Ferradini et al. 
2006; Lawn et al. 2005; Stringer et al. 2006; Wools-Kaloustian et al. 2006), 
conditions which are more prevalent among PTB patients than non-PTB patients in 
our cohort.  The results of the secondary (hypothesis-generating) analysis 
suggested that patients with both PTB and one of these key risk factors (low BMI, 
low CD4 count), may be at increased risk of death in the setting of current treatment 
for PTB and HAART therapy.  Future investigators should rigorously test these 
hypotheses. 
Although a substantial number of people in this cohort became LTFU, rates of 
LTFU did not differ between those with or without PTB and did not appear to be 
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informative with regard to the PTB-mortality relationship; the effect of PTB on 
mortality was very similar with or without control for LTFU (see Figure 5.1b and 
analysis S6).  This should increase our confidence in other reports about the PTB-
mortality relationship, e.g., Stringer et al.(Stringer et al. 2006), which suffered from 
high rates of LTFU but did not model the censoring process explicitly. 
In conclusion, the robust analysis of this large South African cohort strongly 
indicates that the effect of treatment for PTB on mortality following initiation of 
HAART may be of limited or no clinical importance and that initiation of HAART soon 
after start of PTB treatment does not increase risk of death.  These results 
complement several other pieces of emerging evidence, including the randomized 
trial results (mentioned above) arguing for a earlier initiation of  HAART in patients 
with non-TB opportunistic infections(Zolopa et al. 2008), reports suggesting that 
PTB-associated IRIS is not as dangerous as previously thought(Lawn et al. 2008; 
McIlleron et al. 2007; Murdoch et al. 2008), and evidence that virologic response can 
be achieved in the presence of co-administration of rifampicin with 
efavirenz.(Manosuthi et al. 2008; Manosuthi et al. 2005)  While only the results of an 
ongoing randomized controlled trial (ACTG 5221) will provide a definitive answer to 
the important question of optimal time of initiation of HAART in PTB patients, results 
of this study, taken in context with these other recent findings, argue that the 
presence of PTB treatment should not delay initiation of HAART. 
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Table 5.1a.  Characteristics of 7,512 individuals initiating HAART in Themba Lethu 
Clinical Cohort from 1 April 2004 to 31 March 2007 by pulmonary tuberculosis (PTB) 
treatment status at baseline. 
 
 
Prevalent PTB 
(n = 1197) 
No PTB 
(n = 6315) p-value 
Female gender 695 (58.1) 4300 (68.1) <0.0001 
Age (Median, IQR) 35 (30-40) 35 (31-42) 0.0134 ‡ 
African ethnicity 1144 (95.6) 6022 (95.4) 0.7483 
Employment  
  
 Employed, student, retired 358 (29.9) 2372 (37.6) 
 Not employed or unknown 760 (63.5) 3460 (54.8) 
 Missing 79 (6.6) 483 (7.7) 
<0.0001 
BMI 
  
 <18.5 393 (32.8) 1041(16.5) 
 18.5-24.9 663 (55.4) 3473 (55.0) 
 25.0-29.9 110 (9.2) 1229 (19.5) 
 ≥30 31 (2.6) 572 (9.1) 
<0.0001 
Hemoglobin 
  
 Normal 330 (27.6) 3353 (53.1) 
 Low  864 (72.2) 2881 (45.6) 
 Missing 3 (0.3) 81 (1.3) 
<0.0001 
CD4 count (cells/mm3) 
   
 Median (IQR) 58 (22-116) 94 (34-165) <0.0001 ‡ 
 Mean (95% CI) 78 (74-83) 115 (112-118) <0.0001 † 
 ≤50 501 (41.9) 1865 (29.5) 
 51-100 271 (22.6) 1152 (18.2) 
 101-200 284 (23.7) 1981 (31.4) 
 201-350 44 (3.7) 581 (9.2) 
 >350 12 (1.0) 183 (2.9) 
 Missing 85 (7.1) 553 (8.8) 
<0.0001 
WHO stage IV at baseline 207 (17.3) 548 (8.7) <0.0001 
History of ART (any) 11 (0.9) 211 (3.3) <0.0001 
Pregnant 20 (1.7) 552 (8.7) <0.0001 
Peripheral neuropathy 89 (7.4) 231 (3.7) <0.0001 
History of PTB 60 (5.0) 796 (12.6) <0.0001 
Figures are expressed as number (% total), except where noted.  P-values are 2-sided by chi-square 
test, † t-test or ‡ Wilcoxon rank sum test.  After adjustment for altitude, lower limit of normal 
hemoglobin is 12.35 g/dl for men; 11.35 g/dl for non-pregnant women; and 10.35 g/dl for pregnant 
women. 
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Table 5.1b.  Selected characteristics of 1,197 individuals receiving treatment for 
pulmonary tuberculosis (PTB) at time of initiation of HAART by length of time 
between initiation of PTB treatment and initiation of HAART. 
 
Time between initiation of PTB treatment and HAART 
0-30 days 31-60 days 61-120 days  > 120 days Characteristic at initiation of HAART (n=334) (n=289) (n=320) (n=254) 
p-value 
BMI < 18.5 108 (32.3) 117 (40.5) 103 (32.2) 65 (25.6) 0.0032 
Low hemoglobin 259 (77.5) 234 (81.0) 232 (72.5) 139 (54.7) <0.0001 
CD4 count 
     
Median (IQR) 43 (15-88) 52 (21-104) 82 (36-133) 68 (27-138) <0.0001† 
Mean (95% CI) 60 (53-67) 69 (62-77) 95 (86-105) 92 (80-104) <0.0001† 
CD4<50 176 (52.7) 134 (46.4) 101 (31.6) 90 (35.4) <0.0001 
WHO stage IV 63 (18.9) 49 (17.0) 60 (18.8) 35 (13.8) 0.3525 
Peripheral neuropathy 20 (6.0) 20 (6.9) 30 (9.4) 19 (7.5) 0.4108 
History of PTB 18 (5.4) 18 (6.2) 15 (4.7) 9 (3,5) 0.5281 
Figures are n(%) unless otherwise noted.  P-values are 2-sided by chi-square test or  † one-way 
ANOVA.
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Table 5.2.  Estimates of hazard ratios from marginal structural models of the main 
analyses of the effect on all-cause mortality of current treatment for pulmonary 
tuberculosis (PTB) at time of HAART initiation. 
 
Crude 
(unweighted) 
estimates 
Adjusted for 
confounding and 
censoring  Main exposure 
HR 95% CI HR 95% CI 
M
o
de
l 1
 
All PTB 1.71 1.31-2.23 1.06 0.75-1.49 
> 120 days 1.89 1.17-3.06 1.26 0.65-2.43 
61-120 days 1.34 0.80-2.23 0.89 0.48-1.63 
31-60 days 1.62 0.97-2.72 1.07 0.58-1.96 Mo
de
l 2
 
≤ 30 days 2.02 1.31-3.11 1.27 0.78-2.09 
 
Model 1 estimates the effect of prevalent, treated PTB on outcome of mortality.  Model 2 estimates 
the effect of the same exposure by length delay between initiation of PTB treatment and initiation of 
HAART.  Both models adjust for both confounding and LTFU using inverse probability of exposure 
and censoring weights; components and specification of weight models are described in the 
Appendix.
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Figure 5.1. Survival curves by status of current treatment for pulmonary tuberculosis 
(PTB) at baseline, unadjusted (5.1a), and reweighted for confounding only (5.1b). 
 
1a   
 
  
1b 
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Figure 5.2.  Estimates of adjusted hazard ratios from main analyses 1 and 2 and 
sensitivity analysis S1-S7. 
  
 
S1: Pulmonary tuberculosis (PTB) treatment started within 30 days before HAART. S2: PTB 
treatment started within 30 days before or after HAART. S3: restricted follow-up to first four months of 
HAART.  S4: standardized mortality ratio (effect of the exposure among the exposed).  S5:  
Traditional Cox proportional hazards model.  S6:  Exposure weights only; no censoring weights.  S7:  
Pulmonary and extrapulmonary TB together. 
  
 
 
 
  
 
 
 
CHAPTER 6 
TUBERCULOSIS TREATMENT AND RISK OF STAVUDINE SUBSTITUTION IN 
FIRST LINE ANTIRETROVIRAL THERAPY 
 
INTRODUCTION 
 
 The rollout of highly active antiretroviral therapy (HAART) to individuals living 
with human immunodeficiency virus (HIV) has expanded rapidly in the last five 
years.  In sub-Saharan Africa alone, rapid scale-up of HAART expanded access 
from 100,000 in 2003 to 1.3 million people or about 28% of those in need by the end 
of 2006 (WHO 2007). 
An important challenge faced by rollout programs is the management of 
adverse drug reactions in the face of limited resources (both people and time) and 
limited choice of antiretroviral drugs (Bolhaar and Karstaedt 2007; Boulle et al. 2007; 
Ferradini et al. 2006; Stringer et al. 2006).  In particular, the inclusion of the 
nucleoside reverse transcriptase inhibitor stavudine as a component of standard 
first-line HAART throughout sub-Saharan Africa remains controversial because of 
relatively high rates of adverse reactions.  While inexpensive and highly potent, 
stavudine causes significant toxicity and has been implicated as a chief cause of 
symptomatic hyperlactatemia, lactic acidosis, lipid disorders, lipodystrophy, and 
peripheral neuropathy in various populations of HIV-positive individuals (Boulle et al. 
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2007; Colebunders et al. 2005; Currier 2002; Currier 2007; Currier and Havlir 2005; 
Subbaraman et al. 2007).  In one study from South Africa, over 20% of patients 
required substitution of stavudine because of toxicity by 36 months, most often for 
reasons of lipodystrophy or peripheral neuropathy (Boulle et al. 2007). 
These toxicities may have significant implications for the success of HAART.  
They cause substantial morbidity (Boulle et al. 2007; Falco et al. 2002; Subbaraman 
et al. 2007), can impact adherence to HAART (Bolhaar and Karstaedt 2007; Boulle 
et al. 2007), and may lead to treatment interruptions and resulting in increased risk 
of death (Bolhaar and Karstaedt 2007) and virological failure (Parienti et al. 2004).  
While the risk factors for hyperlactatemia, the most clinically severe stavudine 
toxicity, have been well-characterized, the risk factors for all-cause stavudine 
substitution itself remain largely unexamined (Boulle et al. 2007; Forna et al. 2007; 
Hawkins et al. 2007). 
Despite the high prevalence of tuberculosis (TB) among individuals receiving 
HAART in sub-Saharan Africa and the widely recognized importance of TB in the 
HIV epidemic (WHO 2004), the impact of both HAART and TB treatment on the 
incidence of stavudine substitution remains almost entirely unexplored. A search in 
PubMed for “tuberculosis and stavudine” performed in May 2008 yielded only 17 
citations, of which only two addressed issues of toxicity (PubMed).  Two small 
studies from England (Breen, Lipman, and Johnson 2000; Dean et al. 2002) 
observed higher than expected rates of adverse events with stavudine and TB 
treatment.  No studies have comprehensively addressed these issues in the 
developing world.  This gap in the literature is particularly concerning because 
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isoniazid, which is given for six months as part of standard TB treatment (Republic of 
South Africa Department of Health 2004; Subbaraman et al. 2007), has been 
implicated in peripheral neuropathy (Moyle and Sadler 1998; Subbaraman et al. 
2007), one of the most commonly reported stavudine toxicities (Amoroso et al. 2007; 
Boulle et al. 2007; Hawkins et al. 2007; Moyle and Sadler 1998). 
Our objective was to estimate the effect of TB treatment on incidence of all-
cause stavudine substitution in a large HAART rollout clinic in Johannesburg, South 
Africa. 
 
METHODS 
 
Study site, clinic procedures, data collection.  This study was conducted 
on the Themba Lethu Clinical Cohort, a prospective cohort of adults initiating 
HAART.  The clinic is located in Helen Joseph Hospital, Johannesburg, South Africa, 
and funded by the South African Government, Gauteng Province SA, PEPFAR, and 
USAID, and operated as a collaborative project with the Clinical HIV Research Unit 
of the University of the Witwatersrand and the non-profit Right To Care.  Themba 
Lethu is one of the largest single clinics providing HAART in South Africa and has 
initiated patients on HAART at a rate of approximately 200 per month since April 
2004.  After initiating HAART, patients are scheduled for monthly pharmacy visits 
and clinical visits to Themba Lethu Clinic at 4 months and every 6 months thereafter. 
Clinical data as well as CD4 counts, hemoglobin, and other laboratory diagnostics 
are collected at all visits, except for viral loads which are not collected at baseline.  
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All data were stored in the TherapyEdge™ (TherapyEdge Inc., USA) database, and 
analyzed in SAS v9.1.3 (SAS Institute, NC, USA). 
Therapy for TB is usually initiated outside of Themba Lethu Clinic.  The 
standard course of TB treatment in South Africa is six months:  two months of 
isoniazid, rifampicin, pyramizade, and ethambutol followed by four months of 
isoniazid and rifampicin (Republic of South Africa Department of Health 2004).  The 
course of therapy is longer if the patient does not respond to treatment, has 
relapsed, or has drug resistant TB.  Vitamin B6 (pyridoxine) is commonly prescribed 
at time of initiation of TB treatment.  Amitriptyline  is commonly prescribed for 
individuals experiencing peripheral neuropathy (Saarto and Wiffen 2007) in the 
Themba Lethu Clinic. 
Study eligibility and definitions.  Patients were eligible for this study if they 
initiated a stavudine-containing HAART regimen at Themba Lethu Clinic between 
April 1 2004 to March 31 2007 (Republic of South Africa Department of Health 
2004). 
The exposure of interest for the main analysis was TB treatment, defined as 
therapy for pulmonary or extrapulmonary TB which included isoniazid.  There were 
three specific exposure categories:  ongoing TB treatment at time of HAART 
initiation; recent initiation of TB treatment; and incident TB treatment during HAART.  
Ongoing TB treatment was defined as TB treatment started at least two weeks 
before initiation of HAART.  A two-week cutoff was chosen based on the South 
African National ARV Guidelines recommendation to wait at least two weeks 
between initiation of TB treatment and HAART.  Recent initiation of TB treatment 
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was defined as initiation of TB treatment 0 to 14 days before initiation of HAART.  
Last, incident TB treatment was defined as any TB treatment which began after 
initiation of HAART.  A schematic diagram for these exposure categories is shown in 
Figure 6.1. 
In analyses of ongoing and recent TB treatment, patients were censored at 
time of incident TB.  In the analysis of incident TB treatment, individuals who had 
ongoing or recent TB treatment became eligible for incident TB one month after the 
recorded completion of their previous course of TB treatment, or nine months after 
the initiation of the previous course of therapy, if no end date was available.  When 
these patients became eligible for the incident TB analysis, they were marked as 
having a history of TB treatment (just as patients with ongoing or recent TB 
treatment might have such a history).  Individuals who experienced multiple 
episodes of incident TB were censored at the second episode. 
The outcome of all-cause d4T substitution was defined as the event of 
substitution of a single drug (most often zidovudine [AZT]) for d4T while the rest of 
the regimen remained unchanged.  Patients were still at risk during treatment 
interruptions and after drug substitutions for drugs other than d4T.  Drug substitution 
events in which d4T and other drugs were substituted simultaneously (multi-drug 
substitutions) were considered competing events and cause for censoring in the 
main analysis, but were included as outcomes in a sensitivity analysis. 
Statistical analyses. There were three main analyses, corresponding to the 
three exposures defined above.  In all analyses, we controlled for confounding and 
censoring using inverse probability of treatment and censoring (IPTC) weights (Cole 
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et al. 2007; Hernán, Brumback, and Robins 2000; Robins, Hernán, and Brumback 
2000).  Analyses were implemented as discrete time hazard models, and evaluated 
using log-binomial generalized estimating equations models, which controlled for 
within-individual correlation using an “independent” correlation matrix for robust 
standard errors in the presence of repeated observations (Hernán, Brumback, and 
Robins 2000). 
Stabilized weights for TB treatment were estimated using ordinary logistic 
regression, and histograms of multivariate treatment weight models were examined 
to ensure that the positivity assumption (see Appendix) was met (Hernán and 
Robins 2006). The estimation of stabilized censoring weights was complicated 
because of the issue of competing risks (Matsuyama and Yamaguchi 2007) of multi-
drug substitution, death, and lost to follow-up, all of which may be informative with 
respect to the outcome of stavudine substitution.  In a marginal structural model, the 
most intuitive solution to this problem is to extend IPTC weights to encompass 
multiple causes of censoring (Matsuyama and Yamaguchi 2007).  Because initial 
analysis showed little change in estimates and confidence intervals when modeling 
outcomes of lost to follow-up and death separately, we estimated a single weight for 
both outcomes and a separate weight for the competing risk of multi-drug 
substitution (except in sensitivity analysis). 
Possible predictors for both the weight and censoring models were gender, 
ethnicity, employment status, age, history of antiretroviral therapy, previous history 
of TB treatment; and baseline measures of pregnancy, peripheral neuropathy, 
hemoglobin (adjusted for sex, pregnancy, and altitude), BMI, CD4 cell count, and 
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WHO stage (IV or other), calendar date, and whether treatment was initiated after 
October 2006 (when all consultation fees were eliminated by the Department of 
Health).  In addition, time-varying censoring models accounted for time-updated 
measures of hemoglobin, CD4 count, BMI, and initial virologic success (measured at 
month 6), as well as for month of follow-up as both a continuous and categorical 
variable.  Predictors were removed from weight models if they were not found to 
confound the outcome in traditional proportional hazards regression using 
backwards elimination (with an alpha of 0.10 for removal).  Some of these variables 
were subsequently added back to both the weight and stabilization models to 
increase the stability of the final IPTC weights. 
Preliminary analysis indicated that the effect of TB treatment on hazard of 
stavudine substitution decreased markedly with time and thus violated the 
proportional hazards assumption.  We therefore we included a categorical time-
interaction term (Cole et al. 2007) to allow the hazard ratio (HR) to change at the 
beginning of the third month of concomitant TB treatment and HAART.  We included 
an additional time-interaction term for months 3-6, as TB treatment lasts 6 months 
except in cases of drug resistance or retreatment (Republic of South Africa 
Department of Health 2004). 
Secondary and sensitivity analyses. For each of the three main models, we 
performed several sensitivity analyses.  We included multi-drug substitutions 
(excluding switches to second-line HAART) as outcomes (S1); we replaced the 
treatment portion of the IPTC weights with simple adjustment for confounding (S2); 
we truncated IPTC weights to the 99th and 1st percentile to ensure that no individual 
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observations contributed excessively to effect estimates (S3); we estimated the 
relative effect of the exposure among the exposed (the standardized morbidity ratio) 
for each group (Sato and Matsuyama 2003) (S4); and we restricted the referent 
group to those without recorded history of TB (S5) to ensure that lingering peripheral 
neuropathy from previous drug exposures did not bias the results. 
We performed one additional sensitivity analysis (S6) for ongoing TB 
treatment only, stratifying results by length of TB treatment prior to initiation of 
HAART in two categories chosen based on treatment guidelines (Republic of South 
Africa Department of Health 2004): 2 weeks to 2 months after initiation of TB 
treatment (15-60 days), and after two months (the continuation phase of TB 
treatment, 61+ days). 
 
RESULTS 
 
A total of 7067 individuals contributed 88916 person-months of follow-up to 
this analysis, while 445 patients were excluded because they were not receiving one 
of three standard first-line HAART regimens.  More than half of the excluded patients 
(n=253, 57%) were receiving AZT-3TC-EFV, which is clinically indicated for patients 
suffering peripheral neuropathy at time of HAART initiation.  However, only 65 of 
these 253 patients were being treated for TB at baseline, and these patients were 
only slightly more likely to have TB than other patients (risk ratio [RR] 1.25 95% CI 
1.01-1.54). 
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Ongoing therapy for TB at time of HAART initiation was present in 1272 
individuals (18.0%), of which 964 (75.7%) had pulmonary TB.  TB treatment was 
started recently with respect to HAART in 202 individuals (2.9%), of which 164 
(81.2%) had pulmonary TB.  Characteristics of those with and without TB at baseline 
are summarized in Table 6.1.  Compared to those who were not receiving therapy 
for TB at initiation of HAART, individuals who were being treated for TB at baseline 
or who initiated TB recently with respect to HAART were less likely to have a history 
of TB, and were more likely to be male and have advanced disease (lower CD4 
counts, BMIs, hemoglobin, and/or more WHO stage IV). 
There were 404 first episodes of incident TB during follow-up, at a median of 
99 (intraquartile range [IQR] 31-273) days of follow-up and a mean of 179 days.  
There were 15 second episodes of incident TB recorded.  The rate of first episode of 
incident TB was 5.5 (95% CI 5.0-6.0) per 100 person-years of follow-up.  Of these 
404 first episodes, 371 occurred in patients still at risk of stavudine substitution. 
There were 842 recorded single-stavudine substitutions.  There were an 
additional 375 multi-drug substitutions which included stavudine; of these, 172 were 
drug regimen switches to second-line HAART (AZT-DDI-LPVr), and most of the 
remainder were switches to LPVr-EFV.  Median time to single-stavudine substitution 
was 347 (IQR 175-535) days, and to multi-drug substitution was 357 (IQR 254-488) 
days.  Crude rate of single-stavudine substitution was 12.4 (95% CI 11.6-13.3) per 
100 person-years. Kaplan-Meier curves for single-stavudine substitutions stratified 
by TB treatment status at baseline are shown in Figure 6.2. 
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Of the 842 stavudine substitutions, 714 were attributed clinically to either 
peripheral neuropathy (n=362, 43% of 842), lipodystrophy (n=205, 24%), lactic 
acidosis or symptomatic hyperlactatemia (n=168, 20%), or two of these three factors 
(n=21, 2%).  Those who switched for peripheral neuropathy were more likely to have 
TB either at baseline or during follow-up (RR=1.53, 95% CI 1.33-1.75); those who 
switched for lactic acidosis or lipodystrophy were less likely to have TB (RR=0.58, 
95% CI 0.48-0.71).  
A total of 260 individuals (3.7%) died during follow-up and 1252 (17.7%) 
became lost to follow-up. 
Results from the main analysis are shown in Table 6.2.  Compared to those 
who were not being treated for TB, patients with ongoing TB treatment had a crude 
hazard ratio (HR) for stavudine substitution of 2.78 (95% CI 1.61-4.79) for the first 
two months of follow-up, 2.24 (95% CI 1.61-3.12) for months 3-6, and 1.10 (95% CI 
0.88-1.37) thereafter.  The adjusted (weighted) HR estimates, corrected for 
confounding, loss to follow-up, death, and the competing risk of multi-drug 
substitution were similar but slightly closer to the null. 
Those with recent TB treatment had crude estimates of HR of 5.05 (95% CI 
2.14-11.93) for the first two months, 2.33 (95% CI 1.14-4.79) for months 3-6, and 
0.95 (95% CI 0.56-1.63) thereafter.  In the adjusted analysis the estimates were 6.54 
(95% CI 2.58-16.57), 1.39 (95% CI 0.63-3.06), and 1.03 (95% CI 0.55-1.93). 
For patients with incident TB treatment, the crude estimates of HR were 1.26 
(95% CI 0.72-2.22), 1.15 (95% CI 0.64-2.08), and 1.66 (95% CI 0.67-4.07) for 
months 0-2, 3-6, and 7+ respectively, with similar estimates in the adjusted analysis. 
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Sensitivity analysis results.  Results from the sensitivity analysis confirmed 
the main results both in magnitude and overall trend (effect in the first two months, 
but a smaller or null effect thereafter) (Appendix II, Figures A2.1- A2.3), and suggest 
that the effects of ongoing TB treatment do not depend strongly on length of TB 
treatment prior to initiation of HAART (Table 6.3). 
 
DISCUSSION 
 
Concomitant administration of TB treatment and HAART is common in sub-
Saharan Africa, especially at time of initiation of HAART.  In our cohort, the 
prevalence of TB treatment at time of HAART initiation was 20.9%.  Our results 
show that the presence of TB treatment at the time of HAART initiation puts patients 
at higher risk of requiring a substitution for stavudine, especially if HAART is initiated 
soon (≤14 days) after the start of TB treatment.  Initiation of TB treatment in patients 
who were already using stavudine did not appear to raise the risk of stavudine 
substitution. 
The effect of TB on d4T substitution is strongest in the first two months of 
treatment when the two drug regimens are initiated close together in time, with a 2-
month adjusted HR estimated at 6.54.  After two months of HAART, the effect was 
smaller, probably due to depletion of susceptible patients.  With recent initiation, the 
short term risk of stavudine substitution is very high, and thus patients at risk of 
stavudine substitution by TB co-medication are removed from the population sooner, 
explaining the large drop in effect in this population.  After completion of TB 
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treatment (≥ 7 months), there was no longer an effect of TB treatment on the risk of 
stavudine substitution. 
In light of the strong effect we observed of prevalent TB treatment (ongoing or 
recent) on risk of stavudine substitution, we were surprised to see little to no effect of 
incident TB treatment on the outcome.  There are several possible explanations for 
this observation.  First, because these patients have been taking stavudine prior to 
initiation of TB treatment, it is possible that these patients have grown accustomed 
to stavudine, and are thus at lower risk from TB treatment.  Another possibility is that 
the effect of TB treatment on risk of stavudine substitution is mediated by HIV viral 
load; control of HIV replication may thereby reduce the risk of d4T in conjunction 
with TB treatment.  Last, if patients in whom TB treatment would have most 
increased risk were also at high baseline risk of stavudine substitution, these 
patients might have experienced substitution before developing incident TB, and 
were thus not included in our study due to left-truncation; in this last case, depletion 
of susceptible patients could have caused our analysis of incident TB treatment to 
underestimate the true effect of that exposure on the outcome. 
Analysis S5 provides additional evidence that these results may have 
underestimated the true impact of TB treatment on risk of stavudine substitution. 
Because peripheral neuropathy does not disappear the day TB treatment ends, it is 
possible that in the main analysis, individuals with a somewhat recent history of TB 
treatment may be at higher risk of stavudine substitution due to residual peripheral 
neuropathy.  When we restrict the reference group to individuals without history of 
TB, the point estimate for the effect of TB treatment on risk of stavudine substitution 
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in the first two months of co-treatment increases slightly for all exposures (ongoing, 
recent, incident) (Appendix II, Tables A2.1-A2.3). 
The largest number of single-stavudine toxicities were caused by peripheral 
neuropathy and individuals receiving TB treatment were more likely than others to 
switch for this reason.  This is consistent with our original hypothesis that peripheral 
neuropathy is a key pathway for the interaction of TB drugs and HAART, because 
peripheral neuropathy is caused by both the isoniazid (Moyle and Sadler 1998; 
Subbaraman et al. 2007) and stavudine (Amoroso et al. 2007; Boulle et al. 2007; 
Breen, Lipman, and Johnson 2000; Dean et al. 2002; Hawkins et al. 2007; Moyle 
and Sadler 1998). This result is especially striking given that the great majority of TB 
patients in South Africa are prescribed vitamin B6 (pyridoxine) at time of initiation of 
TB treatment for the prevention of peripheral neuropathy; in addition, amitriptyline is 
frequently prescribed to manage incident peripheral neuropathy.  It is likely that the 
effect of TB on the risk of stavudine substitution would be even higher if these two 
drugs were unavailable.  Conversely rates of peripheral neuropathy may be further 
reduced with additional micronutrient supplementation (Villamor et al. 2008).  
There were several limitations of this study.  First, while focusing on stavudine 
substitution as an outcome ensures that we have captured the most severe 
toxicities, we did not examine the impact of TB treatment on risk of (for instance) 
peripheral neuropathy specifically.  It seems likely that treatment for TB resulted in 
substantial low level peripheral neuropathy, which may remain undiagnosed, 
unreported, or resolves without stavudine substitution.  Thus, the impact of TB 
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treatment on risk of peripheral neuropathy (or other toxicities) may be different (and 
in particular, higher) than the effect of TB treatment on stavudine substitution.  
Second, we estimated the relative hazard rather than absolute risk 
differences.  Because the  absolute risk of stavudine substitution is relatively low 
early on in this study, even a large hazard ratio may translate into a somewhat small 
absolute risk.  For instance, only 220 stavudine substitutions took place during the 
first six months following initiation of HAART; the absolute risk in those with any TB 
treatment at baseline (ongoing or recent) was 5.6%, and in those without was 2.4% 
(risk difference 3.2%, 95% CI 1.9-4.4%).  Thus, in the first six months after HAART 
initiation, there is one stavudine substitution for every 18 patients with TB treatment, 
and one for every 42 patients without.  However, because there are large number of 
individuals who initiate HAART while on TB treatment, we believe these results still 
have considerable relevance to public health. 
 Last, while we strove to control adequately for confounding in this study, it is 
likely that uncontrolled confounding remains; this is especially true for alcohol and 
other drugs which may be implicated in peripheral neuropathy.  Similarly, while we 
attempted to account for several competing risks – including multi-drug substitution, 
death, and lost to follow-up – complete control of these competing risks requires an 
assumption that competing risks can be completely accounted for by observed 
variables, a somewhat heroic assumption analogous to the assumption of no 
uncontrolled confounding (Hernán, Brumback, and Robins 2000; Matsuyama and 
Yamaguchi 2007). 
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Despite these limitations, these results show that co-medication of TB at time 
of initiation of HAART is an important risk factor for stavudine substitution in the 
Themba Lethu Clinical Cohort.  The issue of co-medication with TB drugs and with 
stavudine is a vital issue in the rollout of HAART in sub-Saharan Africa, and 
deserves more attention than it has so far received.  While clearly the results of a 
single observational study should never serve as the sole basis for changes in 
policy, the magnitude and consistency of these results suggest strongly that we may 
wish to reconsider the use of stavudine in first-line HAART among patients with 
ongoing or recent initiation of TB treatment. 
 179 
Table 6.1.  Characteristics of 7,067 individuals initiating HAART in Themba Lethu 
Clinical Cohort from 1 April 2004 to 31 March 2007 by tuberculosis treatment status 
at baseline.  Figures expressed as n (%) unless noted. 
 
No TB 
treatment 
(n=5593) 
Ongoing TB 
treatment 
(n = 1272) 
p-value 
Recent TB 
treatment 
(n = 202) 
p-value 
History of TB 855 (15.3) 64 (5.0) <0.0001 12 (5.9) 0.0003 
Female gender 3861 (69.0) 749 (58.9) <0.0001 114 (56.4) 0.0002 
Age > 40 1656 (29.6) 347 (27.3) 0.0991 60 (29.7) 0.9769 
Employed  2107 (37.7) 396 (31.1) <0.0001 72 (35.6) 0.5587 
BMI 
    
 < 18.5 901 (16.1) 412 (32.4) 60 (29.7) 
 18.5 - 24.9 3085 (55.2) 707 (55.6) 111 (55.0) 
 25.0 - 29.9  1100 (19.7) 124 (9.8) 24 (11.9) 
 ≥ 30.0 507 (9.1) 29 (2.3) 
<0.0001 
7 (3.5) 
<0.0001 
Hemoglobin 
    
 Normal 3014 (53.9) 356 (28.0) 51 (25.3) 
 Low  2508 (44.8) 913 (71.8) 151 (74.8) 
 Missing 71 (1.2) 3 (0.3) 
<0.0001 
0 (0) 
<0.0001 
CD4 count 
     
Median (IQR) 94 (35-164) 
59 
(23-116) <0.0001‡ 
48 
(13-106) <0.0001‡ 
Mean (95% CI) 111 (108-113) 
80 
(75-84) <0.0001† 
70 
(59-81) <0.0001† 
 < 50 1647 (29.5) 525 (41.3) 102 (50.5) 
 50 - 99 1029 (18.4) 303 (23.8) 38 (18.8) 
 100 - 199 1824 (32.6) 306 (24.1) 43 (21.3) 
 200 - 349 506 (9.1) 46 (3.6) 7 (3.5) 
 ≥ 350 115 (2.1) 13 (1.0) 3 (1.5) 
 Missing 472 (8.4) 79 (6.2) 
<0.0001 
9 (4.5) 
<0.0001 
WHO stage IV at baseline 449 (8.0) 228 (17.9) <0.0001 45 (22.3) <0.0001 
History of ART (any) 109 (2.0) 8 (0.6) 0.0010 1 (0.5) 0.1369 
Pregnant 540 (9.7) 24 (1.9) <0.0001 2 (1.0) <0.0001 
Peripheral neuropathy 151 (2.7) 81 (6.4) <0.0001 9 (4.5) 0.1346 
P-values are 2-sided by chi-square test compared to “No therapy”, † t-test or ‡ Wilcoxon rank sum 
test.  After adjustment for altitude, lower limit of normal hemoglobin is 12.35 g/dl for men, 11.35 g/dl 
for non-pregnant women, and 10.35 g/dl for pregnant women. 
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Table 6.2. Hazard ratios and 95% confidence intervals for effect of TB treatment on 
stavudine substitution by period of TB treatment and duration of co-medication for 
TB and HIV. 
 
Crude estimates  
by duration of co-medication  
(in months) Exposure N 
0-2 3-6 7+ 
Ongoing TB 1272 2.78  (1.61-4.79) 
2.24 
(1.61-3.12) 
1.10 
(0.88-1.37) 
Recent TB 202 5.05 (2.14-11.93) 
2.33 
(1.14-4.79) 
0.95 
(0.56-1.63) 
Incident TB 380 1.26 (0.72-2.22) 
1.15  
(0.64-2.08) 
1.66 
(0.67-4.07) 
 
Weighted estimates 
by duration of co-medication 
(in months) Exposure N 
0-2 3-6 7+ 
Ongoing TB 1272 2.31 (1.31-4.08) 
2.37 
(1.58-3.53) 
1.24 
(0.95-1.62) 
Recent TB 202 6.54 (2.58-16.57) 
1.39 
(0.63-3.06) 
1.03 
(0.55-1.93) 
Incident TB 380 1.38 (0.70-2.75) 
1.13 
(0.59-2.15) 
1.26 
(0.43-3.69) 
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Table 6.3.  Hazard ratios and 95% confidence intervals for outcome of stavudine 
substitution by duration of TB treatment prior to HAART initiation (sensitivity analysis 
S6, only among those with ongoing TB treatment). 
 
Time period Length of TB treatment  
previous to HAART initiation n 0-2 months 3-6 months 7+ months 
15-60 days 556 2.64 (1.28-5.42) 
2.66 
(1.72-4.11) 
1.21 
(0.83-1.75) 
61+ days 716 2.15 (1.05-4.40) 
2.16 
(1.23-3.81) 
1.25 
(0.88-1.76) 
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Figure 6.1.  Schematic diagram of TB treatment exposure categories:  ongoing TB 
treatment at time of HAART initiation; recent initiation of TB treatment with respect to 
HAART; incident TB treatment after HAART initiation. 
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Figure 6.2.  Kaplan-Meier analysis of time to d4T substitution by TB treatment status 
at baseline. 
 
  
  
 
 
 
 
  
 
 
 
CHAPTER 7 
DISCUSSION 
 
OVERVIEW 
 
The goal set by the United Nations is Universal Access to HIV medication by 
2010.  Achieving this goal would mean initiating approximately 7 million new 
individuals on HAART over the next two and a half years, and would require a rate of 
initiation an order of magnitude above what has been achieved so far.  The math is 
overwhelmingly against this goal being achieved. 
The wisdom of setting such a goal is debatable.  Of course, it is not the first 
time the WHO has done so.  The 3x5 goal (3 million on therapy by 2005) was not 
reached, but many observers believe that it was the statement – indeed the demand 
– of that goal which inspired many to roll out access to HAART.  And indeed, overall 
access to HAART has increased geometrically over the past five years, leading to 
enormous gains in life expectancy among HIV infected individuals throughout the 
world.  The effects of this expanded access have been felt most acutely in sub-
Saharan Africa in general and South Africa in particular, where nearly 280,000 
individuals, perhaps 30% of those in need, are receiving HAART at present. 
The rollout of HAART in South Africa must be considered by almost any 
measure a great success thus far.  Our results from the Themba Lethu Clinic are a 
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prime example of this success.  As we discussed in Chapter III, over three years of 
follow-up among approximately 7500 patients, virologic suppression remained high, 
CD4 counts have continued to increase, and survival has been excellent.  These 
results are typical of other reports of cohort in the literature, and taken with these 
other reports demonstrate that high quality of care is achievable in many situations 
despite a high rate of initiation of new patients on HAART.  Indeed, the results from 
the Themba Lethu Clinic point towards the future, in that they were achieved with a 
rate of new patient initiation of 200 per month, or nearly 4 times that reported 
elsewhere. 
At the same time, many large rollout cohorts – including ours – have suffered 
from significant losses to follow-up, and relatively high rates of drug toxicity and drug 
substitution.  Losses to follow-up may lead us to underestimate the extent of 
mortality in our cohort, while drug toxicities are both problematic in the short term for 
reasons of morbidity and sometimes mortality, and in addition may lead to faster 
virologic failure as toxicities lead to reduced adherence.  Worse, the limited 
antiretroviral drug options available in sub-Saharan Africa (in many cases only a first 
and second line of HAART) will limit the available options for those same patients 
who experience drug substitutions for reasons of either virologic failure or toxicity.  
Going forward, issues of management and durability of HAART and patient retention 
will both be essential to ensuring that the early successes of the rollout, now 
demonstrated, are not themselves lost to follow-up. 
Another extremely important issue moving forward is the impact of TB in 
HAART programs.  The impact of TB on HIV in this context remains 
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underappreciated:  despite the fact that nearly 17% of patients at Themba Lethu 
Clinic initiate HAART while receiving ongoing treatment for TB, TB clinics and HIV 
clinics remain without organizational integration in South Africa and elsewhere.  
Likewise, the impact of TB therapy on stavudine toxicities is almost entirely 
unexplored in the literature to date. 
 
STUDY FINDINGS 
 
Our findings on TB highlight several of these key issues.  Concerns about the 
impact of TB even in the presence of HAART persist; in the largest and most 
rigorous study to date, we have shown that given treatment for both TB and HAART, 
individuals with TB are not at higher risk of death than others initiating HAART; and 
what greater risk of death may be observed is due to the greater preponderance of 
risk factors for death among those with TB, including WHO stage IV disease, low 
body mass index, and low CD4 cell count.  These results will help refocus clinical 
attention away from TB and towards these key determinants of death, and should 
help allay fears about the risks of initiating HAART within one month of initiating TB 
therapy, as we did not see an increased risk among these individuals when 
considered separately. 
Our results on the increased rate of stavudine substitution seen with 
concomitant therapy for TB point in a different direction.  Starting HAART soon after 
starting TB therapy results in a hazards ratios as large as 6.53 for substitution of 
stavudine, a first-line HAART drug well known for causing significant toxicity.  This 
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analysis, then, suggests that the longer we can wait after initiation of TB therapy to 
start HAART, the lower the risk of subsequent d4T substitution (chiefly due to 
peripheral neuropathy).  One caveat in this analysis is that a relatively small number 
of d4T substitutions occur early in HAART, and so while the hazard ratio is large, the 
absolute risk differences are likely to be substantially smaller.  On the other hand, 
considering that Universal Access proposes to place seven million individuals on 
HAART in a relatively short period of time, even a small absolute risk difference may 
prove to have significant public health impact. 
Nonetheless, considering that individuals with TB tend to be significantly more 
immunosuppressed than others, and in light of similar results from other 
opportunistic infections (Zolopa et al. 2008), there is little doubt that delaying HAART 
in individuals with TB will lead to unnecessary deaths.  Given that our study shows 
no increased risk of death from starting HAART soon after TB therapy initiation, we 
feel that in absence of conclusive results from (forthcoming) randomized controlled 
trials such as ACTG 5221, this study argues strongly for the initiation of HAART no 
later than two weeks after the initiation of TB therapy. 
 Nonetheless, there are clearly short and medium term risks to co-
administration of TB therapy and stavudine.  This is a reason to reconsider 
stavudine as part of first-line HAART, assuming a less toxic alternative can be found 
at comparable cost.  Clinicians on the ground in South Africa frequently voice a 
desire for widely available Tenofovir (TDF), which is the best alternative but remains 
expensive in that setting. 
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FUTURE DIRECTIONS 
 
Methods moving forward.  The larger lesson of this work, however, is how 
much remains unknown that may be vital for ensuring a high quality of care as the 
rollout continues and expands.  Meeting the challenges posed by an expanding – 
and ever more quickly expanding – scale-up throughout sub-Saharan Africa will take 
a great deal of very smart epidemiology.  We must ask the right questions and 
answer those questions rigorously and with the right and most appropriate methods. 
With regards to epidemiologic methods, we have made several small 
advancements in methodology in the course of this dissertation which are worth 
emphasizing here, as they will serve this work going forward.  First, we have 
developed SAS code which can display non-parametric life-tables from discrete-time 
hazard models, allowing reweighting not only by baseline treatment weights, but in 
addition by time-varying inverse probability of censoring weights.  This code 
represents an incremental advance over previous methods (Cole 2004; other) for 
presenting such data, in that previous methods did not allow for reweighting to 
compensate for censoring.  In fact, the method is relatively simple, relying on the key 
intuition that for every observed person-month of experience in a discrete time 
hazard model, there is a single weight, which represents the number of person-
months for which the observed person-month must account in the reweighted 
pseudo-population.  The size of the pseudo-population in a given month for the life-
table calculation, therefore, is simply the sum of the weights among individuals 
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observed that month; and the number of outcome events in the same time is simply 
the sum of the weights among those who had the outcome.   
We have not included these curves in previous chapters, because such 
curves are not easily publishable in the literature until the method of their calculation 
itself has been published.  Nonetheless, the code is included in Appendix 1, and we 
plan to submit it for publication.  We note that we have used life-table calculations 
rather than the similar but more familiar Kaplan-Meier curves because discrete time 
hazard models for marginal structural models typically use relatively coarse time 
units, such as person-months, for which the life-table censoring assumptions are 
more reasonable.  More importantly, as the time-unit of consideration approaches a 
limit of 0, life-tables converge to Kaplan-Meier estimators (just as discrete time 
hazard models converge to the proportional hazards model under similar 
conditions).  
Secondly, we believe that we have made a significant methodological 
contribution in our recognition – touched on briefly in Chapter II – that reweighting 
(or, for that matter, randomization) cannot be relied upon to control confounding 
when evaluating a time-varying hazard.  This issue was brought to our attention in 
our analysis in Chapter V, in which we investigated the time-varying effect of TB 
medication on risk of d4T substitution, looking mainly at a dichotomous time-
interaction before and after 3 months of follow-up.  The key insight here is that even 
assuming perfect control of confounding at baseline through reweighting, outcomes 
which are measured contingent on previous outcomes are subject to selection.  In 
 190 
particular, in our study patients were only at risk of an outcome of d4T substitution 
after month 2 if they did not have such an event in months 0 to 2. 
At first glance, this situation looks like a well-known assumption of hazard 
models; that they model risk conditional on survival – this is not bias, but instead is 
assumption and definition.  But with deeper inspection, the problem becomes clear:  
by selecting out those individuals who were at high risk of outcome early, we have 
changed the composition of individuals at risk of later outcome.  As such, control of 
confounding implemented at the level of the entire population may no longer 
complete control confounding in this selected, secondary group.  This problem is 
similar to that described in the randomized controlled trials literature on principal 
stratification, in which analysis of outcomes subject to right-censoring can be biased, 
but to our knowledge this problem has not yet been described in the literature on 
observational trials; it has potentially important applications for vast numbers of 
analyses.  We plan to perform simulation studies to confirm this theoretical 
argument, and publish the findings in the methodological literature. 
Future research.  Above, we noted that asking the right questions will be 
essential to ensuring that the rollout maintains a high quality of clinical care.  There 
are several specific areas that I believe are important for epidemiologists to pursue.  
The issue of patient retention is perhaps more vital than any of these issues, but is a 
more programmatic than analytic challenge; as such, I will not address it further 
here. 
First, we must improve our management of toxicities and drug substitution.  
This means, first and foremost, addressing the issue of stavudine.  While the ideal 
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solution at present is universal access to cheap Tenofovir, this is unlikely to happen 
soon due to issues of cost.  In the meanwhile, then, we need to fully delineate the 
relationship between stavudine and other medications and conditions.  In this work I 
have begun investigating that relationship with regards to TB, the most prevalent 
opportunistic infection among HIV-positive individuals in South Africa, though much 
more work remains even with regards to TB, including the impact of TB and TB 
therapy on particular stavudine toxicities.  To the extent that stavudine toxicities can 
be anticipated, they can be managed proactively, which will reduce mortality and 
morbidity, as well as increase patient adherence to the drugs and quality of life.  
Current clinical practice suggests reducing stavudine dose from 40mg to 
30mg in patients with lower BMI, to limit toxicity while maintaining high virologic 
efficacy.  However, little rigorous observational analysis has been performed on the 
effect of stavudine dose on virologic or drug toxicity outcomes.  If stavudine 
continues to play a key role in initial HAART regimens, we must think in terms of 
harm reduction; evaluating the outcomes of stavudine dose reductions is a key part 
of the stavudine harm reduction puzzle.  I am currently working with several 
investigators from Themba Lethu to answer these and related questions.  Another 
related issue is that of TB and virologic suppression, and how TB may interact with 
different doses of stavudine; and while there is some documentation that TB does 
not affect rate of initial virologic suppression, there is much less information on how 
TB may affect long-term risk of virologic failure, and how incident TB interacts with 
all virologic outcomes. 
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Another area where epidemiology might help prevent excess toxicities is by 
creating predictive clinical algorithms of who is at high risk of stavudine (or other) 
toxicities.  However, preliminary analysis, presented in conference in March 2008, 
suggest that constructing rigorous models of this sort will be quite difficult; risk of 
stavudine toxicity is predicted strongly by almost no factors besides TB therapy (a 
result consistent with our finding in Chapter V of little confounding of the TB-d4T 
substitution relationship).  As a result, building predictive models has so far been 
unsuccessful.  However, the application of recursive partitioning algorithms (such as 
CART) to the problem may yield better predictive models than using parametric 
models such as logistic regression; this may be an area of future study. 
All of these techniques can also help ensure high quality care from midlevel 
healthcare workers.  The more we can simplify first-line HAART regimens and 
reduce the probability of important toxicities, the easier the job of managing HAART 
will be for individuals with less training.  In general, epidemiology, applied to the right 
problems, can greatly aid the goals of universal access.  This dissertation has made 
a start, but there is much further to go. 
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APPENDIX I: 
WEIGHT AND FINAL MODELS FOR ANALYSIS IN CHAPTER V 
 
The final structural model (to which the weights were applied) was implemented as a 
weighted pooled log-binomial (discrete time hazard) model, and specified as 
 
 log (pr(Dk(t)=1 | Dk(t-1)=0)) = β0 + β1*X0k 
 
where Dk(t) is an indicator of the outcome (death) at time t for patient k, X0k is an 
indicator variable for the exposure of PTB at time 0 for patient k, β0 is the intercept, 
and β1 is the estimated log-hazard ratio of the effect of PTB on the outcome of 
death. 
 
In both analyses, the main exposure of baseline PTB does not vary in time, but may 
affect future risk factors for death:  for instance, baseline PTB may affect CD4 
reconstitution during follow-up, which may put patients at higher risk of subsequent 
death.  However, such an effect should properly be considered part of the causal 
action of PTB on mortality; adjustment for such a factor would therefore result in a 
biased estimate of PTB on mortality.  Thus, exposure weights relied only on baseline 
covariates for this analysis.  However, because risk of mortality and LTFU both 
varied in time and with time-dependent changes in other variables, it was important 
to consider time-updated covariates in models for censoring weights. 
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There were four weight models specified for the main analysis of Model 1.  The 
weight component of inverse probability of exposure weights (IPEW, more typically 
called inverse probability of treatment weights(Hernán, Brumback, and Robins 
2000)) model (EW) included terms for gender, ethnicity, employment status, age, 
history of antiretroviral therapy, history of PTB, and baseline measures of 
pregnancy, peripheral neuropathy, hemoglobin (adjusted for sex, pregnancy status, 
and altitude), BMI, CD4 cell count, and WHO stage (IV or other), year of enrollment 
(measuring years starting at baseline), and whether treatment was initiated after the 
elimination of all fees for clinical care.  The stabilization component of the IPEW 
(e.g., Appendix A.3.2 in (Hernán and Robins 2006)) included only prevalence of PTB 
at baseline. 
 
The weight component of the inverse probability of censoring weights (IPCW) model 
(CW), included all terms of model EW as well as a term for the exposure of PTB, 
terms for month of follow-up and cubic spline terms for month of follow up (with 
knots at the approximate 5th, 25th, 50th, 75th and 95th percentiles of survival time), 
and time-updated measures of hemoglobin, CD4 cell count, and BMI.  The 
stabilization component of the IPCW included all terms of Model CW except for time-
updated hemoglobin, CD4, and BMI.  Inclusion of interaction terms among key 
predictors of PTB prevalence did not markedly change re-weighted effect estimates, 
and so were not included in the final weight models. 
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In Model 2, which examined PTB by category of lead-time, the same models were 
specified, but PTB itself was a five-categorical non-ordinal (nominal) variable, 
categorized by lead-time (>120 days, 61-120 days,  31-60 days, ≤30 days; and one 
category of no PTB).  Probabilities of being in each category were estimated using 
polytomous logistic regression. 
 
For both Model 1 and Model 2 we checked the positivity assumption by examining 
histograms of the conditional probability of exposure for PTB (see Figure A1); we 
judged that positivity assumption was met in these data, and a similar evaluation for 
the reduced weight model (S7) yielded similar results.  The mean of our stabilized 
weights was 1.00 in both Model 1, and Model 2; representative values of stabilized 
and unstabilized weights for Model 1, and stabilized weights for Model 2 and the 
reduced weight model S7 are shown in Table A1.1. 
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Table A1.1.  Weight distributions for Model 1 (stabilized and unstabilized), Model 2 
(stabilized only), and reduced and stabilized Model S7.  
 
 
Mean Median IQR Range 
Model 1, unstabilized 2.33 1.36  1.21 - 1.77 1.01 - 76.05 
Model 1, stabilized 1.00 0.93 0.87 - 1.05 0.19 - 11.32 
Model 2, stabilized 1.00 0.94 1.05 - 0.88 0.15 - 9.95 
Model S7, stabilized 1.00 0.97 0.90 - 1.05 0.24 - 5.10 
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Figure A1.1.  Probability of having treated pulmonary tuberculosis (PTB) at baseline 
in Model 1, by PTB status at baseline (i.e., propensity score curves for PTB). 
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APPENDIX II: 
RESULTS OF SENSITIVITY ANALYSES S1-S5 FOR CHAPTER VI. 
 
 
Figure A2.1.  Sensitivity analyses for effect of ongoing TB treatment at time of 
HAART initiation on risk of stavudine substitution. 
 
M: main analysis.  S1: multi-drug substitution. S2: adjustment for confounding without treatment 
weights. S3: truncating weights at 1st/99th percentiles.  S4: standardized morbidity ratio (effect of the 
exposure among the exposed).  S5: reference group restricted to those without any history of TB. 
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Figure A2.2.  Sensitivity analyses for effect of recent initiation of TB treatment at time 
of HAART initiation on risk of stavudine substitution. 
 
M: main analysis.  S1: multi-drug substitution. S2: adjustment for confounding without treatment 
weights. S3: truncating weights at 1st/99th percentiles.  S4: standardized morbidity ratio (effect of the 
exposure among the exposed).  S5: reference group restricted to those without any history of TB.
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Figure A2.3.  Sensitivity analyses for effect of incident TB treatment at time of 
HAART initiation on risk of stavudine substitution.  Note that the standardized 
morbidity ratio (S4) is not well-defined for this exposure. 
 
M: main analysis.  S1: multi-drug substitution. S2: adjustment for confounding without treatment 
weights. S3: truncating weights at 1st/99th percentiles.  S4: standardized morbidity ratio (effect of the 
exposure among the exposed).  S5: reference group restricted to those without any history of TB.  * 
Quantity not well-defined. 
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APPENDIX III: 
DETAILS OF MODELS USED FOR TREATMENT, CENSORING, AND 
COMPETING RISK FOR CHAPTER VI 
 
 
All hazard ratios were estimated using stabilized inverse probability of 
treatment and censoring weighted marginal structural models, implemented as 
weighted pooled log-binomial models (a generalized linear model with a log link and 
a binomial distribution function).  Each weight comprised three factors:  a stabilized 
treatment weight; a stabilized censoring weight; and a stabilized competing risk 
weight, which modeled the probability of multi-drug substitution including stavudine, 
but excepting switches to second-line HAART (which is the result of virologic failure 
and not drug intolerance/toxicity).  Because initial analysis showed little change in 
either estimates or confidence intervals when deaths and switches from first to 
second line HAART were considered as losses to follow-up, the censoring weights 
accounted for all three events. 
The inclusion of competing risk weights in our overall inverse probability 
weights has only been described once previously in the literature (Matsuyama and 
Yamaguchi 2007).  However, the intuition behind such an application of inverse 
probability weights is relatively straightforward, as it just considers multiple censoring 
categories, modeled separately.  Where in other, similar analyses the exposure has 
been a composite such as “treatment AND not censored”, in this analysis the 
exposure is simply a larger composite, “treatment AND [not censored OR no 
competing risk]”. 
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Covariates considered for inclusion in all models included gender, ethnicity, 
employment status, age, history of antiretroviral therapy, history of TB; baseline 
measures of pregnancy, peripheral neuropathy, hemoglobin (adjusted for sex, 
pregnancy, and altitude), BMI, CD4 cell count, and WHO stage (IV or other), 
calendar date, and whether treatment was initiated after October 2006 (when all fees 
for treatment were eliminated).  Time varying models (of the exposure of incident TB 
treatment, censoring, or competing risks) also considered time-updated measures of 
hemoglobin, CD4 count, BMI, and virologic success (measured only after month 6), 
and month of follow-up as both a continuous and categorical variable. 
The final weight and stabilization treatment models controlled for two 
exclusive sets of covariates.  Set A, included in only the final weight model for 
treatment, comprised those variables that were confounders of the TB treatment-d4T 
substitution relationship.  Set B, included in both the final weight and stabilization 
models for treatment, comprised those variables which predicted TB treatment but 
were only weakly (or non-) predictive of the outcome.  The reason for this separation 
of predictive factors is that the inclusion of covariates which predict exposure but 
which are not confounders can lead to instabilities in weights, an effect we observed 
in preliminary weight models.  We assigned “true confounder status” and thus 
membership in Set A or B, using a Cox proportional hazards model for confounding 
only, using backwards elimination.  Our elimination criteria for elimination were a chi-
square p-value >0.10 and a change-in-estimate of <0.10 on the log scale. 
The final treatment weight model used the following factors to predict 
probability of TB:  gender, age, history of antiretroviral therapy, pregnancy, 
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peripheral neuropathy at baseline, BMI, year of HAART initiation, and whether 
clinical care was free or not.  In addition, both the weight and stabilization models for 
treatment contained the following factors:  history of TB treatment, ethnicity, 
employment status, a dichotomous indicator for anemia, WHO stage (IV or 
otherwise), and categorical CD4 count. 
We did not implement such a selection process for models for stabilized 
censoring or competing risk weights; in both cases, all baseline variables and the 
exposure were included in stabilizing portions of weights (numerators), while all 
baseline and time-updated covariates as well as the exposure were included in 
weight models (denominators) (Hernán, Brumback, and Robins 2000).  All weights 
were estimated using ordinary logistic regression, and final stabilized inverse 
probability of treatment, censoring, and competing risk weights were calculated by 
multiplying the three component weights together. 
The positivity assumption states that, given their observed covariates, there is 
a non-zero probability that an individual who was being treated for TB could have 
conceivably not had TB, and vice-versa; this assumption is essentially equivalent to 
the assumption that there is no complete confounding.  We evaluated the positivity 
assumption by visually examining histograms of multivariate predicted probability of 
exposure by observed exposure status (a process equivalent to the comparison of 
propensity score distributions).  Because there was substantial overlap in these 
curves, we judged that the positivity assumption was approximately met in all 
analyses. 
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The final structural model (to which the weights were applied) for analyses of 
recent and ongoing TB treatment was implemented as a weighted pooled log-
binomial (discrete time hazard) model, and specified as 
 
 log (pr(Sk(t)=1 | Sk(t-1)=0)) =  
β0 + β1*Xtk + β2*I(3≤t≤6)*Xtk + β3*I(t≤7)*Xtk + I(3≤t≤6) + I(t≤7) 
 
where Sk(t) is an indicator of the outcome (stavudine substitution) at time t for patient 
k, Xtk is an indicator variable for the exposure of TB treatment at time t for patient k, 
I(.) represents a 0/1 indicator variable for the truth of the statement (.), β0 is the 
intercept, β1 is the estimated log-hazard ratio of the effect of TB treatment on the 
outcome of death for months 0-2, β1+β2 is the estimated log-hazard ratio of the effect 
of TB treatment on the outcome of death for months 3-6, and β1+β3 is the estimated 
log-hazard ratio of the effect of TB treatment on the outcome of death for months 7+. 
The final structural model for the analysis of the incident TB treatment was 
similar but omitted the last two indicator terms for month of follow-up, because those 
terms are assumed in the exposure model for incident TB treatment (as in (Cole et 
al. 2007)). 
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